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1. INTRODUCTION 
Diabetes mellitus is one of the most prevalent non-communicable diseases in India and the world 
over. It is estimated that there are over 60 million diabetics in India and this number is expected 
to increase significantly over the next few decades (1).  
Insulin resistance (IR) is the hallmark of type 2 diabetes mellitus (T2DM), which is the most 
common type of diabetes. The pathogenesis of IR is complex and multi-factorial. A number of 
risk factors, including obesity and genetic predisposition, have been shown to be associated with 
IR. However, the molecular mechanisms involved have not been fully elucidated (2). 
Iron is a transition metal and an essential micronutrient. It is required for the synthesis of 
hemoglobin and is therefore essential for erythropoiesis. Approximately 25 mg of iron is 
required every day for normal erythropoiesis in the bone marrow. More than 95% of this is 
provided by the recycling of iron derived from senescent erythrocytes. The macrophages that 
form the reticuloendothelial system, especially in the spleen, play a major role in this process. 
The rest of the daily iron requirement is derived from absorption of dietary iron, which occurs in 
the duodenum. Duodenal absorption of iron is a highly regulated process. Any increase in iron 
absorption in excess of the requirement results in iron overload, as the body has no 
physiologically regulated mechanisms to excrete iron. Such iron overload has been shown to be 
associated with tissue damage seen in conditions like hereditary hemochromatosis and 
thalassemia (3). 
A large number of epidemiological studies have shown a strong association between serum 
ferritin levels, an indicator of body iron stores, and IR. For example, the National Health and 
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Nutrition Education Survey (NHANES) done among 9486 adults in USA, showed that the odds 
ratio for newly developed T2DM was 4.94 in males and 3.61 in females who had serum ferritin 
that exceeded 300 µg/L (4). This and a number of other studies have shown that this association 
remains strong even after adjusting for age, sex, race, body mass index (BMI), smoking and C-
reactive protein (CRP) levels (5–9). In addition, the “normal” range of serum ferritin (15-300 
µg/L in males and 15-200 µg/L in females) is quite wide and values at either end of this range 
may be associated with health risks that currently remain unknown (10).  
Although a strong association exists between increased body iron stores and T2DM, the 
molecular interactions between processes involved in iron homeostasis and insulin sensitivity are 
not known. There is some evidence that supports the view that iron overload may play a causal 
role in the pathogenesis of diabetes mellitus. For example, the incidence of diabetes is higher is 
conditions characterized by iron overload, viz. hereditary hemochromatosis (11) and thalassemia 
(12,13).  Decreasing body iron stores, by iron chelation or phlebotomy in these conditions, tends 
to improve insulin sensitivity (14–16). These findings are supported by results from research 
using animal models of T2DM, where dietary iron overload was associated with insulin 
resistance (17) and iron restriction/phlebotomy was associated with improved insulin sensitivity 
(18,19). 
Insulin acts by binding to its cell surface receptor and triggering multiple intracellular signaling 
cascades. The phosphorylation and activation of Akt is a key event in this pathway (20). 
Activated Akt phosphorylates several downstream targets, which mediate the effects of insulin 
on metabolism, cell growth and proliferation (21). Although iron overload is thought to be 
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associated with insulin resistance, very little is known about the effects of increased intracellular 
iron on the insulin signaling pathway. 
The mechanism(s) by which iron accumulates in the body in diabetes is not known. It has been 
hypothesized that inappropriately low levels of hepcidin, the chief regulator of systemic iron 
homeostasis, may play a key role in mediating increased iron stores in T2DM (22). Hepcidin is a 
small-molecular-weight peptide (25 amino acids) secreted mainly by hepatocytes (23). It binds to 
ferroportin (the only known transporter in mammalian cells that exports iron) and triggers its 
internalization and degradation (24). Since ferroportin is expressed on the basolateral surface of 
enterocytes and also on macrophages, hepcidin decreases duodenal iron absorption and also 
inhibits iron recycling by macrophages.  
Studies on hepcidin in patients with T2DM have reported variable findings, with some studies 
showing increased serum hepcidin levels in diabetics (25,26), while others show decreased levels 
(27–29); still others show no significant differences (30). The reasons for these varying reports 
are unclear. A number of factors regulate hepatic hepcidin synthesis. It is known that hepcidin 
expression is induced in response to increased liver iron levels, increased transferrin saturation 
and inflammatory mediators such as interleukin-6 (IL-6). On the other hand, hepcidin expression 
is decreased in response to iron-deficiency anemia, hypoxia and erythropoiesis (31). The effects 
of IR per se on hepatic hepcidin expression and on factors that regulate it are not known. 
Among the factors that regulate hepatic hepcidin expression, inhibitory signals from the bone 
marrow, mediated by certain regulators secreted by erythroid precursors (“erythroid regulators of 
hepcidin”), play a very important role (32). Although the identity of these erythroid regulators is 
not clearly known, growth differentiation factor 15 (GDF15) (33), twisted gastrulation factor 
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(TWSG1) (34) and erythroferrone (ERFE) (35) have been proposed to be potential candidates. It 
is known that T2DM is associated with hyperinsulinemia and that insulin is a growth factor for 
erythropoiesis (36–38). However, the effects of insulin resistance on erythropoiesis or on the 
expression of GDF15, TWSG1 and ERFE in erythroid precursors are not clearly known.  
In summary, a number of epidemiological studies have shown that raised serum ferritin, a marker 
of body iron stores, is associated with insulin resistance. There is evidence to suggest that iron 
overload may play a causal role in the pathogenesis of insulin resistance, although the molecular 
mechanisms are not known. Dysregulation of hepcidin (the chief regulator of systemic iron 
homeostasis) has been reported in some studies on patients with diabetes. However, there is very 
little information available on the effects of insulin resistance on factors that regulate hepcidin 
expression, especially the erythroid regulators. Several critical questions remain unanswered: Is 
iron-overload a cause or a consequence of IR? Does increased intracellular iron impair insulin 
signaling? What are the effects of IR on regulation of hepatic hepcidin expression? Do these 
changes affect expression levels of proteins involved in iron homeostasis? The studies carried 
out and described in this thesis attempt to answer these questions. 
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HYPOTHESIS OF THE PROPOSED STUDY  
Increased intracellular iron levels may impair insulin signaling in hepatocytes, thus contributing 
to insulin resistance (IR) in these cells. Insulin resistance may affect expression of hepcidin and 
other iron-related proteins in the liver, resulting in dysregulation of systemic iron homeostasis. 
One of the ways in which IR may affect hepatic hepcidin expression may be through its effects 
on erythropoiesis. This may result in suppression of hepatic hepcidin expression (via up-
regulation of the erythroid regulators of hepcidin in the bone marrow) and increased intestinal 
iron absorption, leading to iron overload. Iron accumulation within cells may further exacerbate 
insulin resistance, thus constituting a vicious cycle. 
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2. AIMS AND OBJECTIVES 
The overall aim of this study was to systematically investigate the interactions between iron and 
insulin at the molecular level, and to elucidate possible mechanisms by which events involved in 
iron homeostasis and insulin resistance are linked. 
 
The specific objectives of this study were: 
1. To study the effects of iron on insulin signaling in mouse primary hepatocytes in vitro. 
2. To study the time-course of development of, and interactions between, insulin resistance and 
alterations in iron metabolism, in a mouse model of type 2 diabetes mellitus (T2DM). 
3. To study the effects of insulin resistance on terminal erythroid differentiation in the bone 
marrow and the expression of putative erythroid regulators of hepcidin, in a mouse model of 
T2DM. 
4. To study links between insulin resistance and iron metabolism in patients newly diagnosed to 
have diabetes mellitus or pre-diabetes by determining 
a. serum hepcidin levels and markers of iron status in these patients  
b. expression of erythroid regulators of hepcidin in reticulocytes in peripheral blood, 
isolated from these patients  
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3. REVIEW OF LITERATURE 
Iron is an essential micronutrient that plays multiple roles in the body. As a constituent of heme, 
it is present is several important proteins, including hemoglobin, myoglobin, cytochrome P450 
enzymes and in components of the electron transport chain in the mitochondria. Iron is also part 
of iron-sulfur clusters, which are critical components of proteins involved in redox reactions, 
especially in the mitochondrial electron transport chain. In addition, iron acts as a cofactor for 
several enzymes that play important roles in cellular metabolism (39) 
3.1. Review of current understanding of systemic iron homeostasis 
On average, an adult has about 3–4 grams of total body iron, which is mainly present in 
hemoglobin (~2500mg), ferritin (~1000mg) and myoglobin (~300mg). The body guards its iron 
zealously and there is very little loss of iron, usually less than 1 mg per day in males and slightly 
more in pre-menstrual females due to menstrual blood loss. This loss is replaced by intestinal 
absorption of dietary iron. Iron released by breakdown of senescent RBCs in the 
reticuloendothelial system (chiefly in the spleen), is recycled; about 25 mg of iron is supplied to 
the bone marrow for erythropoiesis from this source each day. Iron is stored as ferritin in various 
organs, chiefly the liver. A small amount of iron (3-4 mg) circulates in blood bound to 
transferrin, which is the iron transport protein (39) (Fig. 3.1). 
3.1.1. Duodenal absorption of dietary iron 
Since there are no physiological mechanisms for iron excretion from the body, iron entry by 
absorption of dietary iron, is strictly regulated (32).  
11 
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Iron absorption chiefly occurs in the duodenum. The apical membrane of duodenal enterocytes 
expresses divalent metal transporter 1 (DMT1 or Nramp2), which transports non-heme iron (and 
other divalent cations to a lesser extent) across the luminal membrane into the enterocyte (40). 
DMT1 transports iron in its ferrous (Fe
2+
) form; however, the majority of dietary iron is in the 
ferric form (Fe
3+
). A number of factors help in the reduction of ferric iron to its ferrous form. The 
enterocytes express on its apical membrane several enzymes (called brush-border 
ferrireductases) that catalyze the conversion of Fe
3+
 to Fe
2+
. The physiologically most important 
ferrireducatase is the duodenal cytochrome b (dcytb) (41). In addition, gastric acid and other 
reducing agents found in food (like ascorbic acid) also aid iron absorption by facilitating 
reduction of Fe
3+
 to Fe
2+
. Dietary heme is taken up duodenal enterocytes by independent 
mechanisms. The intestinal heme transporter has not been definitively identified (42). Once 
transported into the enterocyte, heme is catabolized by the microsomal enzyme, heme 
oxygenase, to release iron in the cytosol (43). 
Inside the enterocyte, iron can either be stored or transported into circulation across the 
basolateral membrane. Iron stored as ferritin in the cytosol is lost when enterocytes turnover 
(every 2-5 days in humans) and is therefore not absorbed into systemic circulation. Iron export 
from the cell is mediated by ferroportin (or Ireg1) which is the only known cellular iron export 
protein (44,45). Iron transported into systemic circulation is tightly bound to the plasma protein, 
transferrin. Transferrin binds iron in its Fe
3+
 form, and this requires a membrane-bound 
ferroxidase on enterocytes, a copper-containing protein called hephaestin. Hephaestin catalyzes 
the conversion of Fe
2+
 to Fe
3+
 (46) (Fig. 3.2). 
13 
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3.1.2. Iron transport in the blood 
Free iron is toxic due to its ability to catalyze redox reactions, resulting in oxidative damage of 
tissues. Therefore, iron is transported in blood tightly bound to the protein, transferrin. 
Transferrin has two high-affinity sites for binding Fe
3+
. The plasma concentration of transferrin is 
about 300 mg/dL. This amount of transferrin can potentially bind a total of about 300 µg of iron 
(per deciliter of plasma) and is referred to as the total iron-binding capacity (TIBC) of blood. 
However, serum iron levels are normally only about 50-150 µg/dL; this is because, under normal 
conditions, transferrin is saturated with iron only to an extent of about 25 to 45%. Transferrin 
saturation (Tfsat) decreases under conditions of iron deficiency (< 15% indicates severe iron 
deficiency), and increases under conditions of iron overload (>45%) (39).  
Most of the iron found in circulation is bound to transferrin. However, a very small amount of 
iron is also found in circulation loosely complexed with citrate, acetate or albumin. This is 
referred to as non-transferrin bound iron (NTBI). This form of iron is toxic; its levels increase in 
plasma when transferrin saturation approaches 75 – 80%. This is seen in conditions of iron 
overload. Significant tissue damage can occur under these conditions (47). 
3.1.3. Cellular uptake of plasma iron 
All cells express transferrin receptors (TfR1) on their surface to take up iron from the circulation. 
Erythroid precursor cells in the bone marrow, which are the largest consumers of iron, show very 
high expression levels of TfR1. This receptor has a high affinity for holo-transferrin (transferrin 
to which iron is bound).  Once transferrin is bound to TfR1, the complex undergoes 
internalization, by receptor-mediated endocytosis (Fig. 3.3).  
15 
 
 
16 
 
Within the acidic environment of the endosome that is formed, iron is released and transported 
into the cytosol via DMT-1. TfR1 bound to apo-transferrin (transferrin devoid of iron) is 
recycled back to the cell surface. Apo-transferrin is then released into the circulation, where it 
becomes available to bind more iron. This process is called the transferrin cycle; it occurs several 
times a day (39) (Fig. 3.3). 
3.1.4. Iron recycling by macrophages 
RBCs have an average lifespan of 120 days. Following this, macrophages (especially in the 
spleen) take up senescent RBCs (erythrophagocytosis) and break them down in order to release 
heme from hemoglobin. Heme is transported into the cytosol form the endosome by the heme 
transporter, HRG1 (heme responsive gene – 1) (48). In the cytosol, heme is catabolized by the 
enzyme, heme oxygenase 1 (HO-1), which releases free iron while converting heme into 
biliverdin. Iron is either stored within the macrophages as ferritin or transported out via the iron 
exporter, ferroportin (Fig. 3.4). This iron, which is in its ferrous form, is oxidized to its ferric 
form by the plasma protein, ceruloplasmin, which has ferroxidase activity. Ferric iron then binds 
to transferrin and is transported to other cells, chiefly the bone marrow. About 25 mg of iron is 
recycled each day in this manner (39). 
3.1.5. Cellular iron storage 
Ferritin is the cytoplasmic iron storage protein; it forms spherical structures consisting of 24 
subunits, which can store 3000-4500 ferric atoms in its core. Ferritin is made up of two types of 
subunits – H (heavy) and L (light).  
17 
 
 
18 
 
The H subunit of ferritin has intrinsic ferroxidase activity that facilitates the uptake of cytosolic 
Fe into the ferritin core (31). Ferrous iron is made available for storage in ferritin by the 
cytoplasmic chaperone protein, poly (rC) binding protein – 1 (PCBP-1) (49).  
Ferritinophagy, a specialized form of autophagy, is the process by which ferritin is degraded in 
lysosomes in order to release iron (50). The cargo receptor, nuclear receptor coactivator 4 
(NCOA4), plays a key role in mediating the induction of ferritinophagy in response to decreased 
intracellular iron (51).  
A soluble form of ferritin is present in the plasma and is commonly considered a marker of body 
iron stores. Plasma ferritin is mainly made up of L-ferritin, is poorly glycosylated and contains 
very little iron. In mice, it has been shown that serum ferritin is derived mainly from 
macrophages (52). Serum levels of ferritin have also been shown to increase in response to 
inflammation (53). 
3.2. Hepcidin, the central regulator of iron homeostasis 
Iron homeostasis is characterized by the coordinated regulation of iron absorption in the 
duodenum, iron utilization in the bone marrow, iron recycling in the macrophages and iron 
storage in the liver and spleen. Hepcidin, a peptide synthesized and secreted primarily by the 
liver, is the chief hormone that regulates iron homeostasis (32). In humans, it is coded by a single 
gene on chromosome 19. In mice, two genes (Hamp1 and Hamp2) code for hepcidin, however, 
only Hamp1 is involved in regulation of hepcidin levels in blood (54).  It is synthesized as a 
preprohormone of 84 amino-acids.  It undergoes proteolytic cleavage to remove a 24-amino acid 
signal sequence to form prohepcidin, which is then cleaved by a furin-like prohormone 
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convertase to generate a 25-amino acid (2.7 kDa) peptide, which is the mature form of hepcidin 
(55) (Fig. 3.5). Hepcidin circulates mostly free in plasma with a small proportion (<0.3%) 
weakly bound to albumin and α2-macroglobulin (56,57).  
3.2.1. Mechanism of action of hepcidin 
Hepcidin acts by binding to ferroportin, the only known iron exporter, and inducing its 
internalization and proteasomal degradation (24). It therefore decreases intestinal iron absorption 
and also release of iron from macrophages, resulting in hypoferremia. Hepcidin excess (as seen 
in chronic inflammatory conditions) is characterized by decreased circulating iron levels and 
resultant anemia; on the other hand, hepcidin deficiency (as seen in hemochromatosis) results in 
tissue iron overload (32). 
The 6 amino acids at the N-terminal of hepcidin are highly conserved; they are critical for its 
interaction with the extracellular loop of ferroportin (58,59). Alterations, either in the N-terminal 
sequence of hepcidin or in critical amino acids that constitute the extracellular loop of ferroportin 
(e.g., C326S in ferroportin), result in disruption of the hepcidin-ferroportin interaction (60–62). 
Binding of hepcidin to ferroportin results in rapid induction of  ubiquitination of critical lysine 
residues in the intracellular domains of ferroportin, resulting in proteasomal degradation of the 
protein (63,64).  Hepcidin is also known to induce alterations in gene expression of ferroportin 
and other iron-related proteins, especially in the duodenum (65). However, the mechanisms 
involved are not clear.  
20 
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3.2.2. Regulation of hepcidin 
Transcriptional regulation is the only well-established mechanism by which hepcidin is 
regulated. There are a number of factors that are known to regulate it, with some increasing and 
others decreasing its expression in the liver (Fig. 3.6). Signaling through the bone morphogenetic 
protein–SMA/Mothers Against Decapentaplegic (BMP-SMAD) pathway is the predominant 
transcriptional regulator of hepcidin (Fig. 3.7). BMPs can powerfully induce hepcidin gene 
expression (66). The hepatic BMP receptor (BMPR) is a heterodimer consisting of type I (Alk2 
or Alk3) and type II (ActRIIA) subunits (67,68). Binding of BMPs to its receptor, results in 
phosphorylation-mediated activation of receptor-regulated SMADs (R-SMADs or SMAD1/5/8). 
Phosphorylated R-SMADs heterodimerize with co-SMAD (SMAD4); the complex translocates 
to the nucleus where it binds to BMP-response elements (BMPRE) in the hepcidin promoter (69–
71). Although multiple BMPs have been shown to activate hepcidin, in mice the most important 
in vivo regulators of hepcidin are BMP6 (72) and probably BMP2 (73). Hemojuvelin (HJV) is a 
membrane GPI-anchored BMP co-receptor that is expressed in hepatocytes and skeletal muscle. 
In the hepatocytes, HJV is essential for BMP-BMPR interactions that regulate hepcidin (74–76).  
Matriptase-2, a membrane-associated serine protease (TMPRSS6), regulates hepcidin expression 
by down-regulating signaling via the BMP-SMAD pathway (77,78). It has been suggested that 
matriptase-2 acts by cleaving HJV, the BMP co-receptor, thus decreasing BMP-induced hepcidin 
expression (79).  Neogenin is a membrane receptor that is also known to increase hepcidin 
expression via the BMP-SMAD pathway (80). It has been shown to interact with HJV (81) as 
well as matriptase-2 (82); however the exact mechanisms and significance of neogenin-mediated 
hepcidin regulation are not clear. 
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3.2.2.1 Regulation of hepcidin expression by plasma iron levels  
Hepcidin expression is regulated by changes in plasma iron levels. Although the mechanisms 
involved have not been clearly elucidated, it is hypothesized that transferrin receptor 2 (TfR2), 
the classical hemochromatosis-associated protein (HFE) and HJV may play important roles 
(83,84). The model that has been proposed, based on current evidence, is shown in Fig. 3.8. On 
the hepatocyte sinusoidal (basolateral) membrane, holo-transferrin competes with HFE for 
binding to TfR1 (as they have overlapping binding sties on TfR1) (85). Binding of holo-
transferrin to TfR1, results in displacement of HFE from TfR1; free HFE then interacts with 
holo-transferrin-bound TfR2 on the cell surface. This trigger an intracellular signaling pathway 
(probably the BMP-SMAD pathway) that induces hepcidin (86,87) 
3.2.2.2 Regulation of hepcidin by liver iron stores 
Hepatic hepcidin expression is known to be regulated by liver iron stores. It has been shown that 
liver Bmp6 mRNA expression in mice is strongly correlated with liver iron stores, as well as with 
hepcidin expression, suggesting that BMP6 may be the “stores regulator” of hepcidin (88,89). 
Mice lacking the BMP6 gene (Bmp6
-/-
) have very low levels of hepcidin and develop massive 
iron overload (90). However, the association between BMP6 and liver iron stores has not yet 
been demonstrated in humans. In addition, the site of BMP6 synthesis in response to iron 
overload is not clear. It has been shown that Bmp6 expression increases in response to iron 
overload in non-parenchymal cells of the liver, but not in the parenchymal cells (91). BMP6 
released from liver sinusoidal cells act on the neighboring hepatocytes in a paracrine manner, to 
increase hepcidin expression via the BMP-SMAD pathway (92).  
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It has also been shown that liver sinusoidal cells take up ferritin and regulate expression of Bmp6 
and hepcidin in response to ferritin-derived iron (93). The molecular mechanisms that regulate 
Bmp6 expression in these cells are not known. It has also been shown that hepatic iron stores can 
regulate Hamp1 expression by modulating Tmprss6 expression (94). 
3.2.2.3 Regulation of hepcidin by erythropoietic signals 
Increased erythropoiesis is associated with suppression of hepatic hepcidin expression and 
increased duodenal iron absorption (95–97). This ensures iron availability to support 
erythropoiesis. In pathological conditions, such as thalassemia (which is characterized by 
ineffective erythropoiesis), erythropoiesis-mediated hepcidin suppression contributes to iron 
overload and tissue damage (98,99). Factors secreted by the erythroid precursors in the bone 
marrow, called the “erythroid regulators” of hepcidin, are known to be potent suppressors of 
hepatic hepcidin expression (Fig. 3.9). The identities of these factors are not clearly known 
(100). Growth differentiation factor–15 (GDF-15), twisted gastrulation factor 1 (TWSG-1) and 
erythroferrone (ERFE) have been identified as putative erythroid regulators of hepcidin. 
Among the erythroid regulators of hepcidin that have been identified, ERFE (or erythroferrone), 
a member of the tumor necrosis factor superfamily, has been reported to be the most promising 
candidate (35,101). Mice lacking the gene for ERFE showed impaired suppression of hepcidin in 
response to phlebotomy and erythropoietin (EPO) administration (35). Its expression in the 
marrow was increased during iron deficiency and acute hemolysis (101). In addition, it was 
shown to play role in suppression of hepcidin in thalassemic mice and during recovery from 
anemia of inflammation (102,103).  
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GDF-15 is a divergent member of the TGF-β family and is highly expressed by late erythroid 
precursors (104).  Serum GDF-15 is markedly elevated in patients with thalassemia and other 
causes of ineffective erythropoiesis (105,106); it has been shown to inhibit hepcidin expression 
in vitro at these high levels (33). However, mice lacking the gene for GDF-15 were able suppress 
hepcidin in response to acute blood loss (105). In addition, its levels were not increased in a 
mouse model of thalassemia (35,70), thus questioning its pathophysiological importance as a 
regulator of hepcidin.  
TWSG1 is a modulator of the BMP-SMAD signaling pathway; it is highly expressed in early 
erythroblasts. Treatment of hepatocytes with TWSG1 in vitro has been shown to suppress 
hepcidin expression (34). As with GDF-15, it has been shown that phlebotomy did not increase 
expression of TWSG1 in mouse bone marrow (35). In addition, TWSG1 levels were not 
modulated by iron deficiency or in response to blood loss (101). Therefore, the current evidence 
suggests that TWSG1 may not play an important role as a physiological regulator of hepcidin. 
3.2.2.4 Regulation of hepcidin by hypoxia 
Hepcidin expression is suppressed in response to hypoxia and this response is thought to be 
mediated by hypoxia-inducible factors (HIFs) (107,108). Although it has been shown that HIFs 
can directly suppress hepcidin expression in hepatocytes (107), it is now known that hypoxia-
induced hepatic hepcidin suppression is mediated by increased erythropoiesis in response to 
erythropoietin (108,109). Hypoxia may also increase blood levels of platelet-derived growth 
factor–BB (PGDF-BB), which suppresses hepcidin via the cAMP response element binding 
protein–H (CREB-H (110). 
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3.2.2.5 Regulation of hepcidin by inflammation and other stress signals 
Hepcidin expression is increased in response to inflammation. This response may be part of the 
innate immune mechanism aimed at decreasing the availability of iron to invading pathogens 
(111). The pro-inflammatory cytokine, interleukin-6 (IL-6), has been shown to induce hepcidin 
by signaling through the Janus kinase 2–signal transducer and activator of transcription 3 (Jak2-
STAT3) pathway (112–114). The BMP-SMAD pathway also plays a role in hepcidin induction 
by IL-6 (115). Other mediators of inflammation, like Activin B, may also play a role by 
activating the BMP-SMAD pathway (116,117). 
In addition to these, it is known that hepcidin expression can be increased in response to 
endoplasmic reticulum stress (118,119) and gluconeogenic signals (120) acting via CREB-
H/SMAD and PGC-1α/CREB-3l3 respectively.  
3.3. Insulin, the central regulator of energy homeostasis 
Insulin was discovered in 1921 by Banting and Best, who extracted from pancreatic tissue “an 
islet cell factor that had potent hypoglycemic activity”. Insulin was the first protein that was 
proven to have hormonal action. In addition, it was the first protein to be crystallized, sequenced 
and synthesized by chemical methods. It was also the first protein to be synthesized by 
recombinant DNA technology for commercial use.  
Insulin is a low-molecular weight protein (5.7 kDa), which consists of two polypeptide chains (A 
and B) linked to each other by two inter-chain disulphide bonds. The A and B chains have 21 
and 30 amino acids respectively. Insulin is synthesized in pancreatic beta cells as a 
preprohormone. Following removal of the 23 amino acid leader sequence in the endoplasmic 
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reticulum, it forms proinsulin. Proinsulin undergoes a series of proteolytic cleavages to form 
equimolar amounts of C-peptide and mature insulin. Mature insulin is packaged into granules in 
the Golgi apparatus and stored in the cytosol. 
3.3.1. Insulin secretion 
On average, the human pancreas secretes about 40 to 50 units of insulin per day. Glucose is the 
most potent insulin secretogogue. Apart from glucose, amino acids (arginine and leucine), ketone 
bodies and certain gastrointestinal peptides (such as glucagon-like peptide 1 and 
cholecystokinin) can stimulate insulin release. In response to glucose stimulation, insulin release 
occurs in two phases. The first phase release is swift and short-lasting, while the second phase is 
slow and occurs over a period of 2 to 4 hours. A reduction in the first-phase release of insulin is 
one of the earliest signs of beta cell failure in type 2 diabetes. 
The process of glucose-induced insulin secretion in beta cells is shown in Fig 3.10. Glucose 
enters beta cells via glucose transport protein 2 (GLUT2). Inside the beta cell, glucose is 
phosphorylated by glucokinase. This is considered the rate-limiting step in the process of insulin 
secretion. Further metabolism of glucose-6-phosphate by glycolysis, the citric acid cycle and 
finally oxidative phosphorylation, results in formation of ATP. ATP binds to and inhibits the 
ATP-sensitive K
+ 
channels, resulting in depolarization. Membrane depolarization activates 
voltage-sensitive calcium channels, which results in calcium influx into the cell. Increased levels 
of intracellular calcium trigger exocytosis of insulin-containing granules. Glucose-induced 
insulin secretion can be augmented by incretins (such as glucagon-like peptide 1) secreted from 
neuroendocrine cells in the intestine following ingestion of food.  
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Once secreted into the portal vein, about 50% of insulin is rapidly degraded in a single pass 
through the liver. Consequently, insulin has a very short half-life of 3-5 minutes.  
3.3.2 Overview of the insulin signaling pathway (121,122) 
Insulin binds to its receptor on insulin-sensitive tissues, such as the liver, skeletal muscle and 
adipose tissue. This receptor is a dimer of dimers; it consists of 2 extracellular α subunits and 2 
transmembrane β subunits, which are held together by disulphide bonds (Fig. 3.11). Binding of 
insulin to the α subunits results in phosphorylation of tyrosine residues on the β subunits. These 
are recognized by phosphotyrosine-binding domains of adaptor proteins, such as insulin receptor 
substrates 1 and 2 (IRS 1/2). Phosphorylation of IRS 1 and 2 at specific tyrosine residues 
provides docking sites for binding of phosphoinositol-3-kinase (PI3K) via src homology 2 (SH2) 
domains. PI3K catalyzes the conversion of the membrane phospholipid, phosphatidylinositol 
(4,5)-bisphosphate (PIP2) to phosphatidylinositol (3,4,5)-trisphosphate (PIP3). PIP3 forms a 
docking site for phosophoinositide-dependent protein kinase–1 (PDK-1), which then recruits and 
phosphorylates protein kinase B or Akt at two key residues, Thr 308 and Ser 473. 
The phosphorylation and activation of Akt lies at the heart of the insulin signaling pathway. In 
the liver, activated Akt phosphorylates glycogen synthase kinase 3 β (Gsk3β) at Ser9, thus 
inactivating it. Gsk3β, in its active state, phosphorylates and inactivates glycogen synthase 
kinase, thus inhibiting glycogenesis. Insulin-induced inactivation of Gsk3β, thus, activates 
glycogenesis.  
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Akt also phosphorylates and induces the nuclear exclusion of the key gluconeogenic 
transcription factor, forkhead box O1 (FoxO1). FoxO1 is an important transcription factor that 
activates the transcription of gluconeogenic genes, glucose-6-phosphatase (G6Pase) and 
phosphoenolpyruvate carboxykinase (PEPCK). FoxO1 inactivation by Akt (in response to 
insulin) thus decreases expression of gluconeogenic genes. In addition, insulin also 
phosphorylates and inactivates peroxisome proliferator-activated receptor gamma co-activator 1-
alpha (PGC-1α), which (along with FoxO1) plays an important role in the regulation of G6Pase 
and PEPCK. 
In the skeletal muscle and adipose tissue, an important effect of insulin is to induce translocation 
of the insulin-sensitive glucose transporter (GLUT4) from intracellular storage vesicles to the 
cell membrane. The translocation of GLUT4 is mediated by both Akt-dependent and 
independent mechanisms. The Akt independent pathway involves insulin receptor-mediated 
activation of the Cbl-CAP complex, which translocates to lipid rafts on the membrane to interact 
with the adaptor protein Crk and the guanine nucleotide exchange factor, C3G. C3G, in turn, 
activates the GTP-binding protein, TC10, which induces the translocation of GLUT4 to the 
membrane. 
Insulin also increases uptake of amino acids by tissue and stimulates protein synthesis. Gsk3β 
phosphorylates and inactivates the translation initiation factor eIF2B. Insulin, by inactivating 
Gsk3β, promotes protein synthesis by activating eIF2b. Akt also activates the mammalian target 
of rapamycin (mTOR) pathway, which increases protein synthesis by inactivating eIF4B-binding 
protein. In the adipose tissue and liver, insulin increases the mRNA expression of the 
transcription factor, sterol regulatory element-binding protein 1c (SREBP-1C). SREBP-1c is the 
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master regulator of lipid metabolism and increases the transcription of genes involved in 
synthesis of fatty acids, triacylglycerol and cholesterol. Insulin, acting via the adapter protein 
Grb2, can activate the mitogen-activated protein kinase (MAPK) pathway. In this way, insulin 
has growth-stimulatory and mitogenic properties, in addition to its profound effects on 
intermediary metabolism. 
3.3.3 Metabolic effects of insulin 
Insulin has profound effects on the metabolism of glucose, lipids and proteins. The principal 
metabolic effect of insulin is to decrease blood glucose levels. It does so by increasing the 
peripheral cellular uptake of glucose (in the skeletal muscle and adipose tissue) and by 
decreasing hepatic glucose output (Fig. 3.12). 
3.3.3.1 Effect of insulin on glucose uptake from blood 
Under normal conditions, the skeletal muscle is responsible for more than 80% of insulin-
induced decrease in blood glucose levels. In the skeletal muscle and in adipose tissue, insulin 
induces the rapid translocation of glucose transporters (GLUT4) to the cell membrane. This 
mainly involves signaling via the Cbl-CAP-TC10 pathway (described in section 3.3.2) (123–
125). Increase in cell surface GLUT4 levels results in increase glucose uptake into cells from the 
circulation, resulting in a rapid decrease in blood glucose levels. 
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Insulin also increases glucose uptake in the liver, but the mechanism does not involve GLUT 
transporter. Insulin induces glucokinase (126), which phosphorylates glucose transported into 
hepatocytes via GLUT2. Increased phosphorylation of glucose maintains a glucose concentration 
gradient across the cell membrane, which facilitates the movement of glucose into the cell. 
3.3.3.2 Effect of insulin on glucose utilization 
Insulin increases glycolysis in the liver, skeletal muscle and adipose tissue, both by increasing 
the activity and transcription of glucokinase/hexokinase, phosphofructokinase (PFK1) and 
pyruvate kinase. In addition, it increases lipogenesis by increasing the activities of pyruvate 
dehydrogenase, acetyl CoA carboxylase and fatty acid synthase. These effects require signaling 
via SREBP1C (126) (Fig 3.12). 
3.3.3.3 Effect of insulin on hepatic glucose production (HGP) 
Insulin decreases HGP by inhibiting glycogenolysis and gluconeogenesis. The mechanisms 
involved are complex and not fully understood. It brings about this effect through a combination 
of direct effects on the liver and indirect effects (through its effects on extra-hepatic tissues). The 
indirect effects are mediated by inhibitory effects on lipolysis in the adipose tissue, modulation 
of vagal activity mediated by the effects of insulin on the hypothalamus in the brain 
(demonstrated in mice) and by decreasing substrate availability for gluconeogenesis (127)  
In the liver, insulin increases glycogen synthesis by activating glycogen synthase, the rate-
limiting enzyme in glycogenesis. It does so by phosphorylating and inhibiting Gsk3β (as 
described in section 3.3.2). In addition, insulin also activates phospho-protein phosphatase 1 
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(PP1). PP1 dephosphorylates glycogen synthase (activating it) and glycogen phosphorylase 
(inhibiting it), thus coordinately activating glycogenesis synthesis and inhibiting glycogenolysis 
(128).  
Increased hepatic glucose production (HGP), driven primarily by increased gluconeogenesis, is a 
characteristic feature of diabetes (129). Regulation of HGP is a complex process, with glucagon 
and insulin being the primary hormonal regulators. Glucagon stimulates HGP by increasing the 
phosphorylation of the bi-functional enzyme, phosphofructokinase-2/fructose bisphophatase-2, 
thus increasing the gluconeogenic flux. It also increases the transcription of key gluconeogenic 
genes, phosphoenolpyruvate carboxykinase (PEPCK, Pck1) and glucose-6-phosphatase (G6pc), 
by activating cAMP-response element binding protein (CREB), which is a transcription factor 
(130). While glucagon sets the basal tone for HGP, insulin can powerfully suppress it by acting 
through multiple mechanisms. Insulin, acting via its receptors on the cell surface, phosphorylates 
and activates Akt (protein kinase B) (20). Activated Akt phosphorylates several downstream 
targets, including glycogen synthase kinase 3β (Gsk3β) and forkhead box O1 (FoxO1), both of 
which are inactivated by Akt-catalyzed phosphorylation (at Ser9 and Ser256 respectively). 
Inactivation of Gsk3β inhibits glycogenolysis, while that of FoxO1 results in suppression of 
gluconeogenesis (21).  
The effects of insulin on HGP in vivo are apparent within minutes of its secretion from the 
pancreas. It is therefore thought that these acute effects of insulin are not mediated by its effects 
on transcriptional regulation of gluconeogenic genes (131). Although the direct effects of insulin 
on the liver are important for HGP regulation in vivo (132), studies have shown that insulin can 
regulate HGP even in the absence of direct insulin signaling in the liver (133,134). For example, 
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mice lacking insulin receptors (133) or Akt (135) specifically in the liver were able suppress 
HGP in response to insulin. These studies show that the indirect effects of insulin (mediated by 
its effects on extra-hepatic tissues) play an important role in short-term regulation of HGP.  
Insulin-induced inhibition of lipolysis in the adipose tissue has been shown to play a key role in 
HGP regulation. The mechanism that has been proposed is as follows: insulin induces a decrease 
in NEFA in the blood by suppressing lipolysis in the adipose tissue. This results in decreased 
hepatic acetyl CoA levels. Low acetyl CoA decreases the allosteric activation of pyruvate 
carboxylase resulting in decreased substrate flux through the gluconeogenic pathway (136). 
Insulin decreases the availability of gluconeogenic substrates by decreasing the release of 
glucogenic amino acids (such as alanine) and lactate from the muscle. In mice, it has been shown 
that the central effect of insulin (on the hypothalamus) can suppress HGP by decreasing flux 
through G6Pase (137,138). The mechanisms involved are not clear; however it involves the 
orexigenic (appetite-promoting) NPY/AgRP neurons and anorexigenic POMC neurons in the 
brain and IL-6-STAT3 signaling in the liver (139,140). It is not clear whether similar 
mechanisms are operational in humans as well.  
3.3.4 Role of AMP-activated protein kinase (AMPK) in energy metabolism in the liver 
AMP-activated protein kinase (AMPK) is an important intracellular energy sensor (141). AMPK 
activation results in inhibition of anabolic pathways (which consume ATP) and stimulation of 
catabolic pathways (which increase ATP production). The insulin-sensitizing hormone 
adiponectin and the anti-diabetic drug metformin bring about their effects, at least in part, by 
activating the AMPK pathway (142,143). 
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AMPK is activated when the AMP/ATP ratio in the cell increases, indicating an energy-depleted 
state. Binding of AMP to the γ subunit of AMPK induces a conformational change that exposes 
the Thr172 residue on the α-subunit. Subsequent phosphorylation at Thr172 by AMPK kinases 
(AMPKK) is required for full activation of AMPK. Liver kinase B1 (LKB1) is a key AMPKK 
involved in phosphorylation of AMPK at Thr172 (144).  
Activation of AMPK results in initiation of a metabolic program the involves inhibition of 
anabolic pathways, such as fatty acid and protein synthesis, activation of catabolic pathways, 
such as fatty acid oxidation, and increased mitochondrial biogenesis and cellular glucose uptake 
(141) (Fig. 3.13). AMPK decreases HGP by inducing the phosphorylation and inactivation of 
CREB-regulated transcription co-activator 2 (CRTC2), a key transcriptional co-activator 
involved in induction of gluconeogenic genes by glucagon (145). In addition, AMPK also 
inhibits glucagon-induced increase in gluconeogenesis, by activating phosphodiesterase-
mediated cAMP degradation (146).  
3.4. Diabetes mellitus 
Diabetes mellitus refers to a heterogeneous group of conditions characterized by hyperglycemia. 
Depending on the specific type of diabetes, hyperglycemia may result from impaired insulin 
secretion, resistance to insulin-induced uptake of glucose, increased hepatic glucose production 
or a combination of all these factors (147). Chronic hyperglycemia results in secondary 
pathophysiological changes that can result in damage to multiple organ systems. Diabetes is the 
leading cause of chronic renal failure, adult blindness and lower limb amputations due to non-
traumatic causes. In addition, it increases the risk of cardiovascular, cerebrovascular and 
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peripheral vascular disease. Overall, diabetes is one of the leading causes of morbidity and 
mortality world-wide (148).  
3.4.1. Diabetes, a global epidemic 
The International Diabetes Federation reports that, in 2017, there were more than 425 million 
people with diabetes. This figure was projected to go up to 642 million in the year 2040 (149). 
While the prevalence of diabetes has remained more-or-less static in the developed world, it has 
risen rapidly in developing countries. There has also been an epidemiological shift, with diabetes 
no longer being a disease of the affluent in urban areas. In the urban areas, diabetes is now more 
common among the poorer sections of society, while in rural regions world-wide the prevalence 
of diabetes has increased from 5.7% in 1985–89 to 8.7% in 2005–11 (150).  
3.4.2. Diabetes, the Indian scenario 
Recent data from India shows an overall prevalence of 7.3% for diabetes and 10.3% for pre-
diabetes (151). There were marked inter-state differences, which is reflective of the socio-
economic, ethnic and racial diversity in the country. Overall, the prevalence was higher among 
economically disadvantaged populations in urban areas. The prevalence was lower in rural areas 
compared to urban areas; however the differences were less marked, when compared to data 
from the early 2000s (151). 
 
 
 
43 
 
3.4.3. Classification of diabetes 
Diabetes is classified broadly into 4 types as shown in Table 3.1. The two major types are type 1 
and type 2 diabetes mellitus. Type 1 diabetes mellitus (T1DM) is characterized by an absolute 
deficiency in insulin secretion. On the other hand, type 2 diabetes mellitus (T2DM) has a more 
complex pathogenesis characterized by variable degrees of insulin resistance (IR) and impaired 
insulin secretion. These are discussed in detail in section 3.5 and 3.6. 
Apart from T1DM and T2DM, a heterogeneous group of conditions, such as those associated 
with abnormal beta cell development or function, defective insulin action, disorders of the 
pancreas, endocrinopathies and other genetic diseases, are grouped under the third class called 
“other specific types of diabetes” (Table 3.1). Gestational diabetes refers to diabetes mellitus that 
is diagnosed for the first time during pregnancy. Most women with GDM revert to normal 
glucose tolerance after child-birth; however, they have significantly increased risk of developing 
T2DM over the next 10- 20 years (152). 
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Table 3.1: Classification of diabetes mellitus 
I. Type 1 diabetes mellitus (characterized by beta cell destruction leading to absolute insulin 
deficiency) 
a. immune-mediated 
b. idiopathic 
II. Type II (characterized by varying degrees of insulin resistance and insulin secretory defect) 
III. Other specific types of diabetes: 
a. Mutations in specific genes resulting in genetic defects in beta cell development and 
function. 
i. Hepatocyte nuclear factor (HNF)-4α (MODY 1) 
ii. Glucokinase (MODY 2) 
iii. HNF-1α (MODY 3) 
iv. Insulin promoter factor-1 (MODY 4) 
v. HNF-1β (MODY 5) 
vi. NeuroD1 (MODY 6) 
vii. Mitochondrial DNA  
viii. Subunits of the ATP-sensitive K+ channel 
ix. Proinsulin or insulin 
x. Pancreatic islet regulatory proteins  
b. Genetic defects in insulin action 
i. Type A insulin resistance 
ii. Leprechaunism 
iii. Rabson-Mendenhall syndrome 
iv. Lipodystrophy syndromes 
c. Disease of the exocrine pancreas 
d. Endocriopathies – acromegaly, Cushing’s syndrome, pheochromocytoma etc. 
e. Other genetic syndromes  
IV. Gestational diabetes mellitus 
 
Source: Kasper DL, Jameson JL, Hauser S, Loscalzo J, Fauci AS, Longo D. Harrison’s Principles of 
Internal Medicine 19/E (Vol.1 & Vol.2). McGraw-Hill Education; 2015. (Table  417-1, page 2399). 
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3.4.4. Diagnosis of diabetes and pre-diabetes 
As per the criteria of the American Diabetes Association (2017), a diagnosis of normal glucose 
tolerance, pre-diabetes or diabetes can be based on fasting plasma glucose levels, plasma glucose 
2 h after a glucose challenge (oral glucose tolerance test [OGTT]) or glycated hemoglobin 
(HbA1c) levels (153). Normal glucose tolerance is defined as: 
 fasting plasma glucose  < 100 mg/dL (<5.6 mmol/L) 
 plasma glucose 2 h-post glucose challenge in an OGTT < 140 mg/dL (7.8 mmol/L) 
 HbA1c < 5.7% (< 39 mmol/mol) 
Pre-diabetes is defined as: 
 fasting plasma glucose  100 – 125 mg/dL (5.6 to 6.9 mmol/L) or 
 plasma glucose 2 h-post glucose challenge in an OGTT 140 – 199 mg/dL (7.8 - 11.1 
mmol/L) or 
 HbA1c 5.7 % – 6.4 % (39 – 47 mmol/mol) 
Diabetes mellitus is defined as: 
 fasting plasma glucose  ≥ 126 mg/dL (7.0 mmol/L) or 
 plasma glucose 2 h-post glucose challenge in an OGTT ≥ 200 mg/dL (11.1 mmol/L) or 
 HbA1c  ≥ 6.5% (< 48 mmol/mol) or 
 random blood glucose ≥ 200 mg/dL (11.1 mmol/L) in a patient with classic symptoms of 
hyperglycemia, or hyperglycemic crisis 
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3.4.5. Pathophysiology of diabetes mellitus 
3.4.5.1 Type 1 diabetes mellitus (T1DM) 
T1DM is characterized by autoimmune destruction of pancreatic beta cells resulting in insulin 
deficiency. Most, but not all, people with T1DM have a genetic predisposition and develop overt 
hyperglycemia at a relative young age (< 20 years) (147). Such patients are born with normal 
beta cell mass; however, an autoimmune process (probably triggered by an infectious or 
environmental factor) results in progressive loss of beta cells. Patients become overtly diabetic 
when more than 70 – 80% of beta cells are destroyed (154). 
The factors that trigger the autoimmune process are poorly understood. Although beta cells are 
embryologically and functionally similar to other islet cells (such as the alpha [glucagon-
producing], delta [somatostatin-producing] and PP [pancreatic polypeptide-producing] cells), the 
autoimmune process specifically targets the beta cells (154). Infiltration of islets by activated T 
lymphocytes (‘insulitis’) is a characteristic feature of T1DM and occurs early in the pathogenesis 
of the condition (155). In many cases, auto-antibodies targeted against insulin, ICA512/IA-2, 
glutamic acid decarboxylase and the zinc transporter, ZnT-8, are detectable (156). However, 
these are not beta cell-specific and are unlikely to mediate beta cell destruction in this condition. 
Overall, the pathogenesis of autoimmune beta cell destruction is poorly understood. 
 3.4.5.2 Type 2 diabetes mellitus (T2DM) 
The pathogenesis of T2DM involves both IR as well as impaired insulin secretion. Although the 
primary abnormality is not clearly known, it is generally held that IR precedes onset of impaired 
insulin secretion by several years (157).  
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Most of our current knowledge regarding the pathogenesis of T2DM comes from studies done on 
Caucasians. Obesity is one of the most important risk factors for T2DM in this group (158). 
Factors such as a sedentary lifestyle, consumption of high-calorie diet and lack of exercise, have 
led to an increase in the global prevalence of obesity. World-wide, the prevalence of obesity has 
tripled between 1975 and 2016. About 39% of the world’s population is estimated to be 
overweight (BMI of 25-30) and, of these, 13% are obese (BMI > 30) (159).  
Increase in adipose tissue, especially visceral fat, is associated with the development of a chronic 
inflammatory state (160). This results in the development of IR (discussed in detail in section 
3.5.1). Early in the course of the disease, a compensatory increase in insulin secretion by 
pancreatic beta cells maintains glucose tolerance at or near normal levels. However, with 
progressive increase in IR, combined with decreased insulin secretion (‘beta cell failure’), 
hyperglycemia ensues. Initially, hyperglycemia is mainly post-prandial (impaired glucose 
tolerance). However, increasing beta cell failure coupled with increased hepatic glucose 
production, results in fasting hyperglycemia (impaired fasting glycemia). With further increase 
in IR and decrease in beta cell function, the patient eventually develops diabetes (147). These 
events are summarized in Fig. 3.14. 
3.5    Role of insulin resistance in the pathogenesis of T2DM 
Insulin resistance (IR) refers to a condition where tissues (mainly liver, skeletal muscle and 
adipose tissue) respond sub-optimally to the metabolic effects of insulin. Decreased uptake of 
glucose especially by the skeletal muscle results in post-prandial hyperglycemia, while increased 
hepatic glucose production contributes to fasting hyperglycemia (147).  
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3.5.1 Role of adipose tissue in the pathogenesis of IR 
 3.5.1.1 Adipose tissue inflammation and IR 
Adipose tissue inflammation associated with obesity is probably the most important factor in the 
pathogenesis of IR (158,161–163). The mechanisms involved in initiation of inflammation in the 
adipose tissue are not clearly delineated. However, adipocyte hypoxia and death resulting in 
activation of resident macrophages has been proposed to play an important role (164). Once 
initiated, secretion of pro-inflammatory cytokines, such as monocyte chemo-attractant protein 1 
(MCP1), tumor necrosis factor alpha (TNFα) and interleukin-6 (IL-6), by adipocytes and 
macrophages plays an important role in recruiting additional macrophages and initiating a feed-
forward cycle (165,166) (Fig. 3.15). 
Adipose tissue macrophages (ATMs) play an important role in sustaining and exacerbating 
adipose tissue inflammation. The resident ATMs have an anti-inflammatory (or M2) profile, 
while macrophages recruited to the adipose tissue by inflammation have a pro-inflammatory (or 
M1) phenotype (167). The pro-inflammatory macrophages secrete a variety of inflammatory 
mediators, which induce IR in adipocytes, stimulate lipolysis and release non-esterified fatty 
acids (NEFA) into the circulation (168). 
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3.5.1.2 Subcutaneous and visceral adipose tissue  
The distribution of fat in the body can have a major influence on insulin sensitivity. It is well-
recognized that people with peripheral (subcutaneous or gluteofemoral) distribution of fat (fat 
distributed predominantly around the buttocks and thighs) have better insulin sensitivity than 
those with central (visceral or intra-abdominal) distribution of fat (omental and mesenteric fat) 
(169,170).  
There are several factors that may account for this. Intra-abdominal (visceral) fat is metabolically 
more active; it expresses adipokines and pro-inflammatory cytokines to a greater extent than 
subcutaneous fat (171). It also has a larger proportion of immune cells like macrophages and 
lymphocytes.  
Intra-abdominal fat is also more lipolytic and resistant to the anti-lipolytic effects of insulin. On 
the other hand, subcutaneous fat has higher capacity to take up and esterify fatty acids from 
circulation (172). In addition, blood from intra-abdominal fat drains directly to the liver, 
exposing the liver to high concentrations of NEFA and pro-inflammatory cytokines (especially 
1L-6). This may explain why IR develops initially in the liver, while the peripheral tissues are 
still insulin-sensitive (173). 
 3.5.1.3 Gonadal adipose tissue in mice 
In mice, intra-abdominal fat depots include the peri-gonadal (or gonadal), peri-renal (or 
retroperitoneal) and mesenteric (intestinal) adipose tissue. The mesenteric fat pad is most 
analogous to human visceral adipose tissue as it drains directly into the portal vein (174). 
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However, it is not commonly used for experimental purposes due to its limited quantity and 
difficulty associated with surgically accessing and manipulating it. The peri-gonadal fat pad 
(called epididymal fat pad in males and peri-ovarian fat pad in females) is used most commonly 
in animal experiments because it is the largest intra-abdominal fat depot in mice and is easily 
accessible. In addition, it shares many of the metabolic features that are characteristic of visceral 
fat in humans, such as increased metabolic capacity, development of inflammation and 
infiltration of immune cells in response to obesity (or high-fat feeding), secretion of adipokines 
and inflammatory cytokines, etc. (174). However, humans do not have fat pads that are 
analogous to the perigonadal fat pads of mice. Therefore, it has been suggested that these are 
“peri-visceral” in nature and not truly visceral adipose tissue. Nevertheless, most studies done in 
mice have used the peri-gonadal adipose depot as a source of visceral fat (175) 
3.5.2 Role of ectopic lipid accumulation in IR 
Adipose tissue lipolysis and increased NEFA in the blood is associated with deposition of lipids 
in the muscle as well as the liver (ectopic lipid accumulation). In the muscle, IR is strongly 
correlated with intramyocellular lipid content. Lipid-induced IR results in decreased 
translocation of GLUT4 to the membrane in response to insulin, resulting in impaired glucose 
uptake (176–178). Ectopic lipid accumulation in the liver is referred to as non-alcoholic fatty 
liver disease (NAFLD). NAFLD is strongly associated with hepatic insulin resistance and is an 
important component of the metabolic syndrome (179,180). 
The mechanisms by which intracellular lipid induces IR (‘lipotoxicity’) are not fully understood. 
It is generally believed that fatty acid metabolites such as diacylglycerol (DAG), fatty acid CoA 
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and ceramides are important mediators in lipotoxicity (181). DAG can activate novel protein 
kinase C (PKC) isoforms, such as PKCθ, PKCε and PKCδ, which mediate phosphorylation of 
specific serine residues on IRS1 and IRS2, thus inhibiting signaling via the Akt pathway (182). 
Ceramides, acting through multiple mechanisms, including activation of PKCζ, can inhibit 
insulin-induced activation of the Akt pathway (183).  
3.6   Role of beta cell dysfunction in the pathogenesis of T2DM 
It is now known that normal glucose tolerance can be maintained in individuals who have a high 
degree of IR, if beta cell function is preserved. More than 75% of the functional capacity of beta 
cells is lost in patients who are diabetic (184,185). Studies done on Pima Indians have shown that 
irrespective of the degree of IR, only those patients who have a pre-existing defect in beta cell 
function progress to develop diabetes (186). The nature of the beta cell defect is not known; it is 
probably mediated by genetic or environmental mechanisms.  
The beta-cell centric view of pathogenesis of diabetes is shown in Fig 3.16. Impaired or 
inadequate insulin secretion can result in increased lipolysis in the adipose tissue and release of 
NEFA into circulation. Increased release of NEFA results in exacerbation of IR and further 
deterioration in beta cell function, thus constituting a feed-forward cycle. In addition, decreased 
insulin also results in hyperglycemia by decreased peripheral uptake of glucose in muscles and 
increasing hepatic glucose output. Hyperglycemia can itself decrease beta cell function 
(glucotoxicity). In addition, the lack of insulin, acting via the hypothalamus, can increase food 
intake resulting in obesity and exacerbation of IR (158,185). 
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3.7   Role of iron in the pathogenesis of T2DM 
In recent years, there has been an increase in interest in the association between elevated body 
iron stores and diabetes mellitus (10,187). A relationship between increased body iron stores and 
diabetes mellitus was first shown in patients with hereditary hemochromatosis (188). 
Subsequently, it was shown that patients who develop iron overload secondary to other causes, 
such as repeated blood transfusions in thalassemia, were also predisposed to develop diabetes 
mellitus (98). In addition, reports from a number of epidemiological studies have shown a strong 
association between body iron stores and risk of diabetes mellitus (described in section 3.7.1).  
The interest in the role of iron in the pathogenesis of diabetes stems from the fact that body iron 
stores can be manipulated either by dietary means, phlebotomy or by pharmacological chelation 
of iron. Currently, the mainstay of treatment of T2DM consists mainly of controlling blood 
glucose at or near physiological levels in efforts to delay/prevent the chronic complication of 
diabetes. There are very few effective strategies aimed at primary prevention of IR in 
genetically-predisposed individuals. 
3.7.1 Serum ferritin levels and the risk of diabetes mellitus 
Serum ferritin levels in healthy individuals are generally considered to be a marker of body iron 
stores (189–191). A number of epidemiological studies have shown an association between 
increased serum ferritin levels and increased risk of developing diabetes mellitus (192,193). For 
example, the National Health and Nutrition Education Survey (NHANES), showed that the odds 
ratio for T2DM in males and females with serum ferritin > 300 µg/L was 4.94 and 3.61, 
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respectively (4). Even across the reference range of ferritin in apparently healthy women, the 
positive correlation between ferritin and diabetes risk remained strong (26).  
Ferritin levels are known to be elevated in conditions characterized by inflammation. Since 
inflammation plays an important role in the pathogenesis of diabetes, it is possible that elevated 
ferritin in this condition may be due to inflammation. However, multiple studies have shown that 
the association between ferritin and risk of diabetes remains strong after adjusting for potential 
confounding factors, including inflammation (5–9). These studies, therefore, suggest that 
elevated ferritin that is associated with diabetes is representative of increased body iron stores in 
this condition, and not of inflammation. 
Recently, the EPIC-InterAct study (194) studied serum levels of ferritin, iron and transferrin, as 
well as transferrin saturation, in 11,052 cases of incident diabetes and compared them to a 
random cohort of 15,182 individuals. The results of this large study confirmed the reported 
association between serum ferritin and diabetes; however, the other markers of iron status 
studied (serum iron, transferrin and transferrin saturation) did not show a positive association. In 
fact, among women, transferrin saturation > 45% was associated with a significant protective 
effect. These results were interpreted to suggest that “the underlying relationship between iron 
stores and T2DM is more complex than the simple link suggested by the association of ferritin 
with T2DM” (194). 
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3.7.2. Hereditary hemochromatosis and diabetes 
Hereditary hemochromatosis (HH) refers to a group of conditions characterized by decreased 
hepcidin secretion. Most patients with HH are homozygous for the C282Y substitution mutation 
in the HFE protein (classical or type 1 hemochromatosis). Classical hemochromatosis is highly 
prevalent in people of northern European ancestry. Other causes of hemochromatosis, like those 
associated with defects in hemojuvelin or hepcidin (type 2 or juvenile hemochromatosis), 
transferrin receptor 2 (type 3) and ferroportin (type 4) are relatively uncommon and are 
characterized by a more severe iron overload phenotype (195).  
HH was described initially as a triad of cirrhosis, skin pigmentation and diabetes mellitus 
(‘bronze diabetes’). The prevalence of diabetes among patients with HH has been reported to be 
highly variable (196,197). Earlier studies, which were based on a clinical diagnosis of HH, found 
a very high prevalence of diabetes in HH. However, newer studies, which are based on a 
definitive genetic diagnosis of HH, have found a lower prevalence of 13-22% for diabetes and 
18-30% for pre-diabetes (11,198). Nevertheless, these rates are much higher than the background 
prevalence rates of diabetes / pre-diabetes in this population (~5 – 10%). 
Diabetes associated with HH has a complex pathogenesis (199,200). McClain et al (2006) 
showed that among patients with HH who had pre-diabetes, the major metabolic defect was an 
impaired insulin secretory capacity (11). However, these patients were found to display insulin 
sensitivity, rather than IR. Most patients with HH who eventually developed overt diabetes were 
obese, an independent cause for IR. Similar results were obtained in a mouse model of 
hemochromatosis (Hfe
-/-
) where an insulin secretory defect was shown; these mice, however, 
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were insulin sensitive (19). Based on these findings, the authors have suggested that the primary 
defect in HH is impaired insulin secretion. Patients with HH seem to be unable to increase 
insulin secretion to compensate for IR induced by independent risk factors, such as obesity; they 
are therefore pre-disposed to develop diabetes. In support of these findings, it has been shown 
that patients with HH who underwent phlebotomy to reduce body iron stores, showed an 
improvement in insulin secretory capacity, but not in insulin sensitivity (198,201). 
3.7.3 Iron-loading anemias and diabetes 
Conditions characterized by ineffective erythropoiesis are associated with increased body iron 
stores and increased prevalence of diabetes. An example of such a condition is thalassemia 
where impaired production of globin chains results in severe anemia. These patients receive 
multiple blood transfusions, which eventually result in massive iron overload. It is also known 
that thalassemics who are not transfusion-dependent also develop iron overload, due to increased 
intestinal iron absorption (99,202).  
Patients with thalassemia have a high prevalence of diabetes (203,204). Multiple studies have 
shown that both insulin secretory defects and IR co-exist in these patients (12,205–207). Unlike 
in hereditary hemochromatosis, where a tendency towards improved insulin sensitivity has been 
demonstrated, IR is pre-dominant in thalassemia  and precedes the development of diabetes by 
several years (206,207). In addition, decreasing body iron stores through chelation therapy 
significantly improved insulin sensitivity in these patients (14,208). These findings suggest that 
iron plays a role in the pathogenesis of IR associated with iron-loading anemias, such as 
thalassemia. 
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It is not clearly known why iron overload in HH is associated with increased insulin sensitivity, 
while iron overload in thalassemia results in IR. One possible explanation is that this may be 
related to the differences in distribution of iron in the body in these two conditions. HH is 
characterized by a relative deficiency in hepcidin; hence, tissues that express the iron export 
protein ferroportin are relatively iron-depleted (209,210), while those that do not express 
ferroportin or take up non-transferrin bound iron (like the liver, pancreas and heart) are iron- 
overloaded (211). On the other hand, iron loading either due to multiple blood transfusions (as in 
thalassemia) results in induction of hepcidin. Increased hepcidin decreases ferroportin protein 
expression on the surface of cells, resulting in intracellular sequestration of iron (24). In this 
context, very little is known about iron levels in insulin-sensitive tissue, such as skeletal muscle 
and adipose tissue, in these two conditions.  
3.7.4. Evidence to suggest that iron plays a causal role in the pathogenesis of IR 
There is evidence to suggest that iron may play a causal role in the pathogenesis of IR. For 
example, incidence of diabetes in thalassemics has rapidly declined after aggressive iron 
chelation became a routine part of therapy in these patients (14). Insulin sensitivity has been 
shown to be improved by phlebotomy in patients with (15) or without T2DM (16). Phlebotomy 
or dietary iron restriction in Otsuka Long-Evans Tokushima Fatty (OLETF) rats, a model of 
T2DM, resulted in decreased average glycated hemoglobin levels (HbA1c) levels (18). 
Restriction of iron in diet or iron chelation was also shown to significantly protect leptin-
deficient ob/ob mice against diabetes (19). High dietary iron, on the other hand, induced IR in 
mice (17). The above reports show that depletion of body iron stores can increase insulin 
sensitivity, suggesting that iron may play a causative role in diabetes. 
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3.7.5 Iron and obesity-associated IR 
Inflammation in the adipose tissue plays a key role in the development of IR (161). Iron is 
important for adipocyte differentiation and adipose tissue hypertrophy/hyperplasia (212). Since 
inflammation is known to regulate systemic iron homeostasis, there is considerable amount of 
interest in elucidating the interplay between obesity, inflammation and iron homeostasis in 
adipose tissue. 
3.7.5.1 Effect of obesity on iron homeostasis 
Obesity can affect iron metabolism in a number of ways. For example, obesity is associated with 
a chronic, low-grade inflammatory state. Inflammation, acting via IL6-STAT3 signaling in 
hepatocytes, can increase hepcidin levels resulting in hypoferremia (112). In fact, multiple 
studies have shown that obesity is associated with anemia (213–215). 
Obesity has also been shown to be associated with changes in tissue iron content. It has been 
shown that high-fat diet-induced obesity in mice decreased liver iron stores (216,217). Other 
studies have shown that diet-induced obesity resulted in decreased intestinal iron absorption in a 
hepcidin-independent manner, thus contributing to the iron-deficient phenotype seen in these 
mice (218). 
3.7.5.2 Effect of iron on adipose tissue 
Iron is known to be essential for adipocyte differentiation and adipose tissue hypertrophy/ 
hyperplasia (212). Treatment of primary adipocytes with iron resulted in increased lipolysis. In 
addition, iron decreased insulin-dependent glucose uptake in these cells (219). In mice, a high-
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iron diet was shown to result in increased adipocyte iron stores and IR in the visceral adipose 
tissue (17). On the other hand, a low-iron diet was shown to improve insulin sensitivity in ob/ob 
mice (19). These results show that increased adipocyte iron can induce adipocyte IR. In addition, 
iron-induced lipolysis can increase free fatty acid release, ectopic lipid accumulation and 
systemic IR. 
Iron is critical for mitochondrial function (220). It has been shown that depletion of iron in 
adipocytes results in reduction in the transcription factor, Tfam, which decreases mitochondrial 
biogenesis and adipogenesis. On the other hand, excess iron was also associated with impaired 
adipocyte differentiation (221). Therefore, precise control of adipocyte iron concentrations is 
required for mitochondrial function in adipocytes.  
The adipose tissue is an endocrine organ that secretes a number of factors that play a critical role 
in maintaining whole-body energy homeostasis and insulin sensitivity (222,223). Of particular 
importance is the hormone, adiponectin. Adiponectin is an insulin-sensitizing hormone which is 
synthesized and secreted by adipocytes (224). It has been shown that mice fed a high-iron diet 
had decreased serum levels of adiponectin (225). Mice with adipocyte-specific iron overload 
(induced by adipocyte-specific deletion of ferroportin) show decreased mRNA expression of 
adiponectin (225). Similar findings were also seen in human studies where serum ferritin was 
shown to be inversely proportional to adiponectin levels (225–227). It has also been shown that 
serum ferritin levels correlated independently with increased adipocyte IR and decreased 
adiponectin after adjusting for a host of confounding factors (226).  
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Apart from adiponectin, adipocyte iron and serum ferritin levels are known to affect serum levels 
of other adipokines. For example, adipocyte-specific ferroportin knock-out mice were shown to 
have decreased levels of leptin, a hormone involved in regulation of whole-body energy 
homeostasis and food intake (228). Iron levels are also associated with alterations in resistin (17), 
visfatin (229) and retinol-binding protein-4 (230), all of which have been shown to play an 
important role in the development of IR. These results show that iron can play a role in the 
pathogenesis of IR by modulating the secretion of adipokines. 
Adipose tissue macrophages (ATMs) play an important role in adipose tissue inflammation and 
IR (167). It has been shown that ATMs regulate adipose tissue iron homeostasis as well (231). A 
subset of ATMs, with an iron-recycling phenotype, appears to be important in regulating 
adipocyte iron levels. These ATMs have a M2 (anti-inflammatory) phenotype, which is altered 
in obesity. High-fat feeding resulted in a decrease iron content in ATMs and an increase in iron 
in the adipocytes, which resulted in whole-body IR (217,231). 
3.7.6 Effect of iron on pancreatic beta cells and insulin secretory capacity 
Pancreatic beta cells tend to accumulate iron due the high expression of DMT-1 (232). DMT-1 
mediates the uptake of zinc, which is required for formation of insulin secretory vesicles. 
Increased iron in beta cells has been shown to impair its insulin secretory function. For example 
in hemochromatosis, glucose tolerance is primarily due to iron-induced decrease in insulin 
secretion. Both in humans with hemochromatosis as well as in Hfe
-/- 
mice, beta cell function 
tended to improve following iron depletion by phlebotomy (113,117,130). Ob/ob mice, which 
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were fed a low-iron diet or treated with iron chelators, showed significantly improved beta cell 
function (19).  
The mechanisms by which iron induces beta cell damage are not clearly known. Beta cells are 
highly susceptible to oxidative stress (233). It is possible that iron-induced oxidative stress may 
play a role in beta cell dysfunction (described in section 3.6). However, as mentioned above, beta 
cell dysfunction in humans with HH as well as in mouse models of this condition could be 
reversed by iron chelation or phlebotomy. It, therefore, appears that iron does not induce 
permanent damage in beta cells. However, the mechanisms involved and the relevance of iron in 
the pathogenesis of beta cell failure associated with T2DM requires further investigation.  
3.7.7 Molecular mechanisms by which iron affects insulin sensitivity and beta cell function 
Iron can affect insulin sensitivity and beta cell function in a number of ways (10).  
3.7.7.1 Oxidative stress and reactive oxygen species (ROS) 
Iron is a potent pro-oxidant. It can catalyze the formation of hydroxyl radicals through the 
Fenton reaction resulting in oxidative tissue damage. Both iron overload and iron deficiency has 
also been associated with oxidative stress (234).  
ROS can induce IR by multiple mechanisms. For example, oxidative stress can activate 
intracellular stress-sensitive pathways like nuclear factor-κB, p38 mitogen-activated protein 
kinase and JNK resulting in inhibition of insulin signaling via IRS1 and 2 (235). In addition, 
oxidative stress-induced activation of FoxO1, can result in sustained gluconeogenesis even in the 
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presence of insulin (236). It has also been shown that oxidative modification of phenylalanine 
residues on insulin can decrease its binding affinity to insulin receptors (237). 
Beta cells are prone to oxidative damage as they have low expression of anti-oxidant enzymes 
like catalase, glutathione peroxidase and superoxide dismutase (SOD) (238). Oxidative stress can 
impair glucose-induced insulin secretion and induce apoptosis in beta cells (239,240).  
 3.7.7.2 Hypoxia-inducible factors (HIFs) 
Iron is required for prolyl hydroxylase-mediated hydroxylation of HIFs which results in its 
ubiquitination and proteasomal degradation (241). Iron overload is therefore characterized by 
decreased HIF levels. In beta cells, decreased HIF-1α levels result in decreased expression of its 
target genes, Glut1 and Glut2. This results in impaired glucose-stimulated insulin secretion. On 
the other hand, stabilization of HIF-1α (by iron chelation) had the opposite effect (242).  
HIFs are also involved in glucose metabolism by increasing the expression of glucose 
transporters and stimulating glycolytic flux (243). For example, iron depletion augmented 
glucose uptake in the liver by stabilizing HIF-1α (244). 
 3.7.7.3 AMP-activated protein kinase 
AMP-activated protein kinase (AMPK) is a key cellular energy sensor (described in section 
3.3.4). Iron is known to activate AMPK in the liver and in the muscle; however the mechanisms 
that are involved are not clear (245). Increased intracellular iron can induce mitochondrial 
dysfunction resulting in an increase in the AMP/ATP ratio. A high AMP/ATP ratio is known to 
activate AMPK (141). On the other hand, iron-induced oxidative stress can activate the upstream 
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kinase of AMPK, liver kinase B1 (LKB1). Phosphorylation of AMPK by LKB1 can also result 
in AMPK activation (245,246). 
In addition to the above, iron can significantly affect insulin sensitivity through induction of 
epigenetic changes, modifying the activity of iron regulatory proteins (IRPS), regulation of 
circadian rhythms and by regulating the processing and maturation of microRNAs. 
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4. SCOPE AND PLAN OF WORK 
Type 2 diabetes mellitus (T2DM) is a global epidemic that is a major cause of morbidity and 
mortality, all over the world and especially in India. Over the last two decades, there is 
accumulating evidence from epidemiological studies which have shown a close association 
between increased body iron stores and risk of T2DM. However, the molecular basis of the 
cross-talk between iron metabolism and insulin resistance (IR), the hallmark of T2DM, is not 
clear. This study was designed to attempt to systematically study this association. It was 
envisaged that the results of this study would provide a clearer understanding of the role of iron 
in the pathogenesis of IR and also the effects of IR on iron homeostasis in the body. 
Currently, management of diabetes is primarily based on attempts to achieve adequate glycemic 
control in an effort to delay/prevent chronic complications of diabetes (such as nephropathy, 
neuropathy, and retinopathy). There are very few effective strategies aimed at primary 
prevention in genetically pre-disposed persons, other than measures to reduce body weight and 
increase physical activity. Iron stores in the body can be easily manipulated by dietary means, 
phlebotomy or by using iron chelators. A better understanding of the role of iron in the 
pathogenesis of diabetes will possibly provide newer therapeutic options, based on manipulation 
of body iron stores, in the management of diabetes.  
The hypothesis of this study (based on evidence available at the time of designing the study) was 
that increased cellular iron stores may induce IR by inhibiting insulin signaling. Compensatory 
hyperinsulinemia (in an effort to overcome IR) may have a stimulatory effect on erythropoiesis 
in the bone marrow. Increased expression of the erythroid regulators of hepcidin (induced by 
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stimulated erythropoiesis) may down-regulate expression of hepcidin (the chief regulator of iron 
homeostasis) in the liver. This may lead to increased duodenal iron absorption and a consequent 
increase in body iron stores, thus constituting a feed-forward (vicious) cycle. 
In order to test this hypothesis, we first studied the effect of increased intracellular iron on 
insulin signaling in mouse primary hepatocytes in vitro (Study 1). Hepatocytes are insulin-
sensitive cells. These studies were carried out in vitro to avoid factors operational in vivo that 
could potentially confound the effects of iron, per se, on hepatocytes that were of interest.  
In study 2, a time-course analysis of the interactions between IR and iron metabolism was carried 
out, using a mouse model of diabetes mellitus. The high-fat-feeding induced obesity model (in 
C57Bl/6 mice) is one of the most commonly used animal models for studies related to the 
pathogenesis of IR and T2DM. This model was used to study changes in systemic iron 
homeostasis that were induced by IR. 
In study 3, the mouse model of diabetes mellitus (used in study 2) was used to study the effects 
of IR on maturation of erythroid precursors in the bone marrow. In addition, bone marrow 
erythroid precursor cells were used to study expression of putative erythroid regulators of 
hepcidin. 
In study 4, patients newly diagnosed with diabetes or pre-diabetes and age-matched controls 
were recruited to study parameters associated with iron homeostasis. In addition, reticulocytes 
were isolated from blood obtained from these patients to study expression levels of the erythroid 
regulators of hepcidin. 
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In summary, an attempt was made to systematically study the inter-relationships between 
processes involved in iron homeostasis and IR, using in vitro (mouse primary hepatocytes in 
culture) and in vivo (high-fat diet induced IR in mice) models, as well as patients with 
diabetes/pre-diabetes. 
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5. MATERIALS AND METHODS 
5.1. Equipment used 
A. The following equipment available in the Basic Science Laboratory, Department of 
Biochemistry, Christian Medical College were used: 
a. Spectrophotometer (Shimadzu UV-1800, Shimadzu, Japan) 
b. Gel documentation system (Flourochem E system, ProteinSimple, USA) 
c. Gel documentation system (Flourochem SP, Alpha Innotech, USA) 
d. Conventional PCR thermocycler (2720 Thermocycler), Applied Biosystems, USA 
e. Real-time PCR thermocycler (Chromo4 DNA Engine, Bio-Rad, USA) 
f. NanoDrop spectrophotometer (NanoDrop 2000c, Thermo Fisher Scientific, USA) 
g. Elix and Milli Q ultra-pure water system (Millipore, USA) 
h. Horizontal electrophoresis system (Hoefer, Thermo Fisher Scientific, USA) 
i. SDS-PAGE and western blotting apparatus (Mini-PROTEAN 3, Bio-Rad, USA) 
j. Refrigerated table-top centrifuge (MPW R 350 R, MPW, Poland) 
k. Refrigerated table-top centrifuge (Rota 4R V/FM) centrifuge (Plasto Craft, India) 
l. Microplate reader (iMARK microplate reader, BioRad, USA) 
m. Mechanical homogenizer (Remi, Mumbai, India) 
n. pH meter (EasyFive Plus, Mettler Toledo, USA) 
o. Analytical Balance (Analytical Plus, Ohaus, USA) 
p. Test tube roller (250 RM, Tarsons, India) 
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B. The following equipment available in the Core Facility, Centre for Stem Cell Research, 
Christian Medial College, Vellore, was used: 
a. Flow cytometer (BD FACS Aria III, BD Biosciences, USA) 
b. Fluorescence microscope (Leica DMI6000B, Leica Camera AG, Germany) 
 
5.2. Materials 
A. The following chemicals were obtained from Sigma, India: 
Acrylamide, adenosine diphosphate, AEBSF, ammonium acetate, ammonium chloride, 
ammonium molybdate, ammonium persulfate, aprotinin, beta mercaptoethanol, bovine serum 
albumin (BSA), bromophenod blue, chloroform, diethyl pyrocarbonate, desferrioxamine, 
dithiotretol, ethylenediamine tetraacetic acid (EDTA) disodium, dimethyl sulfoxide (DMSO), 
Dulbecco’s modified Eagle’s medium (DMEM), ethylene glycol-bis(β-aminoethyl ether) 
tetraacetic acid, ferric ammonium citrate (FAC), formaldehyde, formamide, guanidium 
hydrochloride, HEPES, iron (standard), leupeptin, MOPS, sodium bicarbonate, isopropanol, 
sodium dodecyl sulphate, sodium metavanadate, PBS tablets, pepstatin, phenol red, 
phenylmethane sulfonyl fluoride (PMSF), sodium azide, sodium pyruvate, TEMED, tergitol 
(NP-40), thioglycollic acid, tris aminomethane, Trizma base, trypan blue and Tri-reagent. 
 
B. The following chemicals were obtained from Sisco Research Laboratories, India: 
Butanol, Coomassie brilliant blue, calcium chloride, dextrose, dinitro phenyl phosphate, 
glycine, potassium dihydrogen phosphate, potassium chloride, magnesium chloride, sodium 
acetate, disodium hydrogen phosphate, nicotinamide adenine dihydrogen phosphate 
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(reduced) (NADPH), sodium dihydrogen phosphate, sodium hydroxide, paraformaldehyde, 
sodium carbonate, sodium chloride, trichloroacetic acid and triton – X 
C. The following chemicals were obtained from Qualigens Fine Chemicals, Mumbai, India: 
Glacial acetic acid, sulphuric acid, hydrochloric acid, methanol and nitric acid 
D. Others chemical used: absolute alcohol (Hayman, England), agarose (Genei, Bangalore, 
India) 
E. All cell culture equipment/consumables (including plates, pipettes, scrapers etc.) were 
obtained from Eppendorf, Germany and Tarsons, India. 
F. All PCR-related consumables (96-well plates, strip tubes, caps etc.) were obtained from 
Axygen Scientific, Thermo Scientific, USA. 
G. All disposable microtubes, pipette tips etc. were obtained from Tarsons, India. 
H. Details of oligonucleotides (used for qPCR) and antibodies (used for western blotting and 
flow cytometry) are given in the methodology section of each study. 
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5.3. Methodology 
Study 1: Iron induces basal activation of Akt but decreases its activation in response to 
insulin in mouse primary hepatocytes 
Mouse primary hepatocytes were loaded with iron in vitro by incubation with ferric ammonium 
citrate (FAC). To study the effects of insulin, FAC-treated hepatocytes were incubated with 
insulin (10nM) for 5 minutes (for study of intracellular signaling events) or 3 h (for gene 
expression studies). Hepatic glucose production assays were carried out to provide a functional 
read-out of the effects of iron, both in the presence and absence of insulin.  
Details of all methods used are provided in the methodology section of study 1 (page 78). 
Study 2: Interactions between insulin resistance and dysregulated iron homeostasis, 
produced by high-fat feeding in mice: a time-course study 
Male C57Bl/6 mice were fed a high-fat diet (HFD) or control diet for various time periods (up to 
24 weeks). Glucose and insulin tolerance tests were carried out to monitor development of 
glucose intolerance and IR. Subsets of mice were euthanized after 4, 8, 12, 16, 20 or 24 weeks of 
feeding. Western blot analyses and qPCR were done to determine expression levels of various 
iron-related parameters in the liver, adipose tissue and duodenum. Iron content of various tissues 
was visualized, using perfusion Perls’ Prussian blue staining. Iron content was also measured in 
the liver, spleen, gonadal white adipose tissue (gWAT) and skeletal muscle. Serum levels of iron, 
hepcidin, ferritin, insulin, adiponectin, triglycerides, C-reactive protein and interleukin-6 (IL6) 
were estimated.  
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Details of all methods used are provided in the methodology section of study 2 (page 126). 
Study 3: Effect of high-fat diet-induced insulin resistance on erythroid maturation and 
erythroid regulators of hepcidin in the bone marrow in mice 
Terminal erythroid differentiation (TED) was studied in the bone marrow and spleen from mice 
fed a control diet or HFD for various durations (as detailed in Study 2), using flow cytometry. In 
addition, erythroid (TER119-positive) cells were isolated from the bone marrow and used to 
determine gene expression of the putative erythroid regulators of hepcidin (erythroferrone 
[ERFE], growth differentiation factor –15 [GDF-15] and twisted gastrulation factor –1 [TWSG-
1]). Serum levels of hemoglobin, GDF-15 and erythropoietin were estimated. 
Details of all methods used are provided in the methodology section of study 3 (page 192). 
Study 4: Dysregulated iron homeostasis in patients newly diagnosed with diabetes mellitus 
or pre-diabetes 
Adult males who were newly diagnosed to have diabetes mellitus (n=40) or pre-diabetes (n=40), 
based on fasting plasma glucose (FPG) levels (as per the criteria of the American Diabetic 
Association [ADA]), were the subjects of the study. Men, who were found to be normoglycemic, 
using the criteria of the ADA, were recruited as control subjects. Anthropometric measurements 
were made on all subjects. Blood samples were obtained for measurement of hematological 
parameters, markers of iron status (ferritin, hepcidin, iron, total iron-binding capacity and 
transferrin saturation), C-reactive protein (CRP) (marker of inflammation) and insulin. 
Homeostatic model assessment–insulin resistance (HOMA-IR) and HOMA-β (indices of insulin 
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resistance and pancreatic insulin secretory capacity respectively), were calculated. In addition, 
reticulocytes were isolated from peripheral venous blood obtained from a sub-set of control and 
diabetic patients to determine gene expression of erythroferrone, a factor known to regulate 
hepcidin levels. 
Details of all subjects who were part of this study and the various methods used are provided in 
the methodology section of study 4 (page 245). 
5.4. Statistical analysis 
Statistical Package for Social Scientists (SPSS), version 16.0, was used for all statistical 
analyses. The Shapiro-Wilk test was used to test for normality of distribution of data. For 
normally distributed data, one-way ANOVA followed by pair-wise comparisons using 
Bonferroni test was done. For skewed data, the Kruskal –Wallis test followed by pair-wise 
comparisons using Mann Whitney test was done. For correlational analysis, Pearson’s 
correlation was used for normally distributed data and Spearman’s correlation for skewed data. 
Multivariate analysis was done using linear regression. A p-value less than 0.05 was taken to 
indicate statistical significance in all cases. 
 
 
 
 
75 
 
STUDY 1 
Iron induces basal activation of Akt but decreases its activation in response to insulin in 
mouse primary hepatocytes 
1. Abstract 
An iron-overloaded state has been reported to be associated with insulin resistance. On the other 
hand, conditions where iron overload occurs primarily in the liver (such as classical 
hemochromatosis) have been reported to be associated with increased insulin sensitivity. The 
reasons for these contradictory finding are unclear. In this context, the effects of increased 
intracellular iron per se on insulin signaling in hepatocytes are not known. This study was 
designed to address this lacuna.   
Mouse primary hepatocytes were loaded with iron in vitro by incubation with ferric ammonium 
citrate (FAC). To study the effects of insulin, FAC-treated hepatocytes were incubated with 
insulin (10nM) for 5 minutes (for study of intracellular signaling events) or 3 h (for gene 
expression studies). Hepatic glucose production assays were carried out to provide a functional 
read-out of the effects of iron, both in the presence and absence of insulin.  
Iron-loading of hepatocytes in vitro resulted in phosphorylation-mediated activation of Akt (with 
accompanying downstream phosphorylation of glycogen synthase kinase 3β and forkhead box 
O1) and AMP-activated protein kinase. This was associated with decreased basal as well as 
forskolin-stimulated gluconeogenesis (forskolin being a glucagon agonist). Iron attenuated 
forskolin-mediated induction of the key gluconeogenic enzyme, glucose-6-phosphatase. It also 
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decreased activation of the Akt pathway in response to insulin, by decreasing protein levels of 
insulin receptor substrates 1 and 2, resulting in insulin resistance.   
Overall, these results show that increased intracellular iron appeared to have dual effects on 
insulin sensitivity in hepatocytes. It increased basal activation of the Akt pathway (in the absence 
of insulin), but decreased activation of this pathway in response to insulin. 
2. Introduction:  
Insulin resistance (IR) is the hallmark of type 2 diabetes mellitus (T2DM). Several lines of 
evidence suggest that iron plays a role in the pathogenesis of IR (10). For example, children with 
thalassemia major, who are treated with repeated blood transfusions and have increased body 
iron stores, develop hyperinsulinemia and IR before they develop diabetes (205). Aggressive iron 
chelation in thalassemics has reduced the incidence of diabetes in such patients (14). Further 
evidence for the role of iron in IR is provided by improvements in insulin sensitivity following 
phlebotomy, both in patients with T2DM (15) and in healthy individuals (16). Iron-deficient rats 
show increased peripheral glucose uptake in response to insulin (247,248). Phlebotomy or 
dietary iron restriction, in a rat model of T2DM, resulted in decreased glycated hemoglobin 
levels (18). Iron chelation significantly protected ob/ob mice from diabetes (19) and improved 
insulin signaling in the rat liver (244). On the other hand, mice fed a high-iron diet have been 
shown to develop insulin resistance (17).  
Hereditary hemochromatosis refers to a group of conditions characterized by increased body iron 
stores, which results from inappropriately low levels of hepcidin, the central iron regulatory 
hormone (249). Although raised iron stores are associated with IR (as described above), other 
studies have shown that insulin sensitivity (based on measurements of plasma glucose and 
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insulin in an OGTT) was increased in patients with classical hemochromatosis and in mouse 
models of the condition (Hfe
-/-
 mice) (11,246). The reason(s) for these apparently contradictory 
findings are not clear; they may be related to the fact that iron overload in hemochromatosis is 
primarily seen in the liver and not in other insulin-sensitive tissues, such as skeletal muscle and 
adipose tissue. Such differences in iron levels in tissues may potentially affect results from 
studies done in humans and animal models of hemochromatosis, as glucose tolerance in vivo is 
determined by factors that regulate insulin sensitivity in the liver and peripheral tissues. For 
example, insulin has been shown to suppress HGP indirectly by inhibiting lipolysis in adipose 
tissue and not only by acting directly on the liver (133). In this context, the effect of increased 
levels of iron per se on hepatic insulin signaling and HGP is unclear. Similarly, it has been 
shown that in mice fed a high-iron diet, AMPK is activated in the liver and skeletal muscle; this 
was associated with decreased HGP (245). However, it is not known whether the decrease in 
HGP in this context was a direct effect of increased levels of hepatic iron or mediated by the 
effects of iron overload in extra-hepatic tissues.  
In the current study, the effects of high intracellular iron levels on insulin signaling and HGP in 
mouse primary hepatocytes were determined. It was chosen to study these effects in vitro in 
order to avoid confounding factors that are operational in vivo that would influence the effects of 
interest in this study.  
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3. Methods: 
3.1. Animals 
Male C57Bl/6 mice, aged between 10 and 12 weeks, were used for all the experiments. These 
were carried out with the approval of the Institutional Animal Ethics Committee at Christian 
Medical College, Vellore, India (IAEC No. 14/2013), in accordance with the regulations of the 
Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA), 
Government of India. 
3.2. Isolation of mouse primary hepatocytes 
Primary hepatocytes were isolated from 8-12 weeks old, male C57Bl/6 mice, using a modified 
collagenase perfusion method, as described earlier (250), with some modifications (251,252). 
Under terminal anesthesia, the inferior vena cava (IVC) of the mouse was cannulated using a 
26G butterfly cannula. After successful cannulation, the portal vain was cut to allow blood to 
drain out. The liver was then perfused with 50 mL Hanks’s buffered salt solution (HBSS), 
containing 25mM HEPES and 0.5 mM EGTA, at a rate of 5-8 mL/min. This was followed by 
perfusion with 60-75 mL of digestion solution (DMEM with 5 mM glucose, 15mM HEPES and 
100 CDU/mL collagenase type IV [Worthington, UK]). Following digestion, the liver was 
excised and hepatocytes were liberated by gently tearing the capsule. The hepatocytes were 
passed through a 100 μm sieve filter, in order to remove tissue debris. The cells were washed 
thrice by adding serum-free DMEM, followed by centrifugation at 50g for 2 min (in order to 
remove hepatic non-parenchymal cells). The hepatocytes obtained in the pellet at the end of the 
centrifugations were re-suspended in DMEM with 10% fetal calf serum (FCS). Viability of the 
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isolated cells (as determined by trypan blue exclusion) was consistently found to be more than 
90%. The cells were seeded in 6 or 12-well collagen-coated plates at a density of 3 x 10
4
 cells 
per cm
2 
and allowed to adhere to the bottom of the wells for 2 h.  
3.3. Treatment of hepatocytes with iron, insulin and/or forskolin 
Two hours after seeding, cells were washed with PBS and maintained in serum-free DMEM.  
Ferric ammonium citrate (FAC) was added to each well. The concentrations used were 0, 7.5, 75 
or 750 µM concentrations. Incubations were carried out for 16 h. This was done to increase the 
intracellular iron content (253). To study the effects of insulin on control and FAC-treated 
hepatocytes, cells were washed with PBS at the end of the 16 hours of incubation. They were 
then treated with insulin (10nM) for 5 minutes (for study of intracellular signaling events) or 3 h 
(for gene expression studies). In a sub-set of hepatocytes treated with FAC (at 75μM) for 16 h, 
the cells were washed at the end of the incubations and then treated with desferrioxamine (DFO) 
(250μM) for 6 h, in order to chelate iron. 
3.4. Determination of cell viability 
At the end of the incubations with FAC, the viability of the cells was determined by MTT assay, 
estimation of lactate dehydrogenase (LDH) activity in the medium and by ethidium homodimer-
1 (EthD-1) staining. 
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 3.4.1 MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) assay 
Metabolically active and viable cells reduce MTT (yellow) to insoluble formazan crystals 
(purple) which are solubilized in isopropanol. The absorbance at 570 nm is indicative of viability 
of cells (254). 
For the MTT assay, hepatocytes were seeded in 12-well plates and incubated for 16 h, either with 
or without FAC at various doses (as described in sections 3.2 and 3.3). Following this, cells were 
washed twice with PBS; they were then incubated with 700 μL serum-free DMEM (without 
phenol red) containing MTT (0.5 mg/mL final conc.), for 4 h. After incubation, the medium was 
carefully removed and discarded. The MTT formazan formed was dissolved in 700 μL of 
isopropanol and its absorbance was measured at 570 nm. Results were expressed as fold-change 
compared to control cells that were not treated with FAC. 
 3.4.2 Lactate dehydrogenase (LDH) activity in the medium 
LDH is a cytosolic enzyme that is released into the medium when the cell membrane is damaged. 
Hence, LDH activity in the medium is often used as a marker of cellular damage in cells in 
culture (255) 
To estimate LDH activity in the medium, 0.1 mL of the medium was added to a reaction mixture, 
containing 2.7 mL of 0.2 M Tris (pH 7.3), 0.1 mL of 6.6 mM NADH and 0.1 mL of 30 mM 
sodium pyruvate. Changes in absorbance at 340 nm were recorded every minute for 5 minutes, 
using a UV- spectrophotometer (Shimadzu UV-1800, Japan). LDH activity was calculated using 
the molar absorptivity for NADH of 6.22 x 10
3 
M
-1
cm
-1
. 
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 3.4.3 Ethidium homodimer-1 (EthD-1) staining 
EthD-1 is a cell-impermeant dye, which is non-fluorescent when it remains extracellular in the 
absence of damage to cellular membranes. EthD-1 enters the cell under conditions where the cell 
membrane is damaged and binds to DNA in the nucleus, producing a bright red fluorescence. 
(255). 
Primary hepatocytes (in 12-well plates), treated with various doses of FAC (as described in 
section 3.2 and 3.2), were washed twice with PBS to remove all traces of the medium. Cells were 
then treated with 250 μL of PBS containing EthD-1 at a final concentration of 4 μM, and 
incubated in the dark for 30 min. Following this, cells were washed with PBS and viewed under 
a fluorescence microscope (Leica DMI6000B) (excitation wavelength = 528 nm, emission 
wavelength = 617 nm). Cells treated with 70% methanol for 30 min (dead cells) were used as 
positive control; dead cells showed bright red fluorescence.  
3.5. Calcein fluorescence quenching by intracellular labile iron  
After treatment with or without FAC, cells were washed twice with PBS and incubated with 
calcein-AM (2 μM final concentration) for 30 min. Following this, cells were washed again with 
PBS. Fluorescence in the cells was visualized under a fluorescence microscope (Leica 
DMI6000B), using the standard fluorescein filter. Intracellular labile iron is known to quench 
calcein fluorescence (256); hence, a decrease in green fluorescence was taken to indicate 
increased intracellular labile iron. 
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3.6. Hepatocyte glucose production assay: 
Hepatocyte glucose production assays were carried out as described earlier (251). Primary 
hepatocytes, incubated with or without FAC for 16 h, were washed twice with PBS and 
incubated in glucose and phenol red-free DMEM (D5030, Sigma-Aldrich, USA) for 1 hour (in 
order to deplete glycogen). Following this, cells were incubated in glucose production buffer, 
which consisted of glucose-free, phenol red-free DMEM supplemented with 44 mM NaHCO3, 2 
mM L-glutamine and 10 nM dexamethasone. Lactate/pyruvate (20mM/2mM) or glycerol 
(10mM), as appropriate, was added as the gluconeogenic substrate. In some subsets of wells, 
insulin (10 nM) and/or forskolin (activator of adenylyl cyclase and hence, mimics the action of 
glucagon) (25 µM) were added. The use of forskolin provided a positive control. After 3, 6, 9 
and 12 hours, an aliquot of the medium (60 μL) was removed for estimation of glucose, by the 
glucose oxidase-peroxidase (GOD-POD) method.  At the end of 12 h, cells were lysed with 
RIPA buffer. The protein content of the lysate was estimated, using the Pierce BCA protein 
assay kit (cat. no. 23225, Thermo Fisher Scientific, USA).  
3.7. Determination of gene expression by quantitative real-time PCR (qPCR): 
Quantitative RT-PCR was used to determine the mRNA expression of genes of interest.  
3.7.1 RNA isolation 
Primary hepatocytes, in 6-well plates, were homogenized in Tri-Reagent (Sigma) (0.5 mL per 
well) and transferred to RNAase-free microfuge tubes. RNA was isolated according to the 
manufacturer’s instructions. Briefly, 0.1 mL of chloroform (0.2 mL per mL of Tri-Reagent) was 
added to each tube; the contents of each tube were mixed vigorously, using a vortex mixer. The 
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tubes were then incubated on ice for 15 min. They were then centrifuged at 12,000g at 4°C for 15 
min. Following centrifugation, the samples separated into 3 distinct layers (lower red organic 
phase containing proteins, middle white interphase containing genomic DNA and upper colorless 
aqueous phase containing RNA). The upper aqueous phase was transferred into fresh tubes, and 
0.25 mL of isopropanol (0.5 mL per mL of Tri-Reagent) was added to precipitate RNA. Samples 
were mixed well and incubated on ice for 5-10 min. After incubation, the samples were 
centrifuged at 12000g for 10 min at 4°C. The precipitated RNA settled at the bottom and on the 
sides of the tube. The supernatant was discarded; the RNA precipitate was washed by adding 0.5 
mL of 75% ethanol (1 mL per mL of Tri-Reagent). The tubes were then centrifuged at 7500g for 
5 min at 4°C. The supernatant was discarded and RNA was allowed to dry on ice for 10-15 min. 
Following this, it was dissolved in 30-50 µL of DEPC water (depending upon the size of the 
pellet). Samples were incubated at 60°C for 5 min to help the RNA dissolve.  
 3.7.2. Quantification of RNA and assessment of purity 
RNA was quantified using a NanoDrop 2000c spectrophotometer (Thermo Fisher Scientific, 
USA). In order to do this, 1–1.5 μL of the dissolved RNA was placed on the pedestal of the 
instrument, to obtain the spectral output and to measure optical density at 260, 280 and 230 nm. 
Nucleic acids such as DNA and RNA absorb maximally at 260 nm. An optical density of 1.0 at 
260 nm indicates RNA concentration of 40 μg/mL; the RNA content of each sample was 
calculated accordingly. 
The purity of the isolated RNA was assessed based on the overall spectral output as well as the 
260/280 and 260/230 ratios (257).  Samples with a normal spectrum with a single peak at 260 nm 
as well as 260/280 and 260/230 ratios > 1.8 were considered to be of acceptable purity for 
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downstream applications (Fig 6.1.1-A). A low 260/280 ratio indicated contamination by phenol 
or protein. On the other hand, a low 260/230 ratio indicated contamination by constituents of the 
extraction reagent (such as guanidine).   
In cases where the 260/280 and/or 260/230 ratio was lesser than 1.8, the samples were subjected 
to further purification by ethanol precipitation. For this, samples were made up to 100 μL with 
DEPC-water; to this, 10 μL of 3M sodium acetate and 220 μL of ice-cold 100% ethanol were 
added and mixed well. Samples were incubated at -20°C for 1-2 hours (or overnight). Following 
this, they were centrifuged at 12,000g for 10 min at 4°C. The supernatant was discarded and the 
RNA pellet obtained was washed with 0.5 mL of 75% ethanol. The samples were then 
centrifuged at 12000g for 10 min at 4°C. The RNA pellet was allowed to dry on ice for 5-10 min 
and re-dissolved in sufficient volume of DEPC-water. The quantity of RNA obtained was 
estimated using the NanoDrop spectrophotometer, and purity was assessed as described earlier. 
 3.7.3 Assessment of integrity of isolated RNA by agarose gel electrophoresis 
The integrity of isolated RNA was assessed by denaturing RNA agarose gel electrophoresis 
(258). Intact RNA electrophoretically resolves into two distinct bands corresponding to 28S and 
l8S rRNAs. The appearance of these two bands, with the 28S band being approximately twice as 
dense as the 18S band, indicates that the RNA in the sample is intact (Fig 6.1.1-B). Degraded 
samples form a smear, rather than 2 distinct bands as described above. Presence of fluorescence 
within the well suggests contamination with genomic DNA. Such samples were subjected to 
DNAase treatment, using a commercially available kit as per manufacturer’s instructions (cat. 
no. AM1907, Ambion Turbo DNA-free kit, Thermo Fisher Scientific, USA). RNA samples were 
either used immediately for cDNA construction or stored at -70°C till further use. 
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 3.7.4 Complementary DNA (cDNA) construction 
The Reverse Transcriptase Core Kit (cat. no. RT-RTCK-03, Eurogentec, Belgium) was used for 
construction of cDNA, as per manufacturer’s instructions. One microgram of the isolated RNA 
was added to a reaction mixture that consisted of 5 mM MgCl2, 500 μM of each dNTP, 2.5 μM 
oligo d(T) primer, 0.4 U/μL RNAase inhibitor and 0.25 U/μL reverse transcriptase (EuroScript 
RT) in a total volume of 20 μL. Samples were incubated at 48°C for 30 minutes to complete the 
reverse transcription reaction. This was followed by incubation at 95°C for 5 minutes to 
inactivate the reverse transcriptase enzyme. cDNA samples were diluted 1:10, using DEPC-
water, prior to the PCR assay. All samples were stored at -20C°. 
 3.7.5 Quantitative PCR reactions 
Quantitative PCR reactions were carried out using the Takyon No ROX SYBR Master Mix 
dTTP Blue kit (cat. no. UF-NSMT-B0701, Eurogentec, Belgium), according to manufacturer’s 
instructions. All PCR reactions were run in duplicate in 96-well plates. Two microliters of 1:10 
diluted cDNA was added to a reaction mixture that consisted of the 2x Takyon master mix (5 μL) 
and forward and reverse primers (at a final concentration of 250 nM), in a total volume of 10 μL. 
The reactions were carried out on a BioRad Chromo4 thermal cycler. The conditions were: 95°C 
for 3 min (Takyon DNA polymerase activation) followed by 40 cycles of 95°C for 10 seconds 
(denaturation) and 60°C for 60 seconds (extension). The expression levels of the genes of 
interest were normalized to Rpl19, which was used as the reference gene. All primers were 
synthesized commercially and were purchased from Sigma, India. Sequences of all primers used 
are listed in Table 6.1.1. Primer pairs were standardized and melting curve analyses were done to 
validate the specificity and efficiency of qPCR reactions.  
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Table 6.1.1: Primers used for qPCR 
Sl. 
No. 
Gene 
Accession 
number 
Primer sequence 
Amplicon 
size (bp) 
1 Acaca1 
NM_13336
0.2  
5’-GCCTCTTCCTGACAAACGAG-3’ 
5’-TGACTGCCGAAACATCTCTG-3’ 
239 
2 Fasn 
NM_00798
8.3  
5’-AAGGCTGGGCTCTATGGATT-3’ 
5’-TGAGGCTGGGTTGATACCTC-3’ 
177 
3 G6pc 
NM_00806
1.3 
5’-TCTGTCCCGGATCTACCTTG-3’ 
5’-GTAGAATCCAAGCGCGAAAC-3’ 
172 
4 Irs1 
NM_01057
0.4  
5’-CCAGCCTGGCTATTTAGCTG-3’ 
5’-CCCAACTCAACTCCACCACT-3’ 
174 
5 Irs2 
NM_00108
1212.1 
5’-GTAGTTCAGGTCGCCTCTGC-3’ 
5’-CAGCTATTGGGACCACCACT-3’ 
190 
6 Gck 
NM_01029
2.4 
5’-TTGCAACACTCAGCCAGACA-3’ 
5’-TGCTCTACCAGAGTCAACGAC-3’ 
147 
7 Rpl19 
NM_00907
8.2 
5’- ATGAGTATGCTCAGGCTACAGA-3’ 
5’- GCATTGGCGATTTCATTGGTC-3’ 
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The Minimum Information for Publication of Quantitative Real-Time PCR Experiments (MIQE) 
check-list and qPCR primer validation data has been provided in Appendix I and II.  
3.8. Western blotting: 
Primary hepatocytes were homogenized in ice-cold RIPA buffer (Tris-HCl 10mM, NaCl 
140mM, EDTA 1.5mM, sodium deoxycholate 0.1%, Triton-X 1%, SDS 0.1%, pH 8.0), 
containing a cocktail of protease inhibitors (cat. no. 5872S, Cell Signaling Technology, USA). 
Homogenized samples were centrifuged at 14,000g for 20 min at 4°C to remove tissue debris. 
Protein content in the supernatant obtained was estimated using the Pierce BCA protein assay kit 
(cat. no. 23225, Thermo Fisher Scientific Inc., USA). The samples were stored at -70°C till 
further use. 
For electrophoretic separation of proteins, samples were heated at 95°C for 5 minutes in 
Laemmli buffer. They were loaded on 10% SDS-PAGE gels (25 μg protein) and subjected to 
electrophoresis at 80V for 90-120 min. Separated proteins were transferred onto PVDF 
membrane (0.45 μm pore size, Immobilon-P, Millipore, Merck, Germany) at 80V over 2 h. After 
completion of transfer, the membrane was washed with TBS-T (25 mM Tris pH 7.4, 3 mM KCl, 
140 mM NaCl, 0.02% Tween-20) and then blocked with 5% BSA (in TBS-T), at room 
temperature for 2 h. After blocking, the membrane was cut into strips based on the molecular 
weight of the proteins of interest and each strip was probed with the appropriate primary 
antibody, overnight at 4°C. Following incubation with the specific primary antibody, membranes 
were washed thrice (5 min per wash) with TBS-T and further probed with appropriate secondary 
antibody, over 2 hours at room temperature. After probing with the secondary antibody, the 
membrane was washed again with TBS-T. Bands obtained were detected using SuperSignal 
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West Dura Extended Duration chemiluminescence substrate kit (cat. no. 34075, Thermo Fisher 
Scientific, USA), according to the manufacturer’s instructions. The intensities of the bands were 
quantified using ImageJ software (NIH, USA); they were normalized to that of β-actin, which 
was used as a loading control. Sources and dilutions of primary and secondary antibodies used 
are shown in Table 6.1.2. 
3.9. Estimation of iron levels 
The iron content in the hepatocytes was measured by a spectrophotometric assay, as described 
previously (259), with certain modifications. Hepatocytes were lysed in RIPA buffer and lysates 
were centrifuged at 14,000g for 20 minutes. Forty microlitres of each supernatant were added to 
40 µL of acid reagent (3M hydrochloric acid and 10% trichloroacetic acid), mixed and incubated 
for 30 min at room temperature. Following acid digestion, samples were centrifuged at 10,000g 
for 10 min. Ten microlitres of the supernatant (acid extract) was mixed with 190 μL of 
chromogen reagent (4M sodium acetate containing 0.01% bathophenanthrolinedisulphonic acid 
and 0.1% thioglycollic acid). The absorbance of the reaction mixture was measured at 540 nm 
after an incubation period of 15 min, using iMark microplate reader (BioRad, USA), and 
compared to readings from a set of iron standards (Sigma, USA). The final results were 
normalized to the protein content of the RIPA lysates used. 
3.10. Statistical analyses: 
Statistical Package for Social Scientists (SPSS), version 16.0, was used for all statistical 
analyses. The Kruskal-Wallis test was used to look for effects of the various treatments on the 
parameters of interest. Pair-wise comparisons were done using the Mann-Whitney test.  
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Table 6.1.2: Primary and secondary antibodies 
Sl. 
No. 
Protein 
Primary antibody (source 
and dilution) 
Secondary antibody# 
1 Phospho-AKT (Thr308) CST* (#9275) 1: 1000 Anti-rabbit   
2 Phospho-AKT (Ser473) CST (#9271) 1: 1000 Anti-rabbit   
3 AKT CST (#9272) 1: 1000 Anti-rabbit   
4 Phospho-GSK3β (Ser9) CST (#5558) 1: 1000 Anti-rabbit   
5 GSK3β CST (#9315) 1: 1000 Anti-rabbit   
6 Phospho-FoxO1 (Ser256) CST (#9461) 1: 1000 Anti-rabbit   
7 FoxO1 CST (#9454) 1: 1000 Anti-rabbit   
8 Phospho-AMPKα (Thr172) CST (#2531) 1: 1000 Anti-rabbit   
9 AMPKα CST (#2532) 1: 1000 Anti-rabbit   
10 Phospho-ACC (Ser79) CST (#11818) 1: 1000 Anti-rabbit   
11 ACC CST (#3662) 1: 1000 Anti-rabbit   
12 IRS1 CST (#2390) 1: 1000 Anti-rabbit   
13 Phospho-IRS1 (Ser307) CST (#2381) 1: 1000 Anti-rabbit   
14 Phospho-IRS1 (Ser789) CST (#2389) 1: 1000 Anti-rabbit   
15 IRS2 CST (#4502) 1: 500 Anti-rabbit   
16 
Phospho-SAPK/JNK 
(Thr183/Tyr185) 
CST (#4668)1: 1000 Anti-rabbit   
17 Ferritin (light chain) 
Santa Cruz Biotechnology 
(sc-14420) 1:1000 
Anti-goat   
18 TfR1 
Invitrogen  (#13-6800)  
1: 500 
Anti-mouse   
19 Beta-actin 
Sigma-Aldrich (#A5316) 1: 
5000 
Anti-mouse   
* CST – Cell Signaling Technology, USA, # All secondary antibodies were purchased from Pierce 
(Thermo Fisher Scientific, USA) 
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Correlation analysis was done by Spearman’s correlation test. A p value of less than 0.05 was 
used to indicate statistical significance in all cases. Data was obtained from at least three 
independent experiments (primary hepatocytes isolated from at least 3 mice), with each done in 
duplicates or triplicates, under the specified conditions.              
 
 
 
 
 
 
 
 
 
 
 
 
                                                                
92 
 
4. Results: 
4.1. Treatment of hepatocytes with FAC increased intracellular iron content 
Primary hepatocytes, treated with FAC, showed increases in cellular iron content (Fig. 6.1.2-A). 
This was associated with increased protein levels of ferritin (Fig. 6.1.2-B) and decreased levels 
of transferrin receptor 1 (TfR1) protein (Fig 6.1.2-C), both of which are indicative of increased 
iron levels in the cells. Intracellular labile iron quenches calcein fluorescence and the degree of 
quenching is indicative of the intracellular labile iron pool (LIP) (256). Fluorescence 
microscopic imaging showed a decrease in calcein fluorescence in hepatocytes treated with FAC, 
indicating an increase in the LIP (Fig.6.1.3). These results show that FAC treatment resulted in 
an increase in intracellular iron, with a concomitant increase in the LIP.  
FAC treatment did not affect cell viability, as determined by the MTT assay (Fig. 6.1.4-A). Cell 
viability was also assessed by estimating LDH in the medium used for cell culture. There was a 
small, but significant, increase in LDH activity in the medium, at the highest dose of FAC used 
(750 μM) (Fig. 6.1.4.-B). Similarly, fluorescence microscopic imaging of cells stained with 
ethidium homodimer-1 showed a small increase in red fluorescence (indicative of cell damage) 
only in cells treated with 750 μM FAC (Fig. 6.1.5). There was, however, no change seen in cells 
treated with 7.5 and 75 μM FAC compared to untreated cells. These 2 concentrations (and not 
the 750 μM concentration) are the ones at which effects of interest were seen in the present 
study, as will be shown in the results described below. 
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4.2. Treatment with FAC increased phosphorylation of Akt and its downstream targets, Gsk3β 
and FoxO1 
Activation of Akt involves phosphorylation at Thr308 and Ser473 (260). FAC treatment resulted 
in increases in phosphorylation of Akt at both Thr308 and Ser473, without affecting total Akt 
levels (Fig. 6.1.6-A, B). Increased phosphorylation of downstream targets of Akt activation, viz. 
Gsk3β (Fig. 6.1.7-A) and FoxO1 (Fig. 6.1.7-B), was also seen.  Incubation of hepatocytes with 
DFO (250µM), an iron chelator, for 6 h after pre-treatment with FAC (for 16 h) resulted in 
significant decreases in intracellular iron content (Fig. 6.1.8-A) and was associated with 
attenuation of iron-induced Akt phosphorylation (Fig. 6.1.8-B). 
4.3. Treatment with FAC activated AMP-activated kinase (AMPK)  
Since AMPK activation is known to trigger the phosphorylation and activation of Akt and 
GSK3β in the liver (261), the effect of iron on AMPK was examined in the current study. 
Treatment with FAC induced an increase in phosphorylation of AMPK at Thr172 (Fig. 6.1.9-A). 
The downstream target of AMPK, acetyl CoA carboxylase (ACC), was also found to be 
phosphorylated (at Ser79) (Fig. 6.1.9-B). Activated AMPK is known to phosphorylate and 
inhibit sterol response element-binding protein 1c (SREBP-1c), resulting in suppression of 
lipogenesis, by decreasing mRNA levels of ACC (Acaca) and fatty acid synthase (Fasn) 
(262,263). In addition, SREBP-1c inhibition results in induction of Irs2 but not of Irs 1 (264). In 
keeping with these reported effects, in the present study treatment with FAC was found to reduce 
mRNA expression of Acaca and Fasn, and increase the expression of Irs2 (Fig. 6.1.10–A, B and 
C). No significant changes were seen in Irs1 expression (Fig. 6.1.10-D). 
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4.4. Treatment with FAC decreased hepatocyte glucose production  
In order to assess the functional consequences of activation of the Akt and AMPK pathways by 
iron, hepatocyte glucose production (HGP) was measured, both in the presence and absence of 
FAC, using either lactate or glycerol as the gluconeogenic substrate. FAC was used at 
concentrations of 7.5 μM and 75 μM for these measurements, avoiding the concentration of 750 
μM at which some extent of cell damage was observed (Fig. 6.1.4 and 6.1.5). Hepatocytes 
treated with FAC at 75 μM showed significantly lower HGP, when compared to control cells or 
those treated with FAC 7.5 μM; the effects seen were similar irrespective of the use of lactate or 
glycerol as the gluconeogenic substrate (Fig. 6.1.11-A and C). At 7.5 μM, FAC tended to lower 
glucose production, when compared to control cells, with the effects being statistically 
significant at 3 and 6 hrs (in the case of lactate-driven basal HGP) (Fig. 6.1.11-A). Forskolin, an 
adenylyl cyclase activator that mimics the effects of glucagon in hepatocytes (265), was used to 
induce HGP and served as a positive control. Forskolin-induced HGP was significantly 
attenuated by FAC (75 μM) treatment (Fig. 6.1.11-B and D). These results show that iron 
significantly decreased both basal and forskolin-induced HGP in hepatocytes. Addition of insulin 
(10 nM) to the medium did not significantly affect basal or forskolin-stimulated HGP induced by 
lactate or glycerol (Fig. 6.1.12), except for a significant decrease in HGP from lactate in the 
presence of FAC at 75 µM, after 12 hours of incubation (Fig. 6.1.12-A). 
Since similar changes in HGP were seen, irrespective of lactate or glycerol being used as the 
gluconeogenic substrate, changes in gene expression of G6pc, an enzyme involved in 
gluconeogenesis from both of these substrates, was investigated. Glucagon, and other adenylyl 
cyclase activators such as forskolin, are known to induce the expression of G6pc in hepatocytes 
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(130). FAC treatment decreased forskolin-induced transcriptional activation of G6pc (Fig. 
6.1.13). In the absence of forskolin, however, FAC treatment (at 75μM) resulted in a small but 
significant increase in expression of G6pc (Fig. 6.1.13).  
4.5. Treatment with iron rendered hepatocytes less sensitive to insulin-induced activation of the 
Akt pathway 
To assess the effect of iron on insulin-induced activation of the Akt pathway, hepatocytes were 
incubated with varying doses of FAC for 16 h, and then treated with insulin (10nM) for 5 min. 
Insulin-induced activation of Akt (Fig. 6.1.14-A), as well as Gsk3β (Fig. 6.1.14-B) (the 
downstream target of activated Akt), was significantly attenuated by treatment with iron. 
Consistent with this, insulin did not suppress G6pc (Fig. 6.1.15-A) or induce glucokinase (Gck) 
(Fig. 6.1.15-B) in FAC-treated hepatocytes. Both of these are known responses to insulin and 
were seen in the absence of FAC treatment (Fig. 6.1.15). These results suggest that increased 
intracellular iron rendered hepatocytes resistant to the effects of insulin.  
4.6. Iron down-regulated protein levels of IRS1 and IRS2  
Insulin receptor substrates 1 and 2 (IRS 1 and 2) are upstream of Akt in the insulin signaling 
pathway. FAC treatment induced decreases in protein levels of IRS1 and IRS2 (Fig. 6.1.16-A 
and B). Phosphorylation of IRS1 at Ser307 (Fig. 6.1.17-A) and Ser789 (Fig. 6.1.17-B), both of 
which are known to inhibit signaling via IRS-1, tended to increase progressively in response to 
increasing concentrations of FAC. However, there was no demonstrable activation of JNK (c-Jun 
N-terminal kinase), a stress-induced kinase known to phosphorylate IRS1 at Ser307 (Fig. 
6.1.18).  
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4.7. Correlation analyses 
Results of correlation analyses showed that, in FAC-treated hepatocytes, intracellular iron levels 
were significantly and positively correlated with p-Akt (Ser473), p-Akt (Thr308), p-Gsk3β 
(Ser9), p-FoxO1 (Ser256) and p-AMPK (Thr172), and negatively correlated with IRS1 and IRS2 
protein levels. In addition, markers of insulin signaling (p-Akt [Ser473], p-Akt [Thr308], p-Gsk 
[Ser9] and p-FoxO1 [Ser256]) were significantly and positively correlated with one another and 
with p-AMPK (Thr172) (Table 6.1.3).  
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Table 6.1.3: Correlation analyses among parameters of interest in primary hepatocytes 
treated with FAC 
Sl. 
no 
Parameter Parameter Spearman’s 
correlation 
coefficient 
p-value 
1 Intracellular iron level vs. p-Akt (Ser473) 0.648 0.004 
p-Akt (Thr308) 0.843 <0.001 
p-Gsk3β (Ser9) 0.771 0.003 
p-FoxO1 
(Ser256) 
0.652 0.008 
p-AMPK 
(Thr172) 
0.812 <0.001 
p-IRS1 (Ser307) 0.470 0.049 
Total IRS1 - 0.667 0.002 
Total IRS2 - 0.684 0.007 
2 p-Akt (Ser473) vs. p-Akt (Thr308) 0.671 0.004 
p-Gsk3β (Ser9) 0.638 0.025 
p-FoxO1 
(Ser256) 
0.574 0.020 
p-AMPK 
(Thr172) 
0.649 0.001 
3 p-Akt (Thr308) vs. p-Gsk3β (Ser9) 0.997 <0.001 
p-FoxO1 
(Ser256) 
0.641 0.007 
p-AMPK 
(Thr172) 
0.747 0.001 
4 p-Gsk3β (Ser9) vs. p-FoxO1 
(Ser256) 
0.713 0.009 
p-AMPK 
(Thr172) 
0.716 0.009 
5 p-FoxO1 (Ser256) vs. p-AMPK 
(Thr172) 
0.515 0.041 
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5. Discussion 
Molecular interactions between insulin signaling and iron in hepatocytes, and their net effect on 
HGP have not been clearly elucidated, as far as is ascertainable from published literature. The 
present study was an attempt to address this lacuna. Mouse primary hepatocytes, which were 
iron-loaded in vitro by incubation with FAC at various concentrations, were used in the present 
study to investigate this. Studies that report findings from work done with primary hepatocytes 
usually report data obtained from at least three independent experiments (primary hepatocytes 
isolated from at least 3 mice), with each done in duplicates or triplicates, under the specified 
conditions (146,266,267). In keeping with this, the present study also shows data obtained from 
experiments done on hepatocytes isolated from at least three different mice. 
The rationale for treating hepatocytes with FAC (a highly soluble form of iron) was to rapidly 
increase intracellular iron content. This model was not meant to mimic a 
physiological/pathological condition in vivo, where iron accumulation tends to occur over a 
prolonged period. The doses of FAC chosen were based on a previous publication, where 
primary hepatocytes treated with similar doses of FAC showed increases in intracellular iron 
levels, without a concomitant decrease in cell viability (253).  In addition, FAC was chosen 
because ferric citrate is a physiologically relevant form of iron. It has been shown that non-
transferrin bound iron (NTBI), which increases in blood in conditions of iron overload (such as 
hemochromatosis and thalassemia), is mainly found as ferric citrate (268,269).  
Treatment of hepatocytes with FAC resulted in increases in intracellular iron content (Fig. 6.1.2). 
There was a concern about the viability of cells incubated with FAC in this study. The MTT 
assay showed no significant damage to the cells even at the highest dose of FAC used. There was 
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a small but significant increase in LDH activity in the medium and increased fluorescence of 
EthD-1 staining at the highest dose of FAC used (750 µM) (Fig 6.1.4-B and 6.1.5). This showed 
that FAC, at this dose, induced cell damage to a certain extent. However, all the effects of 
interest produced by treatment with FAC, which are reported in this study, were seen at 7.5 and 
75 µM concentrations.  No decrease in cell viability was seen at these doses (Fig 6.1.4 and 
6.1.5).  
The results of the present study are summarized in Fig 6.1.19. Overall, the results show that 
increases in intracellular iron had dual effects on insulin sensitivity in hepatocytes. On one hand, 
iron activated the Akt signaling pathway in hepatocytes in a ligand-independent manner, i.e., 
even in the absence of insulin (Fig. 6.1.6 and 6.1.7). In addition, iron activated AMPK, a key 
energy-sensing pathway, which inhibits gluconeogenesis (Fig. 6.1.9). Consequently, 
gluconeogenesis was down-regulated and HGP was decreased by increased levels of intracellular 
iron (Fig. 6.1.11). On the other hand, iron decreased activation of the Akt pathway in response to 
insulin (Fig. 6.1.14), by decreasing levels of IRS 1 and 2 (Fig. 6.1.16), resulting in insulin 
resistance. The findings of this study provide a plausible explanation for why iron overload, in 
general, is associated with insulin resistance, but why improved glucose tolerance and insulin 
sensitivity is seen in classical hemochromatosis (characterized by iron overload primarily in the 
liver) (11,246).  As far as is ascertainable, these findings, in mouse primary hepatocytes, are 
novel and have not been reported earlier. 
117 
 
 
 
 
118 
 
AMPK is activated by its upstream kinase, liver kinase B1 (LKB1), by phosphorylation at 
Thr172 (141). It has been shown previously that LKB1 and AMPK were activated in the liver 
and skeletal muscle of mice fed a high-iron diet (245). Ligand-independent activation of the Akt 
pathway has been shown to occur in response to activation of AMPK (270,271), thus suggesting 
a likely mechanism by which Akt phosphorylation is induced by iron. FAC treatment resulted in 
activation of AMPK, which was highly correlated with phosphorylation of Akt at both Thr308 
and Ser473 (Table 6.1.3). It is, therefore, possible that iron-induced activation of Akt may be 
mediated by AMPK activation. Additional studies with genetic knock-down or pharmacological 
inhibition of AMPK would be required to confirm this.  
Iron decreased basal as well as forskolin-induced HGP (Fig. 6.1.11). Iron also decreased 
forskolin-induced mRNA expression of G6pc (Fig. 6.1.13).  Activation of AMPK has been 
shown to decrease HGP by inducing the phosphorylation and inactivation of CREB-regulated 
transcription co-activator 2 (CRTC2), a key transcriptional co-activator involved in induction of 
gluconeogenic genes by glucagon (145). In addition, AMPK inhibits glucagon-induced increase 
in G6pc expression by activating phosphodiesterase-mediated cAMP degradation (146). 
Activation of the Akt pathway also results in suppression of gluconeogenesis by inhibiting 
FoxO1-induced expression of G6pc (272,273). Therefore, iron-induced activation of Akt and 
AMPK pathways can explain the decrease in HGP and G6pc expression in this setting. 
In the absence of forskolin, despite the fact that iron inhibited HGP, expression of G6pc was not 
found to be decreased; in fact, iron induced a small but significant increase in the mRNA levels 
of these enzymes (Fig. 6.1.13). The reason(s) for decreased HGP in the absence of a decrease in 
G6pc is/are not totally clear; however, it has been shown that activation of AMPK can decrease 
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HGP by allosteric/covalent regulation of the gluconeogenic flux, even in the absence of 
significant decreases in mRNA levels of gluconeogenic genes (146). In fact, it is well established 
that HGP in vivo is regulated by post-translational mechanisms through the control of substrate 
flux, rather than exclusively by changes in gene expression (131). A possible explanation for the 
increase in G6pc expression induced by FAC treatment (at 75 μM) (Fig 6.1.13 and 6.1.15-A) 
may be iron-induced mitochondrial dysfunction, which has been shown to occur in response to 
iron overload and result in increased expression of gluconeogenic genes (274).  
Although treatment with iron activated the Akt pathway, insulin-induced phosphorylation of Akt 
(and its downstream target, GSK3β) was significantly decreased in iron-loaded hepatocytes (Fig 
6.1.14), suggesting that an iron-overloaded state results in resistance to the actions of insulin. 
The functional consequences of this observation were studied by investigating changes in HGP 
in response to insulin treatment. However, insulin did not have an effect on HGP, neither in the 
presence of forskolin nor in its absence (Fig 6.1.12). This is consistent with recent studies which 
have shown that direct insulin signaling in hepatocytes is dispensable for insulin-mediated down-
regulation of HGP (133,134). Regulation of HGP by insulin in vivo has been suggested to be 
mediated by an intermediate extra-hepatic organ/tissue; this is possibly the adipose tissue, via 
changes in free fatty acid levels in blood (136).   
In the present study, iron induced a progressive decrease in IRS1 and IRS2 protein levels (Fig. 
6.1.16). Since IRS1 and IRS2 are up-stream of Akt in the insulin signaling cascade, a decrease in 
the levels of these proteins may account for the impaired phosphorylation and decreased 
activation of Akt induced by insulin in these cells. Phosphorylation of IRS1 at Ser307 and its 
subsequent degradation has been proposed to play a key role in the development of insulin 
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resistance (275). Stress-induced protein kinases, including JNK and mTOR, are known to 
increase phosphorylation of IRS1 at Ser307 (276,277).  Treatment with iron induced an increase 
in the p-IRS1 (Ser307)/total IRS1 ratio (Fig. 6.1.17-A), but did not activate JNK (Fig. 6.1.18). It 
is possible that increased phosphorylation of IRS1 at Ser307 in this setting may be mediated by 
mTOR; this was not investigated in the present study and is a possibility that requires further 
exploration. In addition, iron induced IRS1 phosphorylation at Ser789 (Fig. 6.1.17-B), which is 
known to be mediated by AMPK, and to inhibit signal transduction via IRS1 (270,278). 
Findings of increased basal, but decreased insulin-stimulated Akt activation (as seen in the 
present study) have been shown previously to result in insulin resistance. For example, it has 
been shown that overexpression of a constitutively active form of Akt increased basal glucose 
uptake, but blunted insulin-induced glucose uptake in cardiomyocytes (279). Similarly, 
cardiomyocytes that over-express FoxO1 showed elevated basal, but impaired insulin-stimulated 
Akt phosphorylation and downstream insulin signaling (280). Hfe
-/-
 mice, a model of 
hemochromatosis, also show increased basal, but not insulin-stimulated glucose uptake in the 
skeletal muscle (246). Impaired activation of Akt in response to insulin treatment has also been 
shown in AML-2 mouse hepatocyte cell lines which were iron-loaded (281). The above reports, 
thus, support the findings of the present study. 
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6. Summary and conclusion 
In conclusion, the results of this study show that increased levels of intracellular iron, in mouse 
primary hepatocytes, activated the Akt and AMPK pathways and resulted in decreased HGP. 
Insulin-induced activation of the Akt pathway was, however, impaired in cells with increased 
levels of intracellular iron, possibly due to decreased protein levels of IRS1/2. These findings are 
of relevance in disease conditions characterized by hepatic iron overload (such as 
hemochromatosis, thalassemia and non-alcoholic steatohepatitis), which are known to be 
associated with increased risk of type 2 diabetes. 
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STUDY 2 
Interactions between insulin resistance and dysregulated iron homeostasis, produced by 
high-fat feeding in mice: a time-course study 
1. Abstract  
Increased body iron stores have been reported to be associated with type 2 diabetes mellitus 
(T2DM). However, the temporal association between onset of insulin resistance (IR) in T2DM 
and dysregulated iron homeostasis, and the cross-talk between the various events involved, are 
unclear. In an attempt to address these lacunae, a time-course study was carried out to determine 
the interplay between IR and systemic iron homeostasis, in mice fed a high-fat diet in order to 
induce IR.  
Male C57Bl/6J mice were fed a high-fat (HFD) or control diet for various time periods (4, 8, 12, 
16, 20 or 24 weeks). High-fat feeding induced obesity, hepato-steatosis and insulin resistance 
(IR) in mice. It also resulted in dysregulation of iron homeostasis in the liver as well as the 
adipose tissue. There was a progressive decline in hepatic iron stores with increasing durations of 
HFD-feeding. This was associated with an increase in iron content of the adipose tissue. 
Triglyceride levels in the liver correlated positively with IR and negatively with liver iron 
content; these associations remained significant after adjusting for potential confounders, using 
multiple linear regression analysis. The onset of IR (at 8 weeks), as determined by insulin 
tolerance test, preceded the onset of hepatic iron dysregulation (at 12 weeks). Hepatic expression 
of hepcidin, the chief iron regulatory hormone, was decreased after 24 weeks of HFD and was 
found to correlate positively with protein levels of transferrin receptor 2 in the liver. Other 
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factors known to regulate hepcidin, such as bone morphogenetic protein 6, matriptase–2, serum 
iron levels and inflammation, were not affected by HFD.  
In summary, the results of this study showed that IR induced by HFD-feeding was associated 
with dysregulation of iron homeostasis in the liver and adipose tissue. The onset of IR in HFD-
fed mice preceded that of hepatic iron dysregulation, suggesting that changes in iron homeostasis 
may not play a causative role in the pathogenesis of IR in this model. 
2. Introduction 
Insulin resistance (IR) is the hallmark of type 2 diabetes mellitus (T2DM). It is characterized by 
impaired sensitivity of tissues to the actions of insulin. Several studies have shown a strong 
association between increased levels of serum ferritin (generally considered to be a marker of 
body iron stores) and increased risk of T2DM (4,282,6,283,284). However, serum ferritin is an 
acute phase reactant; its levels are increased in inflammatory conditions (285,286). Since, T2DM 
is associated with chronic low-grade inflammation (287), it is possible that the raised serum 
ferritin levels seen in T2DM may be a consequence of inflammation. The results of the EPIC-
InterAct study showed that other markers of iron status, such as transferrin saturation and serum 
iron, were not associated with increased risk of T2DM (194). In fact, increased transferrin 
saturation (>45%) was reported to be associated with a lower risk of T2DM among women 
(194). It, thus, appears that the association between body iron stores and T2DM is complex and 
is not completely understood.  
Hepcidin, a peptide synthesized and secreted by the liver, is the chief regulator of systemic iron 
homeostasis (32). It regulates systemic iron fluxes and plasma iron levels by binding to 
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ferroportin, the cellular iron export protein, causing its internalization and degradation (24). 
Thus, hepcidin inhibits recycling of iron from macrophages and also decreases intestinal 
absorption of dietary iron.  
A number of factors regulate hepatic hepcidin (Hamp1) expression; these include liver iron 
stores, serum iron levels, inflammation and the erythropoietic drive (31). Regulation of hepcidin 
in response to changes in liver and serum iron levels is mediated predominantly through 
signaling via the BMP-SMAD pathway (66). Although multiple bone morphogenetic proteins 
(BMPs) induce hepcidin, in mice it has been shown that BMP6 is probably the most important 
regulator of the Hamp1 gene in vivo (72). BMP6, in turn, is regulated by hepatic iron stores 
(288). Matriptase-2, a membrane-associated serine protease (Tmprss6), regulates hepcidin 
expression by down-regulating signaling via the BMP-SMAD pathway (77,78). It has been 
shown that hepatic iron stores can regulate Hamp1 expression by modulating Tmprss6 
expression (94). On the other hand, serum iron levels regulate Hamp1 by activating BMP-SMAD 
signaling (independent of BMP6) through a multi-protein complex in which the 
hemochromatosis protein (HFE), hemojuvelin (HJV) and transferrin receptor 2 (TfR2) are 
essential components (86,289).  
Obesity is known to be associated with dysregulation of iron homeostasis  (290–292); however, 
it is not clear whether IR, which is frequently associated with obesity, is a cause or consequence 
of iron dysregulation. In addition, the temporal association between onset of IR and that of 
dysregulated iron homeostasis (including changes in hepcidin, liver iron stores and various 
factors that regulate hepcidin [as described above]), is not clear. 
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IR is associated with chronic low-grade inflammation (287). Systemic inflammation can induce 
Hamp1 through the JAK-STAT3 pathway, activated by interleukin-6 (IL-6) (112). However, 
whether IR-associated inflammation has a significant effect on hepcidin is not clear.  
Adipose tissue metabolism is known to have a major impact on energy homeostasis in the body 
(293). Inflammation in the adipose tissue is a key factor that is involved in initiating and driving 
whole-body insulin resistance in response to obesity (294). It has been shown, both in humans 
and in mice, that increased iron content in the adipose tissue is associated with elevated IR 
(17,226). In addition, adipocyte iron has been shown to regulate the expression of adipokines, 
such as adiponectin (225) and leptin (228), which play critical roles in energy homeostasis. 
However, very little is known about the effect of IR on adipose tissue iron homeostasis. In 
addition, it is not known whether elevated iron content in the adipose tissue is a cause or 
consequence of IR.  
In summary, although increased body iron has been proposed to be associated with T2DM, the 
precise nature of the mechanistic link between iron and IR is not known. For example, the effects 
of IR on iron homeostasis in the liver and adipose tissue are not clear. It is also not known 
whether dysregulation of iron homeostasis is a cause or consequence of IR. The effect of IR on 
hepcidin and the various factors that regulate it (as described above) is not clear. In an attempt to 
answer these questions, a time-course study was carried out in high-fat diet-fed male C57Bl/6J 
mice, which is one of the most commonly used mouse models of T2DM (295).  
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3. Methodology 
3.1. Experimental protocol: 
Male C57Bl/6J mice were used for the study.  All experiments were carried out with the 
approval of the Institutional Animal Ethics Committee at Christian Medical College, Vellore, 
India (IAEC No. 14/2013), in accordance with the regulations of the Committee for the Purpose 
of Control and Supervision of Experiments on Animals (CPCSEA), Government of India.   
At 7 weeks of age, mice were shifted from a regular chow diet (cat no. #D131; Scientific Animal 
Food and Engineering [SAFE], France) to a control diet (CD) (cat no. #D12450J [10% of total 
calories derived from fat]; Research Diets, Inc., USA). Starting at 8 weeks of age, mice were 
either fed a high-fat diet (HFD) (cat no. #D12492 [60% of total calories derived from fat]; 
Research Diets, Inc., USA) or continued on CD for 4, 8, 12, 16, 20 or 24 weeks (Fig 6.2.1). The 
composition of the diets is provided in Appendix III and IV (page 330 and 331). The iron content 
of the regular chow diet (used after weaning and up to 7 weeks of age) was 250 mg/kg, and that 
of CD and HFD were 43 mg Fe/ kg and 58 mg Fe/kg respectively (290,296,297). All mice had 
access to food and water ad libitum. Food intake and weight gain in each mouse were monitored 
at weekly intervals. 
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3.2. Evaluation of insulin sensitivity in vivo 
Glucose tolerance (GTT) and insulin tolerance tests (ITT) were carried out, as described below, 
in order to assess insulin sensitivity in the experimental mice. 
3.2.1 Intraperitoneal glucose tolerance test (GTT) (298) 
GTT was done 3 days prior to euthanasia in mice fed CD or HFD for various durations (as 
described above). To assess glucose tolerance, mice were placed in fresh cages and fasted for 6 
hours with free access to water. They were then given an intra-peritoneal injection of glucose 
(2g/kg body weight). Blood samples were obtained from the tail vein immediately before the 
dose of glucose and 15, 30, 60 and 120 min after it. Glucose levels in these samples were 
estimated, using a glucometer (Bayer Contour, USA).  
3.2.2. Insulin tolerance test (ITT) (299) 
ITT was done 1 day prior to euthanasia in mice fed CD or HFD for various durations. To assess 
insulin tolerance, mice were placed in fresh cages and fasted for 4 hours with free access to 
water. They were then given an intra-peritoneal injection of insulin (Actrapid Human insulin, 
Novo Nordisk, Copenhagen, Denmark) (0.75 U/kg body weight).  Glucose levels were estimated 
in blood samples obtained from the tail vein (using a glucometer), immediately before the insulin 
injection and 15, 30, 45 and 60 min later. 
For both GTT and ITT, the glucose values obtained for each mouse was plotted against time and 
the area under curve (AUC) was estimated, using the linear trapezoid method. 
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3.3 Euthanasia of mice: 
At the end of each of the time points studied (as shown in Fig. 6.2.1), 6 CD and 6 HFD-fed mice 
were euthanized by cervical dislocation under deep anesthesia (using inhalational isoflurane). 
Mice were not fasted prior to euthanasia. Following laparotomy, blood was collected from the 
inferior vena cava. The liver, epididymal white adipose tissue (eWAT) and spleen were isolated 
from each animal; each was weighed. These, along with the duodenum and a sample of skeletal 
muscle (the quadriceps), were immediately snap-frozen in liquid nitrogen and stored at -70°C, 
till further processing.  
3.4 Western blot analysis: 
Snap-frozen liver, adipose and duodenal tissue samples were homogenized (using a mechanical 
homogenizer) in ice-cold RIPA buffer (Tris-HCl 10mM, NaCl 140mM, EDTA 1·5mM, sodium 
deoxycholate 0·1%, Triton-X 1%, SDS 0·1%, pH 8·0), containing a cocktail of protease 
inhibitors (cat. no. P8340, Sigma, India). Homogenized samples were centrifuged at 14,000g for 
10 min at 4°C. Fat that collected at the top was removed; the centrifugation step was repeated. 
Protein content in the supernatants obtained was estimated, using the Pierce BCA protein assay 
kit (cat. no. 23225, Thermo Fisher Scientific, USA).  
SDS-PAGE and electroblotting were carried out, as described in detail in the methodology 
section for Study I.  Briefly, samples were heated at 95°C for 5 minutes in Laemmli buffer, prior 
to loading (50μg protein) on 10% SDS-PAGE gels for electrophoretic separation. Separated 
proteins were transferred onto PVDF membrane (0.45μm, Immobilon-P, Millipore, Merck, 
Germany), blocked and probed with appropriate primary antibody (overnight at 4°C), followed 
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by incubation with secondary antibody (2 hours at room temperature). Sources and dilutions of 
primary and secondary antibodies and blocking agent used are given in Table 6.2.1. Bands were 
detected with a chemiluminescence substrate kit (SuperSignal West Dura, Thermo Fisher 
Scientific, USA), using a gel documentation system (Fluorochem SP, Alpha Innotech, USA). 
The intensities of the bands were quantified using ImageJ software (NIH, USA), and normalized 
to that of β-actin, which was used as a loading control in the case of liver and adipose tissue; for 
duodenal tissue, bands were normalized to total protein visualized by reversible Ponceau staining 
(300). In order to compare samples run on different membranes, inter-membrane normalization 
was done by normalizing the band intensities obtained for a calibrator sample, which was run on 
every gel.  
3.5. Quantitative real-time polymerase chain reaction (qPCR) 
Isolation of RNA, construction of cDNA and PCR reactions were carried out as described in 
detail in the methodology section for Study 1.  Briefly, ~100 mg of tissue (liver, adipose tissue 
and duodenum) was homogenized in 1 mL of Tri-Reagent (Sigma, India) and RNA isolated 
according to manufacturer’s instructions. For samples with increased fat content (adipose tissue 
and liver), homogenates were subjected to a preliminary centrifugation step (12,000g for 10 min 
at 4°C) in order to remove fat in the homogenate, prior to RNA isolation. Isolated RNA was 
quantitated using a NanoDrop 2000c Spectrophotometer (Thermo Fisher Scientific, USA). In all 
cases, integrity of the RNA was assessed by agarose gel electrophoresis. One microgram of 
isolated RNA was used to synthesize cDNA, using the Reverse Transcriptase Core Kit 
(Eurogentec, Belgium) (as described in Study 1). Quantitative PCR reactions were carried out in 
duplicate, using the Takyon qPCR SYBR master mix (Eurogentec, Belgium), using a BioRad 
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Chromo4 real-time PCR machine (as described in Study 1). The expression levels of genes of 
interest were normalized to Rpl19, which was used as the reference gene. Sequences of all 
primers used are listed in Table 6.2.2. The MIQE (Minimum Information for Publication of 
Quantitative Real-Time PCR Experiments) check-list and qPCR validation data are provided in 
Appendix no. I and II (page 323 and 327). 
3.6. Estimation of content of non-heme iron in liver, spleen and skeletal muscle 
Samples of the liver, spleen and skeletal muscle were processed for estimation of iron, as 
described earlier (301). Tissue samples were dried in a hot air oven at 48°C for 48 h; they were 
then weighed and digested in acid reagent (3M hydrochloric acid and 10% TCA) (10 mg of dried 
tissue/100 μL acid reagent) at 65°C for 24 hours. Following this, the digested samples were 
centrifuged at 12,000g for 5 min and the supernatants obtained were used for estimation of iron.  
Non-heme iron was estimated using a colorimetric assay based on bathophenanthrolene dye-
binding, as described earlier (259). Twenty microliters of the supernatant (diluted with 0.1N HCl 
as appropriate) was added to 180 μL of chromogen reagent (consisting of 0.01% 
bathophenanthrolene disulphonate sodium salt [cat. no. 11880, Sigma India] and 0.1% [v/v] 
thioglycollic acid [cat. no. 528056, Sigma, India] in 4M sodium acetate [cat. no. 22342, SRL 
chemicals, India]) in a microtiter plate, mixed and incubated at room temperature for 15 min. 
Absorbance was measured at 540 nm using a BioRad iMark microplate reader. The iron content 
in each sample was estimated based on a set of iron standards prepared by serial dilution of a 
1000 μg/mL stock standard (cat. no. 02583, Sigma, India). The standards were run in parallel 
with the samples. Results were normalized to the dry weight of tissue samples. 
132 
 
Table 6.2.1: Primary and secondary antibodies  
Protein 
Primary antibody (source 
and dilution) 
Secondary antibody
# 
Blocking agent 
Ferritin (light 
chain) 
Santa Cruz Biotechnology 
(sc-14420) 1:1000 
Rabbit anti-goat  IgG 
(H+L) HRP conjugate 
(#31402) 
5% non-fat dry 
milk in TBS-T 
Ferroportin 
Alpha Diagnostics 
(#MTP11-A) 1:1000 
Goat anti-rabbit IgG 
(H+L) HRP conjugate 
(#31460) 
5% non-fat dry 
milk in TBS-T 
TfR2 
Alpha Diagnostics 
(#TFR21-A) 1:1000 
Goat anti-rabbit IgG 
(H+L) HRP conjugate 
(#31460) 
5% non-fat dry 
milk in TBS-T 
Beta actin 
Sigma-Aldrich (#A5316) 
1: 5000 
Goat anti-mouse IgG 
(H+L) HRP conjugate  
(#31430) 
5% non-fat dry 
milk in TBS-T 
p-Akt (Ser 
473) 
Cell signaling technology 
(#9271) 1:1000 
Goat anti-rabbit IgG 
(H+L) HRP conjugate 
(#31460) 
5% BSA in TBS-T 
Total Akt  
Cell signaling technology 
(#9272) 1:1000 
Goat anti-rabbit IgG 
(H+L) HRP conjugate 
(#31460) 
5% BSA in TBS-T 
#
 Secondary antibodies were purchased from ThermoFisher Scientific, USA, and used at a 
dilution of 1:5000 
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Table 6.2.2: Primers used for qPCR 
Sl. 
No. 
Gene 
Accession 
number 
Primer sequence 
Amplicon 
size (bp) 
1 
Hepcidin 
(Hamp1) 
NM_032541.1 
5’- ACATTGCGATACCAATGCAGAA-3’ 
3’- GCAACAGATACCACACTGGGA-5’ 
104 
2 
Transferrin 
receptor 1 (Tfrc) 
NM_011638.4 
5’-GAGGCGCTTCCTAGTACTCC-3’ 
3’-CTTGCCGAGCAAGGCTAAAC-5’ 
121 
3 
Ferroportin 
(Slc40a1) 
NM_016917.2 
5’-TAAAGTGGCCCAGACGTCAC-3’ 
3’-GCAGACAGTAAGGACCCATCC-5’ 
130 
4 BMP6 (Bmp6) NM_007556.2 
5’-AACCTTTCTTATCAGCATTTACCA-3’ 
3’-GTGTCCAACAAAAATAGGTCAGAG-
5’ 
75 
5 
Matriptase-2 
(Tmprss6) 
NM_027902.2 
5’-TGGCCTGGATAAACAGAGGC-3’ 
3’-CTGGAAACATCTCGGCATCTTC-5’ 
84 
6 TfR 2 (Tfr2) NM_015799.3 
5’-GGTCCTGATCACCCTGCTAA-3’ 
3’-GGAGGTCGCTCCAGTACAAC-5’ 
158 
7 Rpl19 (Rpl19) NM_009078.2 
5’- ATGAGTATGCTCAGGCTACAGA-3’ 
5’- GCATTGGCGATTTCATTGGTC-3’ 
104 
8 
Glucokinase 
(Gck1) 
NM_010292.4 
5’ – TTGCAACACTCAGCCAGACA - 3’ 
3’ – TGCTCTACCAGAGTCAACGAC - 5’ 
147 
9 PEPCK (Pck1) NM_011044.2 
5’ – TGGTGGGAACTCACTACTCGG - 3’ 
3’ – ATGCCCAGGATCAGCATATG - 5’ 
105 
10 
Glucose-6-
phosphatase 
(G6pc) 
NM_008061.3 
5’ – TCTGTCCCGGATCTACCTTG – 3’ 
3’ – GTAGAATCCAAGCGCGAAAC – 5’ 
172 
11 
Acetyl CoA 
carboxylasae 
(Acaca) 
NM_133360.2  
5’ – GCCTCTTCCTGACAAACGAG – 3’ 
3’ – TGACTGCCGAAACATCTCTG – 5’ 
239 
134 
 
12 
Fatty acid 
synthase (Fasn) 
NM_007988.3  
5’ – AAGGCTGGGCTCTATGGATT – 3’ 
3’ – TGAGGCTGGGTTGATACCTC – 5’ 
177 
13 
PGC-1α 
(Ppargc1a) 
NM_008904.2 
5’ – CCGTAAATCTGCGGGATGATG – 3’ 
3’ – CAGTTTCGTTCGACCTGCGTAA – 5’ 
114 
14 PPARγ (Pparg2) NM_011146.3  
5’ – GGTGGGCCAGAATGGCATCT – 3’ 
3’ – TCTGGGAGATTCTCCTGTTGA – 5’ 
112 
15 
Adiponectin 
(Adipoq) 
NM_009605.4 
5’ – GTTGCAAGCTCTCCTGTTCC – 3’ 
3’ – CCAAGAAGACCTGCATCTCC – 5’ 
225 
16 ATGL (Pnpla2) NM_025802.3  
5’ – TGTGGCCTCATTCCTCCTAC – 3’ 
3’ – TCGTGGATGTTGGTGGAGCT – 5’ 
158 
17 HSL (Lipe) NM_010719.5  
5’ – GCTGGGCTGTCAAGCACTGT – 3’ 
3’ – GTAACTGGGTAGGCTGCCAT – 5’ 
160 
18 Ferritin (L) (Ftl) NM_010240.2 
5’ – CGGACCCTCATCTCTGTGAC – 3’ 
3’ – CGGAGGTTGGTCAGATGGTT – 5’ 
94 
19 Ferritin (H) (Fth) NM_010239.2 
5’ – AGACCGTGATGACTGGGAGA – 3’ 
3’ – TGAAGTCACATAAGTGGGGATCA–
5’ 
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3.7 Estimation of content of non-heme iron in epididymal white adipose tissue (eWAT) 
The epididymal white adipose tissue (eWAT) is considered a visceral fat depot in rodents. It is 
commonly used as a source of visceral fat in studies done in mice. Approximately 100 mg of 
adipose tissue was weighed and homogenized in 500μL RIPA buffer. The homogenate was 
centrifuged at 14,000g for 10 min; the fat in the homogenate that accumulated at the top at the 
end of this step was removed; the centrifugation step was repeated. The supernatant then 
obtained (100μL) was digested by adding acid reagent (3M hydrochloric acid and 10% TCA) 
(1:2 v/v) and incubated at room temperature for 30 min; it was then centrifuged at 12,000g for 10 
min to remove the precipitated protein. The supernatant obtained was used for estimation of iron. 
Iron estimation in the adipose tissue was carried out by atomic absorption spectrophotometry 
(AAS). This method is more sensitive than the colorimetric methods. This technique was used to 
accurately estimate the low levels of iron found in adipose tissue. AAS-based iron estimations 
were done using a Perkin-Elmer AA200 atomic absorption spectrometer. A Perkin-Elmer iron 
hollow cathode lamp was used as the light source and an atomization temperature of 2300°C was 
provided by an air-acetylene flame. Slit width of 0.2 nm and wavelength of 248.3 nm were used 
as spectrometer parameters. The iron content in each sample was calculated based on readings 
obtained from a set of standards prepared by serial dilution of a standard solution of iron (1000 
μg/mL, cat. no. 02583, Sigma, India). Results were normalized to the wet weight of tissue 
processed. 
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3.8. Visualization of tissue iron by perfusion-Perls’ staining 
The iron content of tissue was visualized in the experimental mice, by in-situ perfusion-Perls’ 
staining, as described earlier (292). Mice, under terminal anesthesia, were perfused (by cardiac 
puncture) with 30 mL PBS supplemented with heparin (5 U/mL) at a rate of 6 mL/min, using a 
peristaltic pump. Following this, perfusion was continued (at 6 mL/min) with 60 mL of Prussian 
blue staining solution (4% paraformaldehyde, 1% potassium ferrocyanide and 1% HCl). One 
hour post-perfusion, liver and adipose tissue were isolated for macroscopic examination; 
photographs were obtained of the tissue. 
3.9. Estimation of serum non-heme iron  
Serum levels of iron (non-heme) were measured, using a colorimetric assay based on 
bathophenanthrolene dye-binding, as described earlier (302). Twenty microliters of serum was 
mixed with acid-reagent (3M HCl in 10% trichloroacetic acid) and allowed to stand at room 
temperature for 30 min. The mixture was centrifuged at 12,000g for 10 min to pellet the 
precipitated proteins. Ten microliters of the supernatant was added to 90 μL of chromogen 
reagent (consisting of 0.01% bathophenanthrolene disulphonate sodium salt [cat. no. 11880, 
Sigma India] and 0.1% [v/v] thioglycollic acid [cat. no. 528056, Sigma, India] in 4M sodium 
acetate [cat. no. 22342, SRL chemicals, India]) in a microtiter plate, mixed and incubated at 
room temperature for 15 min. Absorbance was measured at 540 nm. Iron levels were estimated 
based on a set of iron standards run in parallel.   
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3.10. Estimation of triglyceride content in the liver  
The triglyceride content in liver tissue was estimated, as previously described (303). Lipids from 
liver tissue were extracted by Folch’s extraction procedure. Liver tissue (approximately 100 mg) 
was weighed, homogenized in 750 µL of PBS and the total volume made up to 1 mL (with PBS). 
Two hundred microliters of the homogenate was added to 1200 µL of chloroform: methanol 
mixture (2:1; v/v), and mixed using a vortex mixer, for 10 seconds. To this, 100 µL of PBS was 
added and mixed thoroughly so that the final mixture consisted of chloroform, methanol and 
water in the ratio 8:4:3 (v/v/v). After centrifugation at 2000g for 10 min at 4°C, 200 µL of the 
chloroform layer (bottom layer) was transferred into fresh tubes and evaporated to dryness. The 
dried lipids were re-dissolved in 200 µL of 1% Triton-X100 in absolute alcohol. The tubes were 
kept on a rotator for 4 h to ensure complete dissolution. 
The triglyceride content in the extracted lipid was estimated using a commercially available kit, 
according to manufacturer’s instructions (cat. no. TR212, Randox Laboratories, UK). Briefly, 5 
µL of lipid extract was added to 200 µL of color reagent (R1) in a microplate well, mixed and 
incubated at room temperature for 10 min. Absorbance was measured at 500 nm. The 
triglyceride content was calculated based on a set of standards run in parallel with the samples. 
Results were represented as milligrams of triglyceride per gram liver tissue. 
3.11. Estimation of serum triglyceride: 
Serum triglyceride levels were estimated using a commercially available kit (#10010303, 
Cayman Chemicals, USA) according to manufacturer’s instructions. 
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3.12. Enzyme-linked immunosorbent assays (ELISA) for various analytes of interest 
Serum samples were used for estimation of the following analytes, using commercially available 
ELISA kits: insulin (#10-1247-01, Mercodia, Sweden),  hepcidin (#S-1465.0001, Peninsula 
Laboratories, USA), ferritin (#Ab157713, Abcam, UK), adiponectin (#MRP300, R&D Systems, 
USA), C-reactive protein (#MCRP00, R&D Systems, USA) and interleukin-6 (#DY406-05, 
R&D Systems, USA). All assays were carried out according to manufacturer’s instructions. 
3.13. Histological examination of liver 
Liver tissue was fixed in 10% buffered formalin, embedded in paraffin and sections made for 
histological examination. Tissue sections were stained with H&E for light microscopy. 
Additional sections were stained with Prussian blue for visualization of iron deposits in the liver. 
All slides were examined by a histopathologist. Grading of steatosis was done based on standard 
criteria (304). Steatosis was graded as mild (<33%), moderate (33-66%) or severe (> 66%) 
depending upon the proportion of hepatocytes that showed steatotic changes).  Photographs were 
taken using an Olympus DP21 digital camera attached to an Olympus BX43 light microscope. 
3.14 Statistical analysis 
Statistical Package for Social Scientists (SPSS), version 16.0, was used for all statistical 
analyses. The Kolmogorov–Smirnov and Shapiro–Wilk tests were used to check distribution of 
data. These showed that the data were not normally distributed. Therefore, non-parametric tests 
were used for statistical analysis. The Kruskal-Wallis (KW) test was employed to look for 
significant differences between the various groups studied. For data where the KW test showed 
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significant differences across the various groups studied, pair-wise comparisons between groups 
were made by the Mann-Whitney test. Correlation analyses were done by Spearman’s correlation 
test. Multivariate analysis was performed by stepwise linear regression. A p value of less than 
0.05 was used to indicate statistical significance in all cases.  
4. Results 
4.1. HFD-feeding of the experimental mice induced obesity and hepatosteatosis  
High-fat diet (HFD)-fed mice progressively gained weight through the period of the study; body 
weights were significantly higher in these mice than in control diet (CD)-fed mice, from 4 weeks 
onwards (Fig 6.2.2-A). The weight of epididymal white adipose tissue (eWAT) was significantly 
higher in the HFD-fed mice than in CD-fed mice, at all the time points studied. Maximum 
weights were seen at 16 weeks; eWAT weights tended to decline with longer durations of HFD-
feeding (20 and 24 weeks) (Fig 6.2.2-B). Weights of the liver in HFD-fed mice were also 
significantly higher than those from CD-fed mice; this effect was seen from 16 weeks onwards 
(Fig 6.2.2-C). The content of triglycerides in the liver was significantly elevated in the HFD-fed 
mice, at all the time points studied (Fig 6.2.2-D.  This was associated with the finding of 
moderate to severe hepato-steatosis at 16, 20 and 24 weeks, as assessed by H & E staining of 
liver sections (304) (Fig 6.2.3). 
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4.2. HFD-feeding induced glucose intolerance, insulin resistance and hyperinsulinemia 
HFD-feeding induced glucose intolerance in the mice (as assessed by GTT), as early as 4 weeks 
after initiation of feeding (Fig 6.2.4-A and B). However, there was no significant worsening of 
glucose tolerance with continuing HFD feeding for up to 24 weeks. Results of the ITT in these 
mice showed that HFD-feeding resulted in significantly increased IR from 8 weeks onwards (Fig 
6.2.4-C and D). There was progressive worsening in IR with increasing durations of HFD 
feeding.  
Serum insulin levels (non-fasting) were higher in HFD-fed mice, starting from 12 weeks 
onwards, with highest levels seen at 20 and 24 weeks (Fig 6.2.5-A). Serum adiponectin levels 
(Fig 6.2.5-B) increased initially in response to HFD (after 8, 12 and 16 weeks), but declined later 
at 20 and 24 weeks to levels similar to those in control mice. No significant changes were seen in 
serum triglyceride levels at any of the time points studied (Fig 6.2.5-C). 
4.3. HFD-feeding induced hepatic insulin resistance 
Phosphorylation-mediated activation of Akt is a key event in the intracellular signaling cascade 
triggered by binding of insulin to its cell surface receptor (20). As described above, mice fed 
HFD for 12, 16, 20 and 24 weeks showed increased serum insulin levels (Fig 6.2.5-A). Despite 
hyperinsulinemia, levels of phosphorylated Akt (p-Akt Ser473) were not significantly increased 
in the livers of HFD-fed mice except at 12 weeks (Fig 6.2.6-A). The ratio of liver p-Akt to 
plasma insulin (a marker of the degree of activation of intracellular signaling induced by insulin) 
(305) were generally lower than values in the CD-fed mice, with  significant decreases seen after 
20 and 24 weeks of HFD feeding (Fig 6.2.6-B).  
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Insulin is known to induce the expression of glucokinase (Gck), a glycolytic enzyme (306), and 
to suppress levels of phosphoenolpyruvate carboxykinase (PEPCK/ Pck1) and glucose-6-
phosphatease (G6pc), both of which are key gluconeogenic enzymes in the liver (307). Gck1 
expression was generally higher in HFD-fed mice at all the time points studied, with the increase 
being significant at 12 weeks (Fig 6.2.7-A). There was no significant decrease in mRNA 
expression Pck1 or G6pc in the liver at any of the time points studied, despite significant 
elevations in serum insulin levels in HFD-fed mice (at 12, 16, 20 and 24 weeks) (Fig 6.2.7-B-C). 
Peroxisome proliferator-activated receptor gamma co-activator-1 alpha (PGC-1α / Ppargc1a) is 
a transcriptional co-activator that plays a critical role in modulating hepatic gluconeogenesis and 
is strongly down-regulated by insulin (308). However, despite elevated insulin levels, expression 
of Ppargc1a was not significantly reduced in HFD-fed mice (Fig 6.2.7-D). Similarly, the genes 
for lipogenic enzymes, acetyl CoA carboxylase (Acaca) and fatty acid synthase (Fasn), are 
known to be induced by insulin; however, no significant increase in expression of these genes 
was seen in HFD-fed mice (Fig 6.2.7-E and F).  
Overall, these results show that HFD-feeding in mice significantly dampened insulin-induced 
activation of the Akt pathway in the liver of these animals. Consistent with decreased hepatic 
insulin signaling, expression of lipogenic and gluconeogenic genes were not significantly altered 
in these mice, despite hyperinsulinemia. Taken together, these results appear indicative of 
hepatic insulin resistance induced by high-fat feeding in these mice. 
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4.4. HFD-feeding decreased hepatic hepcidin expression and serum hepcidin levels  
Gene expression of hepcidin (Hamp1) in the liver of HFD-fed mice was reduced at several of the 
time points studied, with significantly lower levels seen at 4 and 24 weeks (Fig 6.2.8-A). Serum 
hepcidin levels were also generally lower in HFD-fed mice at most of the time points studied, 
with significantly lower levels seen at 4, 20 and 24 weeks (Fig 6.2.8-B). Hepatic Hamp1 mRNA 
expression was highly correlated with serum hepcidin levels (Fig 6.2.8-C). 
4.5. Effect of HFD-feeding on liver iron content and iron-related proteins  
HFD-feeding induced a progressive decrease in hepatic non-heme iron content from 12 weeks 
onwards (Fig 6.2.9-A). In situ perfusion of the liver with Perls’ staining fluid, after 24 weeks of 
HFD, showed decreased staining of the liver (Fig 6.2.9-B), confirming reduced iron content. 
Gene expression of transferrin receptor 1 in the liver was increased in HFD-fed mice (Fig 6.2.9-
C), an observation that is also indicative of decreased intracellular iron levels. This was 
associated with decreases in protein expression of ferritin (the iron storage protein) (Fig 6.2.10-C 
and D). However, mRNA levels of ferritin (L) (at 20 and 24 weeks) and ferritin (H) (at 16, 20 
and 24 weeks) were significantly increased by HFD-feeding (Fig 6.2.10-A and B).   Gene 
expression (Fig 6.2.11-A) and protein levels (Fig 6.2.11-B and C) of ferroportin, the only known 
cellular iron export protein, were not significantly affected by HFD feeding.  
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4.6 Effect of HFD-feeding on BMP6, matriptase-2 and TfR2 in the liver 
BMP6 is a powerful inducer of hepcidin (72); it is secreted primarily by hepatic sinusoidal 
endothelial cells (92). Matriptase-2, on the other hand, is a membrane-bound serine protease that 
suppresses hepcidin expression by inhibiting signaling via the BMP-SMAD pathway (78). Both 
BMP6 (88,288) and matriptase-2 (94) are known to be regulated by hepatic iron stores.  In the 
present study, Bmp6 expression in the liver showed significant increases initially (at 4 and 8 
weeks of HFD-feeding); however, its expression in HFD-fed mice was not different from CD-fed 
mice, with after longer periods of HFD-feeding (Fig 6.2.12-A). Matriptase-2 (Tmprss6) gene 
expression was higher in HFD-fed mice; the increases were statistically significant at 8 weeks 
and tended to be statistically significant at 4 weeks (p=0.055) and 24 weeks (p=0.082) (Fig 
6.2.12-B). Transferrin receptor 2 (TfR2) plays an important role in regulating hepcidin 
expression in response to changes in serum iron levels / transferrin saturation (86). TfR2 (mRNA 
and protein levels) were not significantly affected by HFD-feeding at any of the time points 
studied (Fig 6.2.13).  
4.7. HFD-feeding did not affect serum iron levels but increased serum ferritin  
HFD-feeding did not affect serum levels of iron (Fig 6.2.14-A). However, serum ferritin, which 
is commonly considered to be a marker of body iron stores, was significantly increased by HFD-
feeding at 12, 20 and 24 weeks (Fig 6.2.14-B). 
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4.8 HFD-feeding did not affect markers of systemic or hepatic inflammation 
Inflammation is known to affect systemic iron homeostasis and induce hepcidin expression in the 
liver, via interleukin-6 (IL-6) (112). HFD did not affect serum levels of C-reactive protein 
(CRP), a marker of systemic inflammation (Fig 6.2.15-A).  In addition, in both CD- and HFD-
fed mice, levels of IL-6 in the serum were low and below the detection limit (15.6 pg/mL) of the 
assay used for IL-6 estimation, at all the time points studied.  
Hepatic mRNA expression levels of serum amyloid A (Saa1), an acute phase reactant, and IL-6 
were also determined. HFD-feeding did not induce significant increases in Saa1 mRNA at any of 
the time points studied (Fig 6.2.15-B). Gene expression of IL-6 in the liver was found to be very 
low and no significant increases were induced by HFD-feeding at any of the time points studied 
(Fig 6.2.15-C). 
4.9 HFD-feeding resulted in metabolic dysfunction in the adipose tissue 
The effects of HFD-feeding on expression of key genes involved in lipogenesis and lipolysis in 
the epididymal white adipose tissue (eWAT) were determined. Peroxisome proliferator activated 
receptor gamma (PPARγ), the master regulator of adipocyte differentiation and lipogenesis, was 
down-regulated in mice fed HFD for 16, 20 and 24 weeks (Fig 6.2.16-A). Fatty acid synthase 
and adiponectin are known targets of PPAR γ; mRNA levels of these were also down-regulated 
at the same time points (Fig 6.2.16-B and C). Gene expression of key enzymes involved in 
lipolysis, adipose tissue triglyceride lipase (ATGL) and hormone-sensitive lipase (HSL), were 
also found to be suppressed by HFD-feeding at these time points (Fig 6.2.16-D and E). 
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4.10 HFD-feeding resulted in alterations in parameters of iron metabolism in the adipose tissue 
HFD-feeding tended to increase the iron content in eWAT at many of the time points studied. 
The increase was statistically significant at the 24 weeks time point (Fig 6.2.17-A). The weight 
of eWAT was found to be significantly higher in mice fed HFD than in those fed CD (Fig 6.2.2-
B).  The total iron content in the eWAT was calculated by multiplying the iron content per gram 
of adipose tissue by the total weight of the eWAT. This was found to be significantly higher in 
HFD-fed mice than CD-fed mice, from 8 weeks onwards (Fig 6.2.17-B). There was a significant 
negative correlation between levels of iron in the liver and total eWAT iron (Fig 6.2.17-C), 
showing that the decrease in liver iron content was associated with increased iron content in the 
adipose tissue.  
Gene (mRNA) expression of ferritin (L) (at 12, 16, 20 and 24 weeks) and ferritin (H) (at 16, 20 
and 24 weeks) was significantly up-regulated in the eWAT of HFD-fed mice (Fig 6.2.18-A and 
B). However, protein levels of ferritin (L) (Fig 6.2.18-C and D) were not correspondingly 
increased.  Tfrc mRNA expression did not show significant changes, except for an increase in 
HFD-fed mice at 8 weeks (Fig 6.2.19-A). Protein levels of ferroportin were significantly lower in 
HFD-fed mice at 12 and 16 weeks, but unaffected at the other time points studied (Fig 6.2.19-B 
and C).  
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4.11. Effect of HFD-feeding on iron content of spleen and skeletal muscle 
The iron content in the spleen from mice fed HFD was significantly lower at 8 and 12 weeks 
than in that from CD-fed mice (Fig 6.2.20-A). The iron content of the skeletal muscle 
(quadriceps) was not affected by HFD-feeding (Fig 6.2.20-B).  
 
4.12. Effect of HFD- feeding on expression of duodenal proteins involved in absorption of 
dietary non-heme iron  
HFD feeding did not produce any significant effect on mRNA expression of duodenal proteins 
involved in iron absorption, viz. divalent metal transporter – 1 (DMT1), ferroportin and duodenal 
cytochrome b (Dcytb) (Fig 6.2.21-A-C) HFD did not have a consistent effect on protein 
expression of DMT-1, the apical iron transporter (Fig 6.2.22). Western blots for ferroportin using 
RIPA lysates of duodenal tissue did not show a specific band corresponding to the expected 
molecular weight (68 kDa). Under the circumstances, protein levels of duodenal ferroportin 
could not be reliably quantitated. 
4.13. Results of univariate and multivariate analyses 
4.13.1 Insulin resistance – associations with other variables  
Insulin resistance (as assessed by the AUC in ITT) in HFD-fed mice was found to be 
significantly positively correlated with liver triglyceride levels, serum hepcidin (also seen in CD-
fed mice) and serum ferritin and negatively correlated with liver iron (Table 6.2.3).  
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On multivariate analyses using stepwise linear regression, the association of insulin resistance 
with liver triglyceride remained significant (B=82.70, SE=17.9, adjusted R
2
=56%, p<0.001), but 
not those with serum hepcidin, serum ferritin and liver iron levels. 
4.13.2 Liver iron – associations with other variables  
In CD-fed mice, liver iron levels were significantly positively correlated with serum hepcidin 
and serum ferritin and negatively correlated with liver BMP6 mRNA expression. In mice fed 
HFD, liver iron was significantly negatively correlated with liver triglyceride, insulin resistance 
(AUC of ITT) and serum hepcidin (Table 6.2.4). On multivariate analyses using stepwise linear 
regression, the association of liver iron with serum ferritin in CD-fed mice (B= 1.29, SE= 0.46, 
adjusted R
2
=29.6%, p<0.014) and with liver triglyceride in HFD-fed mice (B= -33.93, SE=13.01, 
adjusted R
2
=36.7%, p<0.028) remained significant, while others did not. 
 4.13.3 Hepatic Hamp1 mRNA expression – associations with other variables 
In CD-fed mice, hepatic Hamp1 mRNA expression was positively correlated with liver iron, 
serum insulin and serum ferritin. On the other hand, in mice fed HFD, Hamp1 expression was 
positively correlated with serum insulin, liver Bmp6 mRNA expression and liver TfR2 protein 
levels (Table 6.2.5). On multivariate analyses using stepwise linear regression, the association of 
liver Hamp1 mRNA with serum ferritin in CD-fed mice (B= 0.003, SE= 0.001, adjusted 
R
2
=44.7%, p<0.002) and with liver TfR2 protein levels in HFD-fed mice (B= 1.687, SE=0.604, 
adjusted R
2
=28.6%, p<0.013) remained significant, while the others did not. 
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Table 6.2.3: Correlational analyses of insulin resistance (as assessed by AUC in ITT) with other 
parameters of interest 
Variable Control diet High-fat diet 
 
r* p r* p 
Liver triglyceride -0.059 0.750 0.712 <0.001 
Liver iron 0.248 0.163 -0.620 <0.001 
Serum adiponectin -0.131 0.497 -0.183 0.307 
Serum hepcidin 0.454 0.009 0.387 0.022 
Serum CRP 0.050 0.860 0.212 0.414 
Serum ferritin 0.055 0.829 0.467 0.050 
* Spearman’s correlational coefficients are reported. 
A p value less than 0.05 was taken to indicate statistical significance. Statistically significant 
correlations are highlighted. 
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Table 6.2.4: Correlational analyses of liver iron with other parameters of interest 
Variable Control diet High-fat diet 
 
r p r p 
Liver triglyceride -0.042 0.820 -0.611 <0.001 
ITT (AUC) 0.248 0.163 -0.617 <0.001 
Serum hepcidin 0.551 0.001 -0.504 0.002 
Serum ferritin 0.640 0.006 -0.466 0.051 
Serum CRP -0.386 0.156 0.022 0.933 
Serum iron -0.343 0.051 0.118 0.494 
Liver BMP6 mRNA -0.501 0.008 -0.279 0.132 
Liver matriptase-2 mRNA -0.143 0.428 -0.299 0.090 
* Spearman’s correlational coefficients are reported. 
A p value less than 0.05 was taken to indicate statistical significance. Statistically significant 
correlations are highlighted. 
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Table 6.2.5: Correlational analyses of liver hepcidin (Hamp1) mRNA expression with other 
parameters of interest 
Variable Control diet High-fat diet 
 
r p r p 
Liver triglyceride 0.121 0.509 0.205 0.230 
Liver iron 0.496 0.003 -0.188 0.272 
Serum insulin 0.575 <0.001 0.366 0.028 
Serum ferritin 0.535 0.022 -0.154 0.542 
Serum iron -0.241 0.156 -0.029 0.866 
Liver BMP6 mRNA -0.256 0.172 0.373 0.042 
Liver matriptase-2 mRNA -0.133 0.438 0.245 0.151 
Liver TfR2 protein -0.020 0.938 0.534 0.023 
Liver ferroportin protein -0.289 0.087 0.075 0.663 
eWAT ferroportin protein -0.495 0.061 -0.271 0.328 
* Spearman’s correlational coefficients are reported. 
A p value less than 0.05 was taken to indicate statistical significance. Statistically significant 
correlations are highlighted. 
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5. Discussion  
Male C57Bl/6 mice fed a high-fat diet (HFD) develop many of the features of T2DM that are 
seen in humans, such as hyperglycemia, visceral adiposity and hyperinsulinemia (309–311). This 
model has been extensively used in studies that have investigated the pathogenesis of insulin 
resistance (IR) associated with diabetes mellitus and other related pathological conditions, such 
as non-alcoholic fatty liver disease (NAFLD) (295).  
It has been shown that morphological, histological and metabolic changes induced by HFD are 
related both to the quantum and type of fat present in the diet as well as the duration of feeding 
(312–315). For example, it has been shown that induction of IR in different tissues occurs at 
different time points after initiation of HFD feeding. While increased hepatic glucose output, a 
marker of hepatic IR, is an early finding (developing 3 to 7 days after initiation of HFD-feeding) 
(314,316), development of IR in skeletal muscles occur at later time points (313,316). In 
addition, factors responsible for IR induced by short-term HFD-feeding are different from those 
involved in IR induced by long-term HFD-feeding. For example, adipose tissue inflammation is 
essential for development of whole-body IR in response to long-term HFD-feeding. However, 
the presence of inflammation is not required for short-term HFD-induced IR (312) 
The present study was aimed at systematically documenting the interactions between HFD-
induced IR and iron homeostasis in mice. Since, as described above, the effects of HFD are 
determined by the duration of feeding, a time-course study (from 4 weeks up to 24 weeks) was 
carried out to determine the temporal association between development of IR and changes in 
iron-related parameters in different tissues. Overall, the results of this study are consistent with 
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those reported earlier in this model (295,316,317). HFD-feeding resulted in progressive weight 
gain and development of glucose intolerance and IR. Whole-body IR, as assessed by insulin 
tolerance tests, was significantly higher in HFD-fed mice from 8 weeks onwards (Fig 6.2.4).  
Onset of IR in the liver is one of the early effects of HFD-feeding. Hyperinsulinemic 
hyperglycemic clamp studies have shown that hepatic insulin resistance, as indicated by an 
increased hepatic glucose output, is seen as early as 1 week after onset of HFD feeding (316). 
Induction of hepatic IR is closely associated with alterations in lipid metabolism in the liver 
(182). In the present study, triglyceride levels were found to be significantly increased in the 
liver of mice fed HFD, from 4 weeks onwards (Fig. 6.2.2-D). Multivariate linear regression 
analyses showed that whole-body IR (as assessed by ITT) in mice fed HFD was independently 
associated with liver triglyceride levels, after adjusting for potential confounders (Table 6.2.3), 
suggesting that increased liver TG plays a role, not only in the development of hepatic IR, but 
also in the pathogenesis of whole-body IR. In this context, estimation of NEFA levels in serum 
would have provided useful information on net mobilization of fatty acids from the adipose 
tissue, by lipolysis. However, sufficient volume of serum samples was not available for this 
assay. Future work will address this lacuna. 
It is known that accumulation of triglycerides in the liver is associated with increased levels of 
lipotoxic lipid intermediates such as diacylglycerol (DAG) and ceramide (180). Both DAG and 
ceramide have been shown to impair insulin signaling. DAG is known to activate atypical 
isoforms of protein kinase C resulting in impaired insulin-induced activation of the Akt pathway 
(318).  Similarly, ceramide has been shown to activate the stress kinase, c-Jun amino terminal 
kinase (JNK), resulting in impaired activation of Akt by insulin (319,320).  
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In the present study, p-Akt levels in the liver of mice fed HFD were significantly increased at 12 
weeks (Fig 6.2.6). Increased mRNA expression of glucokinase (Gck) (a known insulin-
responsive gene in the liver) was also seen at 12 weeks (Fig 6.2.7-A). These effects corresponded 
with the onset of hyperinsulinemia at this time point (Fig 6.2.5-A). The lack of increase in p-Akt 
levels and Gck expression in the liver at the later time points, despite the sustained 
hyperinsulinemia suggests impairment in insulin signaling induced by prolonged HFD-feeding 
(Fig 6.2.6-B). These results suggest that hepatic IR is exacerbated after 16 weeks of HFD-
feeding and this was co-incident with augmented TG deposition in the liver (Fig 6.2.2-D), 
hyperinsulinemia (Fig. 6.2.5-A) and whole body IR (6.2.4-D). 
Previous studies that have reported the effect of HFD on hepatic expression of PEPCK and G-6-
Pase have shown inconsistent results; some have shown increases (321–323), while others have 
shown decreases (324,325) or no change (311,326) in HFD-fed mice compared to those fed CD. 
The reasons for this are not clear. However, it is known that expression of these genes are 
induced under fasting conditions and suppressed by feeding (311). Information on whether the 
mice were in the fasted/fed condition at the time of euthanasia is not provided in the studies 
mentioned above. This makes comparison of results between studies difficult. In the present 
study, mice had ad lib access to food at the time of euthanasia.  No significant differences were 
seen in PEPCK and G-6-Pase between CD and HFD-fed mice at any of the time-points studied 
(Fig. 6.2.7). Since insulin is known to decrease the expression of these genes (327), absence of 
suppression of PEPCK and G-6-Pase despite hyperinsulinemia in HFD-fed mice provides further 
evidence for hepatic IR induced under these conditions. Similarly, in the present study, lipogenic 
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genes, acetyl CoA carboxylase (ACC) and fatty acid synthase (FAS) (which are known to be 
induced by insulin (328)) were also not affected by HFD-feeding.  
The liver is the major site for iron storage in the body. HFD-feeding resulted in a progressive 
decrease in liver iron content from 12 weeks onwards (Fig. 6.2.9). Chung et al (2011) have 
previously shown that HFD-feeding for 16 weeks decreased hepatic iron (290). In the present 
study, hepatic iron stores in HFD-fed mice were negatively correlated with liver triglyceride 
content (Spearman’s rho= -0.611, p<0.001) (Table 6.2.4). Linear regression analyses showed that 
this association remained significant, after adjusting for potential confounders (section 4.13.2). 
This suggests that ectopic lipid accumulation in the liver may underlie the decrease seen in liver 
iron stores.  
The liver plays a central role in the regulation of both iron and lipid metabolism. However, the 
molecular mechanisms that underlie the interaction between them are not clear. Several studies 
have shown that modulation of hepatic iron homeostasis can have profound effects on lipid 
metabolism. For example it has been shown that iron deficiency is associated with increased 
hepatic lipid uptake, synthesis and steatosis (329). On the other hand, iron overload has also been 
associated with hepatic steatosis and has been implicated in the pathogenesis of non-alcoholic 
steatohepatitis (NASH) (330).  
The decrease in liver iron content induced by HFD in the present study was associated with a 
progressive decrease in ferritin, the intracellular iron storage protein (Fig 6.2.10). Work in recent 
years has shown that degradation of ferritin occurs primarily in the lysosomes, by a process 
called ferritinophagy. This is a specialized from of micro-autophagy, mediated by the cargo 
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receptor, nuclear receptor co-activator 4 (NCOA4) (50). It is triggered by conditions 
characterized by intracellular iron depletion but the mechanisms involved are not clear. Although 
hepatic steatosis is known to associated with increased autophagy (331), very little is known 
about its effect on ferritinophagy. Ferroptosis, a form of iron-dependent non-apoptotic cell death 
induced by oxidative stress-mediated lipid peroxidation, is strongly associated with 
ferritinophagy (332). Oxidative stress and lipid peroxidation are known to be associated with 
hepatosteatosis (333,334); whether activation of ferritinophagy plays a role in decreasing liver 
iron stores in this setting is not known.  
Although ferritin protein levels were decreased by HFD-feeding, mRNA expression of both 
ferritin (L) as well as ferritin (H) in the liver were significantly increased by HFD-feeding at 16, 
20 and 24 weeks (Fig 6.2.10). Gene expression of ferritin is known to be up-regulated by a 
number of factors, including inflammation and oxidative stress (335). HFD did not induce 
significant inflammation in the liver (Fig 6.2.15). However, as mentioned earlier, hepato-
steatosis is known to be associated with increased oxidative stress in the liver (333,334). It is 
therefore possible that oxidative stress may underlie increased ferritin expression in this setting. 
Additional factors, including ferritinophagy (as described above), may be involved in decreasing 
ferritin protein levels despite increased gene expression in this setting. 
The liver is the most important source of the iron-regulatory hormone, hepcidin (32). HFD 
feeding decreased hepatic Hamp1 expression and serum hepcidin levels (Fig 6.2.8).  It has been 
reported previously that mice fed HFD for 16 weeks had decreased hepatic Hamp1 expression 
(290,291). Similar findings were reported in db/db mice, another mouse model of obesity-
induced IR (336). The findings of the present study are in keeping with these reports. 
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A number of factors regulate hepcidin expression in the liver (Fig 3.6); hepatic iron stores is one 
such important factor (288). The results of the present study show that the decrease in liver iron 
stores (from 12 weeks onwards) preceded the decrease in Hamp1 expression (from 16 weeks 
onwards) (Fig. 6.2.9). This suggested that diminished iron stores in the liver may underlie the 
reduction in Hamp1 expression in this setting. A positive correlation between iron content and 
Hamp1 expression was seen in the livers of CD-fed mice. However, in HFD-fed mice, Hamp1 
expression was found to correlate negatively with liver iron stores, rather than positively (Table 
6.2.7). This suggests that in the setting of HFD-feeding, there may be other factors that may 
regulate hepcidin. 
BMP6, which is primarily secreted by sinusoidal cells in the liver (92), is a powerful inducer of 
hepcidin (88). An increase in BMP6 expression has been consistently demonstrated in response 
to iron loading in the liver (88,91,288). In the present study, although liver iron and Hamp1 
expression were decreased by HFD-feeding, it has not been possible to document concomitant 
decreases in BMP6 (Fig. 6.2.12-A). As far as is ascertainable, there are no reported studies that 
have shown a decrease in BMP6 expression in response to depletion of hepatic iron. The present 
study is in keeping with this. Hence, it appears that BMP6 may not play an important role in the 
regulation of hepcidin in this setting. Correlational analysis showed that hepatic Bmp6 
expression showed a significant negative correlation with liver iron levels in CD-fed mice (Table 
6.2.4). Considering that BMP6 is known to be induced by hepatic iron stores (88,91,288), this 
was an unexpected finding. On multivariate analysis, this negative correlation was not seen. This 
result suggests a ‘suppression effect’ by confounding factor(s) that correlate positively with liver 
iron, but negatively with Bmp6 expression. Changes in such confounding factor(s) will have 
178 
 
opposite effects on liver iron and Bmp6 expression. This may be a possible reason for the 
negative correlation between liver iron and Bmp6 mRNA seen in this setting. Multivariate 
analysis will neutralize the effects of factors causing suppression. As seen in this case, the 
negative correlation was lost when the data was subjected to multivariate analysis.  
Matriptase-2, a membrane-bound serine protease, decreases hepcidin expression by cleaving 
hemojuvelin (78,337). This results in decreased signaling via the BMP-SMAD pathway, leading 
to suppression of Hamp1 expression. Matriptase-2 was found to be essential for down-regulation 
of hepcidin in response to an iron-deficient diet (338). In the present study, the diets used were 
iron-adequate (detailed in the methods section (page 126) and in appendix III and IV (page 330 
and 331), where the diets have been described). HFD-feeding tended to increase matriptase-2 
mRNA expression in the liver at many of the time points studied (Fig. 6.2.12-B). This suggests 
that matriptase-2 may play a role in mediating the down-regulation of hepcidin in the setting of 
the present study. However, there was no significant correlation between expression levels of 
hepcidin and matriptase-2 (Table 6.2.5). In addition, it has been shown that matriptase-2 activity 
is regulated pre-dominantly at the level of protein stability, and not by transcriptional 
mechanisms (339). At the time that this part of the study was carried out, an antibody specific to 
mouse matriptase-2 was not available commercially. Hence, it was not possible to determine 
matriptase-2 protein levels as part of this study.  
TfR2 is a trans-membrane protein that is highly expressed in hepatocytes. TfR2 binds to holo-
transferrin (albeit with much lower affinity than TfR1) and triggers an intracellular signaling 
pathway that results in increased Hamp1 expression (289). Levels of TfR2 in hepatocytes have 
been shown to be regulated by changes in iron status of the body (340). The results of the present 
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study show that neither TfR2 mRNA nor its proteins levels were significantly affected by HFD-
feeding at any of the time points studied (Fig. 6.2.13). However, TfR2 protein was significantly 
positively correlated with Hamp1 mRNA expression in mice fed HFD (Table 6.2.7). This 
association remained statistically significant after adjusting for the effects of potential 
confounders (by multivariate linear regression analysis). These results suggest that TfR2 may be 
involved in regulation of hepcidin in the setting of HFD feeding. Additional work would be 
required to determine if this is so.  
Systemic inflammation is known to induce hepcidin. This effect is mediated primarily by IL-6, 
which signals via the JAK-STAT3 pathway to increase Hamp1 expression (112). HFD-feeding 
did not increase serum levels of CRP or IL-6 (Fig 6.2.15-C). Hence, there was no evidence of 
systemic inflammation in the experimental mice in the present study. In addition, mRNA 
expression of Saa1 (an acute phase reactant widely used as a marker of hepatic inflammation) or 
Il-6 in the liver were also not elevated by HFD (Fig 6.2.15). These results are consistent with 
those reported in an earlier study where mice were fed HFD for 24, 40 and 52 weeks (341). In 
this study, van der Heijden et al. show that hepatic inflammation developed only after 40 weeks 
of HFD and was not seen at 24 weeks (341). The lack of induction of hepcidin and absence of 
inflammation seen in the mice in the present study are consistent.  
Serum iron levels are known to regulate hepcidin. Although the mechanisms involved are 
incompletely understood, a multi-protein iron-sensing complex on the hepatocyte membrane 
(that includes HFE, TfR2 and HJV as essential components) is involved in regulation of Hamp1, 
in response to changes in serum iron/transferrin saturation. Serum iron levels were not 
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significantly altered by HFD-feeding at any of the time points studied. Therefore, it does not 
seem that serum iron influences hepcidin levels in this setting. 
Factors secreted by the bone marrow in response to an increased erythropoietic drive are known 
to powerfully repress hepatic Hamp1 expression. The effects of HFD-feeding on erythroid 
maturation in the bone marrow and expression of the erythroid regulators of hepcidin in 
erythroid precursor cells (isolated from the bone marrow [TER119+ cells]) were studied in 
detail. These results are described in Study 3. HFD-feeding was not found to significantly affect 
the expression levels of the erythroid regulators of hepcidin, suggesting that they are not 
involved in Hamp1 regulation in this setting.  
Interestingly, hepatic Hamp1 expression showed a positive correlation with serum insulin levels 
in CD and HFD-fed mice (Table 6.2.5). It has been reported earlier that insulin can induce 
Hamp1 gene expression in HepG2 cells, a hepatoma cell line (342). However, in a separate set of 
experiments that were not part of the present study, it was found that treatment of mouse primary 
hepatocytes with insulin (under similar experimental conditions) did not induce hepcidin (data 
not shown). Hence, it does not appear that insulin directly affects Hamp1 expression in mouse 
primary hepatocytes.  Additional studies would be required to investigate this aspect further.  
Overall, the results of this part of the study show that HFD-feeding decreased hepatic Hamp1 
expression; this was associated with decreased liver iron levels. Factors such as BMP6, 
matriptase-2, inflammation, serum iron level and erythroid regulators of hepcidin, all of which 
are known to regulate Hamp1 expression, did not appear to do so in the setting of this study.  
TfR2 protein levels were found to be positively associated with Hamp1 expression in HFD-fed 
181 
 
mice. Recently, it has been shown that hepcidin can be powerfully regulated by epigenetic 
modifications involving histone acetylation / deacetylation (343). Such epigenetic modifications 
were shown to be essential for down-regulation of hepcidin in response to iron deficiency and 
erythropoiesis. Whether such mechanisms are involved in regulation of hepcidin, in response to 
changes in liver iron stores is not known. Additional work would be required to look into this 
interesting possibility. 
Inflammation in the adipose tissue plays a key role in the pathogenesis of whole-body IR. HFD-
feeding is known to produce inflammation in adipose tissue, which is exacerbated by the 
infiltration of pro-inflammatory immune cells (especially macrophages) into the adipose tissue 
(165,166). Studies in mice have shown that gonadal WAT (in contrast to the subcutaneous and 
mesenteric WAT depots) has limited fat storage capacity. In response to long-term high-fat 
feeding (when body weight exceeds ~40g), expansion of the gonadal WAT was found to decline 
and was associated with marked exacerbation of IR  (164,317,344). The observations of the 
present study are in agreement with these reports; eWAT weights (Fig 6.2.2) increased initially 
but tended to decline after 16 weeks of HFD (when the body weights were >40 g) and was 
associated with increased IR (Fig 6.2.4), hyperinsulinemia (Fig 6.2.5-A), a decline in serum 
adiponectin levels (which were elevated at earlier time points [Fig 6.2.5-B]) and exacerbation of 
hepatosteatosis (Fig 6.2.2-D and 6.2.3). These results support the view that the limited 
expandability of eWAT results in ectopic accumulation of fat in the liver and muscle, resulting in 
metabolic abnormalities (lipotoxicity) (164).  
Inflammation induced in the adipose tissue by HFD has been shown to be associated with 
metabolic dysfunction in the adipose tissue (344). In the present study, mRNA expression of 
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PPARγ, a key transcription factor involved in adipocyte differentiation and maturation, was 
down-regulated after 16 weeks of HFD-feeding. PPARγ is known to be an insulin-responsive 
gene. In the present study, a decrease was seen in mRNA expression of this gene; this may be 
secondary to IR in adipose tissue. Levels of mRNA of known targets of PPARγ (fatty acid 
synthase and adiponectin) were also down-regulated, in parallel with PPARγ (Fig 6.2.16). 
Surprisingly, genes encoding the lipolytic enzymes, ATGL and HSL, were also found to be 
down-regulated at the same time points. A possible explanation for this finding is the fact that 
lipolysis is tightly coupled to both fatty acid synthesis and fatty acid oxidation by mechanisms 
that are not well characterized (345,346). Therefore, a decrease in lipogenesis (due to IR) may 
conceivably result in a concomitant decrease in expression of genes involved in lipolysis as well. 
The physiological significance of such coupling is not well understood. Overall, the results of the 
present study suggest that HFD-feeding in mice resulted in metabolic dysfunction in adipose 
tissue.  
Iron is essential for adipocyte differentiation and mitochondrial biogenesis (212,221).  Expansion 
of adipose tissue depots, in response to HFD feeding, has been shown to be associated with 
increased iron demands (347). In the present study, there was a significant increase in the iron 
content in the eWAT in response to HFD feeding (Fig. 6.2.17-A). This inversely correlated with 
liver iron content (Fig 6.2.17-C). These observations are in agreement with those reported in 
other studies (291,292). For example, Orr et al. have shown that HFD-feeding increased the iron 
content in adipocytes (292). Similarly, Park et al. have shown that HFD-induced decreases in 
hepatic iron stores were inversely proportional to body adiposity (291). 
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Elevated iron content in adipose tissue has previously been shown to be associated with 
increased IR in humans (226,348,349) and in mice (17,350). The mechanisms involved in these 
events are not clear. Increased levels of iron in adipose tissue can down-regulate the expression 
of adiponectin, an important insulin-sensitizing adipokine (225,226). Studies have also shown 
that increased levels of iron in the adipose tissue can increase the basal rate of lipolysis, thus 
increasing levels of free fatty acids in the blood and promoting ectopic lipid accumulation (219). 
HFD-feeding has also been shown to produce alterations in iron content of macrophages in 
adipose tissue, resulting in polarization of the macrophages towards a pro-inflammatory (M1) 
phenotype (292). It is, therefore, plausible that the increased iron content in adipose tissue seen 
in the present study may contribute to whole-body IR induced by HFD-feeding.  
Absorption of iron in the duodenum is a highly regulated process. Gene (mRNA) expression of 
the proteins involved (DMT1, ferroportin and dcytb) was not significantly altered by HFD-
feeding (Fig 6.2.21).  Protein levels of DMT-1 were also not affected (Fig 6.2.22). Despite 
attempts to determine protein levels of duodenal ferroportin by western blotting, it was not 
possible to detect a specific band corresponding to ferroportin (~68 kDa) in the RIPA lysates 
prepared from duodenal mucosal samples. Other investigators have reported the use of a 
membrane preparation of duodenal mucosa in order to detect ferroportin by western blotting 
(210,351). However, it was not possible to do so in the present study due to logistical constraints. 
Hence, it is not possible to comment on this aspect and this is a limitation of the study. 
It has been reported that HFD-feeding decreases duodenal iron absorption (218,291). In the study 
by Sonnweber et al (218), duodenal uptake of radio-labeled iron was measured in mice fasted for 
24 hours, after 10 weeks of HFD-feeding. The authors showed that iron transport across the 
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apical membrane of duodenal enterocyte was decreased. However, the reason for decreased iron 
uptake is unclear, since mRNA and protein levels of DMT-1 were found to be (paradoxically) 
increased in their study. In another report, Park et al (291) show decreased expression of dcytb in 
mice on a HFD for 16 weeks, with no significant changes in DMT-1 and ferroportin. In the 
present study, mRNA expression of DMT-1, ferroportin and dcytb were found to be highly 
variable with no significant differences in expression levels in CD and HFD-fed mice (Fig. 
6.2.21). The reasons for the differences in findings seen in the present study and those by 
Sonnweber et al and Park et al are not clear. It is possible that differences in experimental 
conditions may contribute. One such example, in the study by Park et al., is that the mice were 
fasted for 12 h prior to euthanasia. In the present study, mice were not fasted. Fasting is known 
to up-regulate hepcidin expression in the liver (120,352). It is plausible that induction of hepcidin 
may produce changes in the expression of duodenal proteins involved in iron absorption. In 
addition, it is not known whether the increased fat content in the HFD diet can have direct effects 
on iron bio-availability. 
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6. Summary and conclusion: 
The current study presents data on the interactions of high-fat feeding-induced insulin resistance 
(IR) and iron metabolism. As far as is ascertainable, this is the first study that has reported a 
time-course analysis of changes in parameters involved in iron homeostasis, associated with 
development of IR. There was a significant increase in whole-body IR (after 8 weeks of high-fat 
feeding) that preceded the onset of dysregulated hepatic iron homeostasis (after 12 weeks). This 
suggests that it is unlikely that dysregulated iron homeostasis in the liver plays a causative role in 
the pathogenesis of IR in this model.  
Hepatic steatosis was independently associated with IR and decreased hepatic iron stores, 
suggesting that ectopic lipid accumulation in the liver may play a role in the pathogenesis of IR, 
as well as in hepatic iron dysregulation. The decrease in hepatic iron stores was associated with 
concomitant increases in the iron content and metabolic dysfunction of the adipose tissue 
studied. Since increased iron in the adipose tissue has been reported to induce IR, it is possible 
that this may contribute to the increase in IR in response to high-fat feeding. The proposed 
sequence of events, showing possible cross talk between development of IR and dysregulated 
iron homeostasis, in response to HFD, is shown in Fig 6.2.23. 
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STUDY 3 
Effect of high-fat diet-induced insulin resistance on erythroid maturation and erythroid 
regulators of hepcidin in the bone marrow in mice 
1. Abstract 
Insulin is known to augment erythropoiesis in vitro by stimulating the proliferation and 
differentiation of erythroid precursor cells. Insulin resistance (IR), the hallmark of type 2 
diabetes mellitus (T2DM), is known to be associated with hyperinsulinemia. However, the effect 
of hyperinsulinemia on erythropoiesis in vivo is not known.  
Erythroid precursors in the bone marrow are known to secrete factors that can powerfully down-
regulate hepcidin expression in the liver. These are referred to as erythroid regulators of 
hepcidin. High-fat diet (HFD)-feeding in mice (a model of IR) was found to decrease hepatic 
hepcidin expression (Study 2). It was not known whether these erythroid regulators are involved 
in mediating hepcidin suppression in this setting. The hypothesis of the present study was that 
HFD-induced hyperinsulinemia may stimulate erythropoiesis in the bone marrow, which may, in 
turn, increase the expression of the erythroid regulators of hepcidin, resulting in hepcidin 
suppression. 
In order to test this hypothesis, terminal erythroid differentiation (TED) was studied in the bone 
marrow and spleen from mice fed a control diet or HFD for various durations (as detailed in 
Study 2), using flow cytometry. In addition, erythroid (TER119-positive) cells were isolated 
from the bone marrow and used to determine gene expression of the putative erythroid regulators 
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of hepcidin (erythroferrone [ERFE], growth differentiation factor –15 [GDF-15] and twisted 
gastrulation factor –1 [TWSG-1]). 
The results showed that HFD-feeding in mice did not stimulate erythropoiesis in the bone 
marrow or spleen. Terminal erythroid differentiation in the bone marrow was similar in the 2 
groups of mice, fed either a control diet or a HFD. However, HFD-fed mice showed increased 
reticulocytes in the marrow, which suggests impaired reticulocyte maturation and release into the 
circulation. HFD did not affect the expression of ERFE, GDF-15 or TWSG-1 in erythroid cells 
isolated from the marrow. Hence, it appears unlikely that these factors play an important role in 
the down-regulation of hepatic hepcidin expression seen in response to HFD-feeding. 
2. Introduction: 
Erythropoiesis refers to the process of differentiation and maturation of hematopoietic stem cells 
into mature erythrocytes. It occurs in the bone marrow, which is the chief erythropoietic organ.  
The spleen can act as an accessory erythropoietic organ (especially in mice) under conditions of 
increased erythropoietic demand (stress erythropoiesis) (353).  
The process of erythropoiesis consists of three phases: formation of early erythroid progenitors, 
terminal erythroid differentiation (TED) and reticulocyte maturation. In the first phase, 
hematological stem cells proliferate and differentiate to form early erythroid progenitor cells 
called burst forming units (BFU-E) and colony forming units (CFU-E) (354). The earliest 
morphologically recognizable erythroid precursor, the pro-erythroblast (pro-E), is derived from 
CFU-E. In the second phase (called terminal erythroid differentiation or TED), pro-E undergoes 
three cycles of mitosis, resulting in the sequential formation of basophilic, polychromatic and 
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orthochromatic erythroblasts respectively, at the end of each mitotic division. Accordingly, each 
pro-E produces 2 basophilic erythroblasts, which, in turn, produce 4 polychromatic erythroblasts 
and then 8 orthochromatic erythroblasts. Therefore, normal TED is characterized by the presence 
of pro-E, basophilic erythroblasts, polychromatic erythroblasts and orthochromatic erythroblasts 
in the ratio of 1:2:4:8. A deviation from this is suggestive of abnormal TED (355,356). In the 
third phase, orthochromatic erythroblasts extrude their nuclei (enucleation) to form reticulocytes. 
Nascent reticulocytes undergo a complex process of maturation where they transform into 
discoid erythrocytes and are released into circulation (357). 
TED is characterized by a progressive decrease in cell size, condensation of chromatin and 
hemoglobinization. Synthesis of hemoglobin is initiated in pro- and basophilic erythroblasts and 
is nearly complete in the orthochromatic erythroblasts. This process is associated with rapid 
synthesis of heme and is characterized by increased demand for iron (358). Erythroblasts obtain 
iron required to support hemoglobinization, by taking up transferrin-bound iron from the blood 
via transferrin receptor 1 (TfR1)-mediated endocytosis. In fact, TfR1 (CD71) is highly expressed 
on the surface of erythroblasts; more than 80% of circulating transferrin-bound iron is utilized by 
differentiating erythroblasts for hemoglobin synthesis (359).  
As described earlier, hepcidin, a small peptide synthesized and secreted by the liver, is the chief 
hormone that regulates iron homeostasis (32). It binds to and degrades the only known 
mammalian protein involved in iron export, ferroportin (24). In doing so, hepcidin decreases the 
recycling of iron from macrophages and also decreases absorption of dietary iron from the 
duodenum, thus limiting iron availability for hemoglobin synthesis. In conditions where 
erythropoiesis is stimulated, such as acute blood loss, anemia and hypoxia, hepcidin levels are 
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powerfully suppressed in order to meet the requirements of iron needed to support erythropoiesis 
(95). This phenomenon is also seen in hematological disorders characterized by ineffective 
erythropoiesis (such as thalassemia), where chronically suppressed hepcidin results in an iron 
overloaded state  (202). 
The mechanisms by which erythropoietic stimuli suppress hepcidin are not entirely clear.  
Several humoral factors secreted by erythroblasts during the process of TED have been shown to 
down-regulate hepcidin expression in the liver (100). These factors are collectively known as 
erythroid regulators of hepcidin.  Erythroferrone (ERFE) (35), growth differentiation factor-15 
(GDF-15) (33) and twisted gastrulation factor 1 (TWSG1) (34) have been proposed to be such 
candidate molecules (described in detail in the review of literature). 
In study 2, high-fat feeding was shown to result in a decrease in hepatic hepcidin (Hamp1) 
expression (Fig 6.2.8). It was also seen that, although hepatic iron stores were decreased by 
HFD, Hamp1 expression did not correlate with liver iron stores. In addition, other factors known 
to regulate Hamp1 expression (such as liver BMP6 and matriptase-2 mRNA expression, serum 
iron and systemic inflammation) were not significantly correlated with Hamp1 expression in 
HFD-fed mice. The effect of the erythroid regulators of hepcidin on Hamp1 expression in this 
setting is not known.  
Insulin resistance (IR) is a characteristic feature of type 2 diabetes mellitus (T2DM). Ever since 
Barbieri and colleagues (360) showed a significant association between IR and markers of 
enhanced erythropoiesis (such as increased RBC count, hematocrit and hemoglobin levels), 
multiple studies done in different parts of the world have confirmed this association (361–366).  
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IR is associated with hyperinsulinemia (due to compensatory increase in insulin secretion), 
especially early in the progression of T2DM (367). Insulin has been shown to stimulate 
proliferation and differentiation of early erythroid progenitors (BFU-E and CFU-E) in vitro 
(36,37,368,369). These cells express insulin receptors (368) and insulin-induced activation 
receptor tyrosine kinase activity is required for the stimulatory effects of insulin in these cells 
(370–372). In view of this, it has been postulated that hyperinsulinemia-induced increase in 
erythropoiesis may explain the increase in hemoglobin, RBC count and hematocrit (described 
above) that are associated with IR (360). In mice, HFD-induced IR has been shown to induce 
enhanced bone marrow hematopoiesis, with proportionate increases in both erythroid and 
myeloid lineages (373). However, very little is currently known about the effects of IR on the 
process of TED in the bone marrow. 
Obesity-induced inflammation in the adipose tissue plays a key role in the pathogenesis of IR 
(165). It is now known that induction of obesity is associated with an increase in bone marrow 
adipose tissue (MAT) (374,375). MAT is metabolically active and can have local, as well as 
systemic, effects which can impact energy metabolism, bone turnover and hematopoiesis (376). 
Although the precise role of MAT as a modulator of hematopoiesis is not clear, it is thought to 
have an inhibitory effect on the hematological niche in the marrow (377). In addition, pro-
inflammatory cytokines secreted by MAT can potentially have a direct inhibitory effect on 
erythropoiesis (378,379). HFD-feeding in mice has been shown to result in an increase in MAT 
(374). Therefore, mice fed HFD have co-existent hyperinsulinemia (which may stimulate 
erythropoiesis) and increased MAT (which may inhibit erythropoiesis). In such a setting, the net 
effects of these factors on TED have not been studied. 
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This study was designed to investigate the effect of HFD on TED in the bone marrow. The 
hypothesis tested was that HFD-induced changes in TED may result in increased expression of 
the erythroid regulators of hepcidin, which may mediate hepatic Hamp1 suppression in this 
setting. In order to test this hypothesis, TED in the bone marrow and spleen (isolated from mice 
fed HFD for various durations - from 4 weeks to 24 weeks as described in study 2) was studied, 
using flow cytometry. In addition, erythroid cells (TER119-positive cells) were isolated from the 
bone marrow to study the expression of the putative erythroid regulators of hepcidin. 
3. Methods 
3.1. Animals 
All animal experiments in this study were done in the mouse model of HFD-induced obesity and 
IR, which was described in detail in Study 2 (page 126). Briefly, 8 weeks old male C57Bl/6J 
mice were fed either a control diet (CD) (Research Diets, Inc., USA, #D12450J, with 10% of 
total calories derived from fat) or a high-fat diet (HFD) (Research Diets, Inc., USA, #D12492, 
with 60% of total calories derived from fat) for 4, 8, 12, 16, 20 or 24 weeks. Six CD-fed and 6 
HFD-fed mice were sacrificed at each time point studied. At the time of sacrifice, blood was 
collected from the inferior vena cava. The tibia and femur from both hind-limbs were removed 
and used for bone marrow isolation (as described below).  
3.2. Preparation of single-cell suspensions of bone marrow  
Single-cells suspensions of bone marrow  were prepared as described by Koulnis et al (380). The 
ends of the femur and tibia were snipped off using a pair of scissors and bone marrow was 
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flushed out with 3–4 mL of ice-cold staining buffer (PBS with 0.2% BSA and 5mM glucose), 
using a syringe fitted with a 26G needle inserted into the marrow cavity. The marrow cells were 
dissociated by repeatedly pipetting the suspension up and down and passing it through a pre-
wetted 40 μm strainer to remove cell clumps. The cells in the suspension were washed twice with 
staining buffer and finally re-suspended in 1 mL of ice-cold staining buffer. 
3.3. Preparation of single-cell suspensions of splenocytes 
The freshly isolated spleen was placed on a pre-wetted 40 μm strainer, kept on top of a 50 mL 
conical tube. The spleen was mechanically disrupted by gently shearing it using a syringe 
plunger. The dissociated cells were washed through the strainer using 3-4 mL of ice-cold 
staining buffer. The splenocytes were washed again with staining buffer, and finally re-
suspended in 1 mL of ice-cold staining buffer. 
3.4. Cell counts 
The isolated bone marrow cells and splenocytes were counted, using a Neubauer hemocytometer. 
Briefly, 50 µL of the cell suspension was mixed gently with 50 µL of 0.4% trypan blue solution 
(cat. no. T8154, Sigma, India). One minute later, 10 µL of the stained cell suspension was 
applied to the hemocytometer chamber. Cells in 4 corner squares were counted; the average 
number of cells in each square was used to calculate the total number of cells using the formula 
given below: 
Total number of cells per mL = average number of cells per square x 10
4 
x 2 (dilution factor) 
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3.5. Flow cytometric analyses 
Flow cytometry was used for immune-phenotyping the bone marrow cells and splenocytes 
isolated, in order to distinguish the successive developmental stages of TED. Flow cytometric 
analysis was carried out in accordance with published protocols (356,381).  
3.5.1. Staining of cells  
For staining, 1 x 10
6
 cells of each sample were re-suspended in 200 µL of ice-cold staining 
buffer, containing rat anti-mouse CD16/CD32 blocking antibody (cat. no. 553142, BD 
Biosciences, USA) at a concentration of 25 µg/mL. An adequate volume of an antibody pre-mix, 
consisting of fluorochrome-conjugated antibodies, was prepared as shown in Table 6.3.1.  
Two hundred microliters of the antibody pre-mix (containing all the three antibodies) was added 
to each of the sample tubes, and mixed by gently inverting the tubes. 
Table 6.3.1: Antibodies used for flow cytometric analyses  
Antibody 
(fluorochrome) 
Clone Reactivity Supplier (cat.no.) 
Conc. 
(mg/mL) 
Dilution 
CD71 (FITC) C2 Mouse 
BD Pharmingen, USA 
(#553266) 
0.5 
mg/ml 
1:200 
TER-119 (PE) TER-119 Mouse 
BD Pharmingen, USA 
(#553673) 
0.2 
mg/ml 
1:200 
C44 (APC) IM7 Mouse 
BD Pharmingen, USA 
(#559250) 
0.2 
mg/ml 
1:200 
FITC – Fluorescein isothiocyanate; PE – Phycoerythrin; APC - Allophycocyanin 
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3.5.2. Preparation of control samples 
A mixture of cells prepared from all the samples, available for analysis on a particular day, was 
used for preparation of controls. The following control samples were prepared: 
 Unstained controls: 1 x 106 cells were re-suspended in 400 µL of staining buffer.  
 ‘Single-stained’ controls: 1 x 106 cells were re-suspended in 200 µL of staining buffer and 
200 µL of each antibody (diluted as shown in Table 6.3.1) was added. Thus, there was one 
‘single-stained’ control for each of the 3 antibodies used.  
 ‘Fluorescence minus one' or FMO controls: 1 x 106 cells were re-suspended in 200 µL of 
staining buffer and 200 µL of an antibody pre-mix containing all the antibodies, except one, 
was added. Thus, FMO for CD71-FITC consisted of an antibody pre-mix containing anti-
TER119 (PE) and anti-CD44 (APC), but not CD71 (FITC). Similarly, FMO for anti-TER119 
(PE) contained anti-CD44 (APC) and anti-CD71 (FITC), but not anti-TER119 (PE) and 
FMO for anti-CD44 (APC) contained anti-CD71 (FITC) and anti-TER119 (PE), but not anti-
CD44 (APC).  
 
3.5.3. Incubations  
All the samples and controls were incubated for 1 hour in the dark at 4°C. At the end of the 
incubations, 3 mL of staining buffer was added to each of the tubes, mixed and centrifuged at 
400g for 5 min at 4°C. This step was repeated; cells were finally re-suspended in 500 μL of 
staining buffer and used for flow cytometric analyses. 
 
196 
 
3.5.4 Data acquisition 
The samples were analyzed using a BD FACS Aria III instrument with 5 lasers (561-nm [Y/G], 
488-nm [Blue], 633-nm [Red], 405-nm [Violet], and 375-nm [UV]) and 11 colors, at the Core 
Facility, Center for Stem Cell Research, CMC, Vellore, India. BD FACS Diva software was used 
for operating the instrument.  
3.5.5 Data analysis 
Data analysis was done using FlowJo, version 10.4. Compensation was done based on the 
‘single-stained’ controls and the compensation matrix generated by the software was applied to 
all the samples within each group. The unstained and single-stained controls showed a high 
degree of specificity for all the three antibodies used (Fig 6.3.1). The FMO controls showed that 
there was no significant spectral overlap between the fluorophores used (FITC, PE and APC) 
(Fig 6.3.2).The gating strategy was based on published protocols (356,380,381) and is described 
in detail in the results section. 
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3.6. Isolation of erythroid cells (TER119-positive cells) from the bone marrow  
TER119 is widely used as a marker for cells of the erythroid lineage (382). It binds to an antigen, 
which is associated with the erythrocyte membrane protein, glycophorin A (GPA). TER119 is 
not expressed by myeloid, lymphoid, BFU-E or CFU-E cells; pro-erythroblasts show moderate 
levels of expression, while basophilic, polychromatic and orthochromatic erythroblasts, as well 
as reticulocytes and erythrocytes, show high expression. TER119 is, therefore, used as a specific 
marker of the erythroid lineage (382,383).  
To isolate TER119-positive cells from the bone marrow, an immuno-magnetic procedure using 
anti-TER119 MicroBeads was employed (cat. no. 130-049-901, Miltenyi Biotec, Germany). In 
this procedure, cells expressing TER119 were labeled with anti-TER119 antibodies, which were 
attached to magnetically active micro-beads. Cells tagged with the beads were then applied to a 
column placed under the influence of a magnetic field. The labeled cells were retained in the 
column, while the unlabeled cells were allowed to flow through. After this, the column was 
removed from the magnetic field and the retained (TER119-positive) cells were eluted. 
 3.6.1 Sample preparation 
Single-cell suspension of bone marrow (prepared as described for flow cytometric analysis 
[Section 3.2]) was used for isolation of TER119-positive cells. The samples were passed through 
a 40 μm strainer, in order to remove cell clumps. For each sample, 1 x 107 cells were aliquoted to 
fresh tubes and re-suspended in 90 μL of separation buffer (PBS containing 0.5% BSA and 2 
mM EDTA). 
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 3.6.2 Magnetic labeling 
The vial containing the anti-TER119 micro-beads was gently inverted several times to re-
suspend the beads. Ten microliters of the beads were added to 90 μL of the cell suspension, 
prepared as described above; mixing was done by flicking the tubes with fingers. They were then 
incubated at 4°C for 15 min. Following incubation, 2 mL of separation buffer was added to each 
sample; the tubes were centrifuged at 300g for 10 min at 4°C. The supernatant was discarded and 
the pellet was re-suspended in 500 μL of the separation buffer.  
 3.6.3. Magnetic separation 
MACS separation columns (MS column; cat. no. 130-042-201, Miltenyi Biotec, Germany) were 
placed on an OctoMACS separator (Miltenyi Biotec, Germany), which can run 8 samples 
simultaneously (Fig 6.3.3) 
The column was pre-wetted by adding 0.5 mL of the separation buffer. Following this, the cell-
suspension (prepared as described above) was applied to the column and allowed to run through; 
the effluent was discarded. The column was washed thrice by adding 0.5 mL of the separation 
buffer. After washing, the column was removed from the OctoMACS separator and placed in a 
fresh collection tube. One milliliter of separation buffer was added and the column was flushed 
out, using the plunger. The elute that was collected in the collection tube contained the TER119-
positive cells that were labeled by the magnetic beads.  
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3.7. Quantitative real-time PCR 
The suspension containing the TER119-positive cells (isolated as described above) was 
centrifuged at 300g for 5 min at 4°C. The supernatant was discarded and the pellet (containing 
TER119-positive cells) was homogenized in 1 mL of Tri-Reagent (Sigma, India), by repeated up 
and down pipetting. RNA was isolated according to the manufacturer’s instructions (as described 
in detail in Study 1). One microgram of isolated RNA was used to synthesize cDNA, using the 
Reverse Transcriptase Core Kit (Eurogentec, Belgium) (as described in detail in Study 1). 
Quantitative PCR reactions were carried out in duplicate, using the Takyon qPCR SYBR master 
mix (Eurogentec, Belgium), on a BioRad Chromo4 real-time PCR machine. The reaction 
conditions were identical to those described in study 1. The expression levels of genes of interest 
were normalized to Rpl19, which was used as the reference gene. Sequences of all primers used 
are listed in Table 6.3.2. The MIQE check-list and qPCR validation data are provided in 
Appendix I and II (page 323 and 327). 
3.8. Estimation of hemoglobin 
Estimation of hemoglobin was done by the Drabkin’s method (384,385). Five microliters of 
whole blood (collected in K2-EDTA tubes) was added to 995 µL of Drabkin’s solution (cat. no. 
D5941, Sigma, India). After centrifugation at 12000g for 5 min, the absorbance of the solution 
was measured at 540 nm, using a spectrophotometer (UV-1800, Shimadzu, Japan). Hemoglobin 
levels (in g/dL) was obtained by multiplying the optical density (OD)  at 540nm by a factor of 
29.32, which was calculated based on the extinction coefficient of cyanmethemoglobin (44,000) 
(386). 
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Table 6.3.2: Primers used for qPCR 
Sl. 
No. 
Gene 
Accession 
number 
Primer sequence 
Amplicon 
size (bp) 
1 TfR1 (Tfrc) NM_011638.4 
5’-GAGGCGCTTCCTAGTACTCC-3’ 
3’-CTTGCCGAGCAAGGCTAAAC-5’ 
121 
2 TfR 2 (Tfr2) NM_015799.3 
5’-GGTCCTGATCACCCTGCTAA-3’ 
3’-GGAGGTCGCTCCAGTACAAC-5’ 
158 
3 ERFE (Erfe) NM_173395.2 
5’-ATGGGGCTGGAGAACAGC-3’ 
3’-TGGCATTGTCCAAGAAGACA-5’ 
100 
4 GDF-15 (Gdf15) NM_011819.3 
5’-GAGCTACGGGGTCGCTTC-3’ 
3’-GGGACCCCAATCTCACCT-5’ 
130 
5 TWSG1 (Twsg1) NM_023053.3 
5’-TGAGCAAATGCCTCATTCAG-3’ 
3’-CAGGGGCAGTTCCCTTCT-5’ 
61 
6 Rpl19 (Rpl19) NM_009078.2 
5’- ATGAGTATGCTCAGGCTACAGA-3’ 
5’- GCATTGGCGATTTCATTGGTC-3’ 
104 
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3.9 Estimation of serum growth differentiation factor–15 (GDF-15) levels 
Estimation of GDF-15 in serum samples was done using a commercially available ELISA kit 
(cat. no. DY6385; Mouse GDF-15 Duo Set ELISA Development System R&D Systems, USA), 
according to the manufacturer’s instructions. 
 3.9.1 Plate preparation: 
The capture antibody (sheep anti-mouse GDF-15) was reconstituted with 1 mL of PBS and 
further diluted to a working concentration of 0.8 μg/mL. It was then coated on a Nunc 96-well 
microplate (100 μL per well). The plate was sealed and left overnight at room temperature. The 
next day, the excess antibody was aspirated and the plate was washed thrice with wash buffer 
(PBS with 0.05% Tween-20). The coated plate was blocked with reagent diluent (PBS with 1% 
BSA) for 1h and washed again before addition of the sample. 
 3.9.2 Preparation of standards and samples 
The vial containing mouse GDF-15 standard was reconstituted with 0.5 mL of reagent diluent, to 
obtain a final concentration of 500 pg/mL. Serial dilutions were made to obtain standards of the 
following concentrations: 500, 250, 125, 62.5, 31.8, 15.6 and 7.8 pg/mL. Serum samples were 
diluted 1: 5, using the reagent diluent. 
 3.9.3 Assay procedure 
One hundred microliters of the diluted serum samples and the prepared standards were added to 
appropriate wells and incubated at room temperature for 2h. All reactions were carried out in 
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duplicate. After incubation, the wells were washed thrice with wash buffer. One hundred 
microliters of detection antibody (biotinylated sheep anti-mouse GDF-15 diluted to a final 
concentration of 100 ng/mL in reagent diluent) was added to all the wells and incubated at room 
temperature for 2 h. Following this, the plate was washed again and 100 μL of reconstituted 
streptavidin-HRP conjugate was added to all the wells and incubated for 20 min at room 
temperature. After washing, 100 μL of substrate solution (1:1 mixture of Color Reagent A 
(H2O2) and Color Reagent B (Tetramethylbenzidine); R&D Systems, Catalog # DY999) was 
added and incubated at room temperature for 20 min. The reaction was stopped by adding the 
stop solution (2N H2SO4). The color was measured immediately using iMark microplate reader 
(BioRad, USA), set to a wavelength of 450 nm with wavelength correction at 540 nm. OD 
readings obtained for the standards were used to plot a standard curve using a 4-parameter 
logistic (4-PL) curve fit. The average OD reading for each sample was used to estimate levels of 
GDF-15. A factor of 5 was used to correct for the 1:5 dilution of serum samples. 
3.10 Estimation of serum erythropoietin (EPO) levels 
Serum levels of EPO was estimated using a commercially available ELISA kit (cat. no. 
MEP00B, mouse erythropoietin Quantikine ELISA kit, R&D Systems, USA), according to the 
manufacturer’s instructions.  
 3.10.1 Standard and sample preparation 
Serial dilutions of the mouse EPO standard were made to obtain standards of the following 
concentrations: 3000, 1500, 750, 375, 188, 94 and 47 pg/mL. Serum samples were diluted 1: 2, 
using the calibrator diluent provided with the kit. 
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 3.10.2 Assay procedure 
Fifty microliters of assay diluent were added to each well. Following this, 50 μL of the diluted 
serum samples and the prepared standards were added to appropriate wells and incubated at 
room temperature for 2h. All reactions were carried out in duplicate. After incubation, the wells 
were washed five times with wash buffer. One hundred microliters of the detection antibody 
(mouse Epo conjugate) was added to all the wells and incubated at room temperature for 2 h. 
Following this, the plate was washed again; 100 μL of substrate solution was added and 
incubated at room temperature for 20 min. The reaction was stopped by adding the stop solution. 
The color was measured immediately using iMark microplate reader (BioRad, USA), set to a 
wavelength of 450 nm with wavelength correction at 540 nm. OD readings obtained for the 
standards were used to plot a standard curve using a 4-parameter logistic (4-PL) curve fit. The 
average OD reading for each sample was used to estimate levels of EPO. A factor of 2 was used 
to correct for the 1:2 dilution of samples. 
3.11 Statistical analysis 
SPSS version 16.0, was used for all statistical analyses. Since the data were found to be skewed, 
non-parametric tests were used for statistical analysis. The Kruskal-Wallis (KW) test was 
employed to look for significant differences between the various groups studied. Pair-wise 
comparisons between groups were made by the Mann-Whitney test. Correlation analyses were 
done by Spearman’s correlation test. A p value of less than 0.05 was used to indicate statistical 
significance in all cases. 
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4. Results 
4.1 Resolution of distinct stages in TED, based on surface expression of CD71, by flow cytometry 
CD71 (or transferrin receptor 1 [TfR1]) is highly expressed on the surface of erythroblasts. Its 
expression peaks in pro-erythroblasts and basophilic erythroblasts and then declines to lower 
levels in reticulocytes; it is not detectable in mature erythrocytes (387). It was shown that TED 
could be resolved into four distinct stages (called ProE, EryA, EryB and EryC) by flow 
cytometry, based on changes in surface expression of CD71 (388) and in cell size (381). 
Bone marrow cells and splenocytes were processed as described in section 3.2 and 3.3. 
Representative images for the gating strategy employed for bone marrow cells are shown in Fig 
6.3.4; an identical procedure was used for gating splenocytes as well. In Fig 6.3.4-A, the parent 
population (P1) was chosen by excluding cellular debris, nuclei and other small events. The P1 
population was further analyzed, with TER119 expression (PE) taken on the x-axis and CD71 
expression on the y-axis (Fig 6.3.4-B). Here, a clear and distinct population of TER119-positive 
cells was gated, based on the FMO control for TER119-PE (shown in Fig 6.3.2). In addition, a 
gate defining a population of CD71
high
 TER119
intermediate
 cells (pro-E) was added. The TER119-
positive population was further analyzed with forward scatter (a parameter that reflects cell size) 
taken along the x-axis and CD71 expression on the y-axis (Fig 6.3.4-C). Here, the cells were 
divided in three distinct populations - EryA (CD71
high
TER119
high
FSC
high
), EryB 
(CD71
high
TER119
high
FSC
low
) and EryC (CD71
low
TER119
high
FSC
low
). EryA represents the early 
erythroblasts (basophilic and polychromatic erythroblasts), EryB represents orthochromatic 
erythroblasts and reticulocytes, and EryC represents erythrocytes. 
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4.2. Resolution of distinct stages in TED, based on surface expression of CD44, by flow 
cytometry 
CD44 is a ubiquitously expressed type-1 transmembrane glycoprotein, which acts as a cell 
adhesion molecule involved  in various cell-cell and cell-matrix interactions (389). CD44 is 
highly expressed on early erythroblasts; its expression decreases in erythroblasts that are more 
mature. Chen et al (355) showed that successive developmental stages during TED could be 
discriminated based on CD44 expression. This method was further refined by Liu et al (356), 
allowing them to resolve the various populations of erythroblasts to a greater extent than that 
achieved previously using CD71 expression. Using this method, six distinct populations were 
defined as shown in Fig 6.3.5. 
Bone marrow cells and splenocytes were processed as described in sections 3.2 and 3.3. 
Representative images for the gating strategy employed for bone marrow cells are shown in Fig 
6.3.5. In Fig 6.3.5-A, the parent population (P1) was chosen by excluding cellular debris, nuclei 
and other small events. TER119-positive cells in the P1 population were gated (based on FMO 
control for TER119-PE) (Fig 6.3.5-B). The TER119-positive cells were further analyzed with 
CD44 (APC) taken on the y-axis (Fig 6.3.5-C) and a gate defining a population of CD44
high
 
TER119
intermediate
 cells (population I) was added. The TER119-positive population was further 
analyzed with forward scatter taken along the x-axis and C44 expression on the y-axis (Fig 6.3.5-
D). Here, the cells were divided in five populations (II to VI) as shown in Fig 6.3.5-E and F. 
Population I represents pro-erythroblast (pro-E); II, basophilic erythroblasts; III, polychromatic 
erythroblasts; IV, orthochromatic erythroblasts; V, reticulocytes and VI, erythrocytes.  
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4.3. Effect of HFD on erythroid maturation in bone marrow 
The proportions of erythroid cells (TER119-positive) in the bone marrow was not significantly 
affected by HFD at any of the time points studied (Fig 6.3.6–A).  
 4.3.1. Analysis of erythroid maturation in the bone marrow, based on CD71 expression 
Flow cytometric analysis of TED, based on CD71 expression and cell size, showed that the pro-
E (pro-erythroblast) (Fig 6.3.6–B) and EryA (basophilic and polychromatic erythroblasts) (Fig 
6.3.7–A) populations were not affected by HFD at any of the time points studied. EryB 
(orthochromatic erythroblasts and reticulocytes) was increased in HFD-fed mice, with the 
increases being statistically significant at 8 weeks and 20 weeks (Fig 6.3.7–B). EryC 
(erythrocytes) tended to be lower in HFD-fed mice but these changes were not statistically 
significant at any of the time points studied (Fig 6.3.7–C). Fig 6.3.8 shows representative images 
of flow cytometric contour plots from CD and HFD-fed mice at all the time points studied. 
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4.3.2 Analysis of erythroid maturation in the bone marrow, based on CD44 expression 
Analysis of TED, based on CD44 expression and cell size, showed that the early erythroblasts 
(pro-erythroblasts, basophilic and polychromatic erythroblasts) tended to be decreased in HFD-
fed mice at 4 and 8 weeks; these changes were, however, statistically significant only for 
polychromatic erythroblasts at 4 weeks (Fig 6.3.9). Longer durations of HFD-feeding (12, 16, 20 
and 24 weeks) did not have a significant effect upon the early erythroblasts.  On the other hand, 
reticulocytes were found to be consistently increased in HFD-fed mice, with the increase being 
statistically significant at 8 weeks (Fig 6.3.9–E). The ratio of pro-, basophilic, polychromatic and 
orthochromatic erythroblasts (I:II:III:IV) was found to conform to the expected ratio of 1:2:4:8 in 
CD  and HFD-fed mice. Fig 6.3.10 shows representative images of flow cytometric contour plots 
from CD and HFD-fed mice at all the time points studied. 
4.4. Effect of HFD on erythroid maturation in the spleen 
TER119-positive cells and early erythroblasts (EryA) in the spleen were not affected by HFD-
feeding (Fig 6.3.11–A and B). The EryB population (orthochromatic erythroblasts and 
reticulocytes) was significantly lower in mice fed HFD for 24 weeks (Fig 6.3.1–C). This was 
accompanied by a corresponding increase in EryC cells at the same time point (Fig 6.3.11–D). 
Fig 6.3.12 shows representative images of flow cytometric dot plots from CD and HFD-fed mice 
at all the time points studied. 
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4.5 Effect of HFD-feeding on hemoglobin 
Hemoglobin levels in blood were not significantly different between CD and HFD-fed mice, 
except at 16 weeks, where HFD-fed mice had significantly higher levels (Fig 6.3.13). 
4.6 Effect of HFD-feeding on gene (mRNA) expression of erythroid regulators of hepcidin in 
TER119-positive cells 
Erythroferrone, GDF-15, and TWSG-1 are putative erythroid regulators of hepcidin expression; 
they are synthesized and secreted by erythroid precursor cells in the bone marrow (100). 
TER119-positive cells were isolated by positive selection (using the MACS immuno-magnetic 
micro-bead system, Miltenyi Biotec, Germany), as described in section 3.6. Gene expression of 
erythroferrone (Fig 6.3.14–A) and TWSG-1 (6.3.14–C) were not significantly different in CD 
and HFD-fed mice at any of the time points studied. GDF-15 expression, on the other hand, was 
found to be significantly decreased after 24 weeks of HFD (Fig 6.3.14–B). 
4.7 Effect of HFD-feeding on gene (mRNA) expression of transferrin receptors 1 and 2 in 
TER119-positive cells 
Expression of TfR1 (390) and TfR2 (391) in bone marrow erythroid cells have been shown to be 
associated with the regulation of hepcidin expression in the liver. In the present study, HFD-
feeding did not have a significant effect on the expression of these genes (Fig 6.3.15). 
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4.8 Effect of HFD-feeding on serum levels of EPO and GDF-15 
There were no differences in serum EPO levels between CD and HFD-fed mice at any of the 
time points studied. Serum GDF-15 levels were significantly elevated after 16, 20 and 24 weeks 
of HFD-feeding (Fig 6.3.16).  
4.9 Effect of HFD-feeding on erythroferrone expression in the skeletal muscle 
ERFE is has been reported to be expressed in the skeletal muscle (392). In view of this, the effect 
of HFD on muscle Erfe mRNA expression was also studied. There was a statistically significant 
increase in mRNA levels of ERFE in the skeletal muscle at 24 weeks of HFD-feeding, but not at 
the other time points studied (Fig 6.3.17). 
4.10 Correlation analyses 
Correlation analyses showed that gene expression of erythroid regulators of hepcidin (ERFE, 
GDF-15 and TWSG-1) in TER119-positive cells correlated among themselves and with those of 
TfR1 and TfR2 (Table 6.3.3). They did not show any correlation with hepatic hepcidin 
expression, either in CD-fed mice or in those fed HFD (Table 6.3.4). GDF-15 and TfR2 mRNA 
correlated positively with hepatic hepcidin in CD-fed mice but not in those fed HFD. In mice fed 
HFD, hemoglobin correlated negatively with hepcidin expression (Table 6.3.4).  
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Table 6.3.3: Correlation among the erythroid regulators of hepcidin, TfR1 and TfR2 (gene 
expression in TER119-positive cells)   
Spearman’s rho ERFE GDF-15 TWSG-1 TfR1 TfR2 
ERFE - 0.32* 0.12 0.38** 0.36** 
GDF-15  - 0.47** 0.51** 0.55** 
TWSG-1   - 0.54** 0.41** 
TfR1    - 0.62** 
TfR2     - 
Spearman’s correlational coefficients are shown 
* p < 0.05, ** p < 0.01 
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Table 6.3.4: Correlational analyses of liver hepcidin (Hamp1) expression with other parameters 
of interest 
Variables All mice CD-fed mice HFD-fed mice 
ERFE mRNA expression in TER119-
positive cells 
0.16 0.05 0.30 
GDF-15 mRNA expression in TER119-
positive cells 
0.34** 0.36* 0.24 
TWSG-1 mRNA expression in TER119-
positive cells 
0.03 -0.05 -0.01 
TfR1 mRNA expression in TER119-
positive cells 
0.19 0.18 0.23 
TfR2 mRNA expression in TER119-
positive cells 
0.25* 0.53** 0.03 
Serum erythropoietin 0.02 0.16 0.17 
Serum GDF-15 0.16 0.29 0.23 
Hemoglobin -0.19 0.13 -0.44* 
Spearman’s correlational coefficients are shown 
* p < 0.05, ** p < 0.01 
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5. Discussion: 
HFD-feeding in mice (a model of IR) was shown to decrease hepatic hepcidin expression (Study 
2). Erythroid precursors in the bone marrow are known to secrete factors (erythroid regulators of 
hepcidin) that can powerfully down-regulate hepcidin expression in the liver (100). However, it 
was not known whether these factors had a role in mediating hepcidin suppression in the setting 
of HFD feeding. Since insulin is known to stimulate erythropoiesis in vitro (37,368,369), it was 
hypothesized that HFD-induced hyperinsulinemia may stimulate erythropoiesis in vivo as well, 
which may, in turn, increase the expression of the erythroid regulators of hepcidin, resulting in 
hepcidin suppression. In order to test this hypothesis, maturation of erythroid precursors in the 
bone marrow was studied in HFD-fed mice. The expression of the erythroid regulators of 
hepcidin in bone marrow erythroid precursors (TER119-positive cells) was also determined, to 
attempt to elucidate their role in HFD-induced suppression of hepcidin. 
Two strategies were used to study terminal erythroid differentiation (TED) by flow cytometry. 
The first was based on CD71 expression (381), while the second was based on CD44 expression 
(356). The latter has the advantage of resolving each stage in TED with greater precision than 
that which could be achieved by the first strategy based on CD71 expression (355). 
The results obtained showed that the proportion of TER119-positive cells in the bone marrow 
was similar in CD and HFD-fed mice. The ratio of pro-, basophilic, polychromatic and 
orthochromatic erythroblasts was similar (in keeping with normal ratios of ~1:2:4:8) in both 
groups of mice, and was not affected by their diet (CD or HFD). The number of early 
erythroblasts (pro-, basophilic and polychromatic erythroblasts) tended to be lower in HFD-fed 
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mice at 4 and 8 weeks and higher at 16 weeks, compared to CD-fed mice. These changes, 
however, were not statistically significant. Overall, the results suggested that the process of TED, 
per se, was not significantly affected by HFD feeding. 
The last stage in TED is the formation of orthochromatic erythroblasts, which then enucleate to 
form immature reticulocytes. The reticulocyte population in the bone marrow (EryB [identified 
based on CD71 expression] and population V [identified based on CD44]) was consistently 
higher in HFD-fed mice than in CD-fed mice (Fig 6.3.7 and 6.3.9). It does not seem likely that 
increased erythropoiesis contributed to this increase, as the proportion of TER119-positive cells 
and early erythroblasts in the bone marrow was not significantly increased by HFD-feeding. It is 
possible that this may be due to delayed release of reticulocytes from the marrow. 
Newly formed (nascent) reticulocytes undergo a complex process of maturation during which 
they transform morphologically into discoid erythrocytes. This process occurs in two stages 
(over approximately 48 hours) and is not well-understood. The first stage (initial 24 hours) 
occurs in the bone marrow. During this time, nascent reticulocytes get rid of their intracellular 
membrane-bound organelles by a process that involves autophagy and exocytosis. They are then 
released into the circulation, where they undergo a further 24 hours of maturation, before they 
become erythrocytes (357,393). For release of reticulocytes from the marrow into the circulation, 
it is essential for them to pass through an endothelial barrier, which separates the marrow 
hematopoietic cords from the blood vessels (sinuses). This process requires a high degree of 
reticulocyte membrane deformability (394–396). The process of reticulocyte maturation, which 
occurs in the marrow, involves distinct changes in membrane fluidity as well as protein 
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composition, which are essential to increase their deformability (395). Impairment in this 
maturation process can hinder their release into circulation.  
It has been shown that diabetes mellitus is associated with decreased erythrocyte deformability 
(397–399). This has also been shown in mice fed HFD (400). Although the reasons for this are 
not well-understood, hyperglycemia-induced glycation of cytoskeletal components and changes 
in membrane composition may play important roles (401,402). It is possible that decreased 
reticulocyte deformability in mice fed HFD may impair the release of reticulocytes from the 
marrow into the circulation; this may account for the increase in reticulocytes in the bone 
marrow seen in the present study. Additional studies would be required to test this hypothesis. 
Insulin has been shown to have a stimulatory effect on erythropoiesis in vitro (as has been 
described earlier (37,368,369)). The stimulatory effects of insulin on proliferation of CFU-E in 
these studies were seen  at concentrations in the range of 50 to 500 µg/L (37,368). In addition, 
these effects were seen in the presence of high concentrations of EPO (>33 ng/mL or 5 U/mL) 
(368). The results of the present study show that HFD-fed mice had insulin levels in the range of 
4-8 µg/L (Fig 6.2.5-A) and EPO in the range of 200-400 pg/mL (Fig 6.3.16-A). These 
concentrations are much lower than those used in the in vitro studies discussed above. It is 
therefore possible that, at the concentrations of insulin and EPO seen in vivo, the stimulatory 
effects of insulin on erythropoiesis may not be substantial. 
Interestingly, hemoglobin levels (Fig 6.3.13), as well as the proportion of early erythroblasts in 
the bone marrow (Fig 6.3.9), increased in HFD-fed mice, at 16 weeks. This corresponded with 
the onset of hyperinsulinemia in this model (described in Study 2 [Fig 6.2.5] and also reported by 
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other investigators (164,344)). However, this effect did not persist with HFD feeding continuing 
for 20 and 24 weeks, although hyperinsulinemia peaked at these time points (Fig 6.2.4). The 
reasons for this are not clear. 
In mice, the spleen is an important accessory organ for erythropoiesis. It contributes significantly 
to ‘stress erythropoiesis’, which occurs in conditions where erythropoiesis is stimulated, such as 
in response to acute blood loss, hemolysis and iron deficiency (353). In the present study, no 
significant change was found in the proportion of TER119-positive cells and early erythroblasts 
(EryA) in the spleen in response to HFD-feeding (Fig 6.3.11). This showed that erythropoiesis in 
the spleen was not stimulated in this setting.  
In the present study, gene expression of ERFE, GDF-15 and TWSG-1 in TER119-positive cells 
was not significantly affected by HFD-feeding (except for a significant decrease in GDF-15 
expression in mice fed HFD for 24 weeks). The expression of ERFE and TWSG-1 also did not 
correlate with that of hepatic Hamp1 expression or serum hepcidin levels. On the other hand, 
GDF-15 expression had a significant positive correlation with hepatic hepcidin expression 
(instead of the expected negative correlation). The explanation for this observation is not clear. 
Overall, these results indicate that ERFE, GDF-15 and TWSG-1 do not appear to contribute 
significantly to hepcidin suppression in this setting. However, it is possible that other hitherto 
unidentified erythroid regulators of hepcidin may be operational, as has been suggested by 
Pasricha et al (100).   
Among the 3 putative candidates that have been identified as erythroid regulators of hepcidin, 
ERFE is considered to be the most relevant, physiologically (100,101). The expression of ERFE, 
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but not that of GDF-15 and TWSG-1, was positively correlated with serum EPO levels and 
negatively correlated with hemoglobin. These findings support the view that ERFE expression in 
the bone marrow is regulated by physiological stimuli that affect erythropoiesis. 
ERFE is also highly expressed in skeletal muscles. It was initially discovered and identified as a 
myokine (‘myonectin’) that regulates systemic lipid homeostasis by increasing fatty acid uptake 
in the liver and adipose tissue (392). However, the role of skeletal muscle-derived ERFE in the 
regulation of hepatic hepcidin expression has not been studied. In the present study, HFD was 
found to increase ERFE mRNA in the skeletal muscle at 24 weeks (Fig 6.3.17). Although this 
corresponded with a significant decrease in hepatic hepcidin expression at the same time point, 
there was no correlation found between skeletal muscle ERFE expression and liver hepcidin 
expression. Additional work would be required to determine whether ERFE in the skeletal 
muscle has any role in regulation of hepcidin.  
Serum levels of GDF-15 were elevated in mice fed HFD for 16, 20 or 24 weeks (Fig 6.3.16). 
Recently, it has been shown that GDF-15 is an important myomitokine (a humoral factor 
released by skeletal muscles in response to mitochondrial dysfunction) that increases insulin 
sensitivity and plays a key role in systemic energy homeostasis (403). It is possible that the 
source for the elevated serum levels of GDF-15 (seen in this study in response to HFD-feeding) 
is the skeletal muscle.  However, expression of GDF-15 in skeletal muscle was not determined in 
the present study. Hence, it is not possible to definitively localize the source(s) of the increased 
blood levels of GDF-15.  In addition, it is also not clear whether elevated serum GDF-15 plays a 
role in mediating hepcidin suppression in this setting; this aspect requires further investigation.  
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Gene expression of ERFE, GDF-15 and TWSG-1 in TER119-positive cells showed strong 
positive correlations among themselves, suggesting that these factors were coordinately 
regulated (Table 6.3.3). It has been reported that TfR1 expression in erythroid cells is associated 
with decreased hepatic hepcidin expression (390). In the present study, expression of TfR1 was 
highly correlated with that of the ERFE, GDF-15 and TWSG-1, but not with that of hepatic 
hepcidin expression (Table 6.3.4). This suggests that TfR1 may be involved in the regulation of 
the erythroid regulators of hepcidin; however, in the current setting, these factors did not affect 
hepatic hepcidin expression. On the other hand, TfR2 expression in TER119-positive cells was 
positively correlated with the erythroid regulators of hepcidin and with hepatic TfR2 and Hamp1 
expression levels. TfR2 in the liver regulates hepcidin expression (404); in erythroid cells, it acts 
as a modulator of EPO signaling (405). It is therefore possible that TfR2 may play a role in 
hepcidin regulation in the liver and EPO-induced expression of erythroid regulators of hepcidin 
in the bone marrow. 
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6. Summary and conclusions: 
In summary, the results presented in this study show that high-fat feeding in mice, with 
associated hyperinsulinemia, did not stimulate erythropoiesis in the bone marrow or spleen. 
Terminal erythroid differentiation in the bone marrow was similar in both groups of mice, 
irrespective of the diet they were fed. On the other hand, HFD-fed mice showed increased 
numbers of reticulocytes in the marrow, which possibly suggests impairments in maturation of 
reticulocytes and their release into the circulation.  
HFD did not affect the expression of the putative erythroid regulators of hepcidin, viz., ERFE, 
GDF-15 and TWSG-1, in erythroid cells isolated from the marrow. Hence, it appears unlikely 
that these factors play an important role in the down-regulation of hepatic hepcidin expression 
seen in response to high-fat feeding. 
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STUDY 4 
Dysregulated iron homeostasis in patients newly diagnosed with diabetes mellitus or pre-
diabetes  
1. Abstract 
Type 2 diabetes mellitus (T2DM) has been reported to be associated with increased body iron 
stores. However, studies that have estimated serum levels of hepcidin, the chief hormone 
involved in regulation of iron homeostasis, in patients with T2DM have shown variable results. 
Possible reasons for this may include differences in many patient-related factors in these studies, 
such as duration since diagnosis of diabetes, extent of glycemic control, therapeutic interventions 
and presence of chronic complications of diabetes. In an attempt to minimize the effects of such 
confounding factors, the present investigation aimed to study hepcidin and other iron-related 
parameters in patients newly diagnosed with diabetes mellitus or pre-diabetes. 
Adult males who were newly diagnosed to have diabetes mellitus (n=40) or pre-diabetes (n=40), 
based on fasting plasma glucose (FPG) levels (as per the criteria of the American Diabetic 
Association [ADA]) were the subjects of the study. Men, who were found to be normoglycemic, 
using the criteria of the ADA, were recruited as control subjects. Anthropometric measurements 
were made on all subjects. Blood samples were obtained for measurement of hematological 
parameters, markers of iron status (ferritin, hepcidin, iron, total iron-binding capacity and 
transferrin saturation), C-reactive protein (CRP) (marker of inflammation) and insulin. 
Homeostatic model assessment–insulin resistance (HOMA-IR) and HOMA-β (indices of insulin 
resistance and pancreatic insulin secretory capacity respectively), were calculated. In addition, 
reticulocytes were isolated from peripheral venous blood obtained from a sub-set of control and 
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diabetic patients to determine gene expression of erythroferrone, a factor known to regulate 
hepcidin levels. 
The results of this study showed that diabetics (but not pre-diabetics) had significantly elevated 
HOMA-IR values, while both pre-diabetics and diabetics showed significantly lower HOMA-β 
values. Serum levels of ferritin and hepcidin were higher in patients with diabetes mellitus than 
in control subjects. In the pre-diabetics, levels of these parameters were similar to levels in 
control subjects. CRP levels also tended to be higher in the diabetic group compared to controls; 
levels in the pre-diabetic group and controls were similar. Classification of patients into sub-
groups, based on CRP levels (using a cut-off of 3.0 mg/L), did not reveal an association of 
ferritin or hepcidin with this marker in either the pre-diabetic or diabetic groups. Serum markers 
of iron status (such as serum iron, TIBC and transferrin saturation), were not significantly 
different in the three groups. Expression of erythroferrone in reticulocytes isolated from 
peripheral blood was similar in the controls and diabetics. 
In conclusion, the results of this study show that, patients, who were newly diagnosed with either 
diabetes mellitus or pre-diabetes, showed evidence of early-onset beta cell failure. Serum levels 
of ferritin and hepcidin were higher in the diabetic group. Additional studies are required to 
elucidate the etiopathological factors that underlie these findings. 
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2. Introduction 
A number of epidemiological studies have shown that increased ferritin levels are strongly 
associated with risk of developing type 2 diabetes mellitus (T2DM) (4,6,192,406). Ferritin levels 
in the blood are indicative of body iron stores, thereby linking iron homeostasis with diabetes 
mellitus. However, as described in the review of literature, the mechanisms that underlie the 
association between the two are not clear.  
Hepcidin is the chief regulator of iron homeostasis in the body. There are very few human 
studies on hepcidin levels in patients with diabetes mellitus. Available literature shows that the 
results of these studies are inconsistent, with some showing increased hepcidin levels in diabetics 
(25,26), while others have shown either decreased levels (27–29,407) or levels similar to those in 
control subjects (30). There is no Indian data in this area, as far as is ascertainable.  
Several factors may contribute to the variable reports on hepcidin and iron-related parameters in 
patients with diabetes mellitus. The duration from the time of diagnosis of diabetes mellitus, 
extent of glycemic control, various therapeutic interventions used (such as use of anti-diabetic 
drugs / insulin), presence of chronic complications of diabetes and inflammation are some factors 
that need to be considered in this context (187). In addition, among women, parity, phase of the 
menstrual cycle (in pre-menopausal women) and menopausal changes can also significantly 
affect iron homeostasis (408,409). In order to avoid these confounding factors, this study aimed 
to look at hepcidin and other iron-related parameters in males who were newly diagnosed to have 
either pre-diabetes or diabetes mellitus. The data obtained was compared with age-matched 
control men, who had normal glycemic status. 
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Among the factors that regulate hepatic hepcidin expression, the most potent regulators are those 
that are known to be secreted by erythroid precursors in the bone marrow (called the erythroid 
regulators of hepcidin). As described in detail in Study 3, putative erythroid regulators of 
hepcidin that have been identified include erythroferrone [ERFE/Fam132b] (35), growth 
differentiation factor-15 [GDF-15] (33) and twisted gastrulation factor-1 [TWSG-1] (34). Recent 
studies done in various mouse models have shown that, among these, ERFE appears to be the 
most promising candidate (100). Whether these factors (ERFE, GDF-15 and/or TWSG-1) play a 
role in regulation of hepcidin in patients with pre-diabetes/diabetes has not been studied. 
Reticulocytes found in the peripheral circulation represent the final stage of erythroid 
development before mature RBCs are formed. It has been shown that RNA in reticulocytes 
represents gene expression during the final stages of erythropoiesis (410). Hence, it is plausible 
that mRNA expression of erythroid regulators of hepcidin in reticulocytes in peripheral blood 
may provide useful information on events in the bone marrow.  
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3. Methods 
3.1 Setting 
The subjects of this cross-sectional observational study were recruited from the out-patient clinic 
of the Community Health and Development Hospital, at Christian Medical College, Vellore, 
Tamil Nadu, India.  
3.2 Subjects  
Male patients, who were referred for medically-indicated estimations of fasting plasma glucose, 
were recruited into the study, using the inclusion and exclusion criteria detailed below.  
3.2.1 Inclusion criteria: 
 Male patients  
 Between the ages of 30 to 70 years 
 Not been diagnosed to have diabetes or pre-diabetes anytime in the past 
3.2.2 Exclusion criteria 
 BMI more than 35 kg/m2 
 Hemoglobin less than 13 g/dL 
 Serum CRP levels more than 12 mg/L 
 Appeared to have complications of diabetes, as assessed by history, clinical findings or 
results of laboratory tests 
Informed consent was obtained from all patients who were recruited. An information sheet for 
patients was provided in English or Tamil, depending on each patient’s preference. Consent 
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forms were also made available in the 2 languages. The information sheet and consent form (in 
both languages) are included in Appendix V to VIII. 
Basic demographic details were collected, using the proforma in Appendix IX. Anthropometric 
measurements (height, weight, waist circumference and hip circumference) were made on each 
subject.  
Patients who were found to be eligible for the study were classified as controls, pre-diabetics or 
diabetics, based on fasting plasma glucose levels, as per the criteria of the American Diabetes 
Association (ADA) (2015) (411). 
Table 6.4.1: Classification of subjects recruited into the study based on fasting plasma glucose 
levels as per ADA criteria (2015)  
Classification Fasting plasma glucose level (mg/dL) 
Control (n = 40) ≤ 99 
Pre-diabetes (n = 40) 100 - 125 
Diabetes mellitus (n = 40) ≥ 126 
 
The sample size for the study was calculated based on data from the study by Jiang et al (26), 
who estimated serum hepcidin levels in patients with diabetes mellitus and age-matched controls. 
Based on this study, in order to achieve an effect size of 0.65, power of 80% and 5% level of 
significance (2-tailed), the number of subjects to be studied was calculated to be 38. Hence, 40 
subjects were recruited in each group (control, diabetic and pre-diabetic). 
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3.3 Collection of blood 
Blood samples were obtained after an overnight fast (defined as no calorie intake for at least 8 
hours prior to collection). A total of 15 mL of blood was collected; 2 mL for glucose estimation 
(in BD Vacutainer Fluoride tubes), 5 mL for serum separation (in BD Vacutainer Serum tubes) 
and 8 mL for hematological parameters and reticulocyte isolation (in BD Vacutainer Heparin 
tubes). Blood collected in serum tubes was allowed to clot; it was then centrifuged at 2000g for 
10 min at room temperature. Serum obtained was aliquoted into 4-5 micro-centrifuge tubes and 
stored at – 70°C until further use. 
3.4. Estimation of hematological parameters 
Hemoglobin, total RBC count, mean corpuscular volume (MCV), mean corpuscular hemoglobin 
(MCH), mean corpuscular hemoglobin concentration (MCHC), reticulocyte hemoglobin content 
(CHr) and absolute reticulocyte count were estimated using the Sysmex XN 9000 automated 
hematology analyzer (Department of Transfusion Medicine and Immunohematology, CMC, 
Vellore).  
3.4 Estimation of parameters in serum  
3.4.1. Hepcidin 
Hepcidin was measured using a commercially available kit (cat. no. S-1337, Hepcidin–25 
[human] EIA kit, Peninsula Laboratories, USA). This is a competitive immunoassay where 
hepcidin in the sample competes with a biotinylated tracer to bind to anti-hepcidin antibodies. 
The amount of biotinylated tracer that is bound is inversely proportional to hepcidin levels in the 
sample.  
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The assay was carried out according to manufacturer’s instructions. Briefly, anti-hepcidin 
antibodies were added to wells in a micro-plate to coat its walls. Standards or serum samples 
(diluted 1:10 using the diluent provided) were then added, along with the biotinylated tracer, and 
the plate was incubated at 4°C overnight. Following this, the plate was washed and incubated 
with streptavidin-HRP conjugate for 1 hour. For color development, TMB 
(tetramethylbenzidine) substrate was added. The reaction was stopped by addition of 2N HCl 1 h 
later. OD readings were taken at 450 nm using an iMark plate reader (BioRad, USA). All 
standards and samples were analyzed in duplicates; the average of the OD readings was used for 
calculations. OD values obtained for the standards were used to plot a standard curve by 4-
parameter logistic regression. Serum hepcidin levels were calculated using equation of the 
standard curve, after adjusting for sample dilution (dilution factor of 10). 
 3.4.2. C-reactive protein (CRP) 
CRP was estimated using a high sensitivity assay (hsCRP). This was a two-site 
chemiluminescent enzyme immunometric assay done using IMMULITE 2000 XPi system 
(Siemens GmBH, Germany), in the Department of Clinical Biochemistry, CMC, Vellore. 
3.4.3. Ferritin 
Ferritin was estimated by a sandwich immunoassay with chemiluminescence detection, using the 
ADVIA Centaur XP immunoassay system (Siemens GmBH, Germany) in the Department of 
Clinical Biochemistry, CMC, Vellore. 
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 3.4.4. Iron 
Iron was estimated by a colorimetric method based on ferrozine dye-binding, using the Roche 
Cobas c702 auto-analyzer (Roche Diagnostics, Switzerland) in the Department of Clinical 
Biochemistry, CMC, Vellore. 
 3.4.5. Total iron-binding capacity (TIBC) and transferrin saturation 
Serum samples were incubated with a known concentration of iron. The iron that remained 
unbound after incubation was estimated using a ferrozine-based assay, as described above. Based 
on this, the amount of added iron that was bound (mainly by transferrin in serum) was calculated 
as the unbound iron-binding capacity (UIBC). TIBC was the calculated as the sum of serum iron 
and UIBC. 
Transferrin saturation was calculated using the formula: 
Transferrin saturation (%) = (Serum iron x 100) / TIBC 
3.4.6. Insulin 
Insulin was estimated by a solid-phase enzyme-labeled chemiluminescent immunoassay, using 
the IMMULITE 2000 XPi system (Siemens GmBH, Germany), in the Department of Clinical 
Biochemistry, CMC, Vellore. 
3.5 Calculation of HOMA-IR and HOMA-β indices 
Homeostatic model assessment (insulin resistance) or HOMA-IR is an index of insulin resistance 
(412). It is calculated using the formula given below: 
HOMA-IR = (Fasting plasma glucose [mg/dL] x Fasting insulin [μIU/mL]) / 405 
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HOMA – β is an index of insulin secretion by the pancreas (412). It is calculated using the 
formula given below: 
HOMA – β (%) = (360 x fasting insulin [μIU/mL]) / (fasting plasma glucose [mg/dL] – 63) 
3.6 Isolation of reticulocytes from blood 
Reticulocytes were isolated from 8 mL of heparinized blood, following a procedure based on 
leukodepletion (described by Bresnick) (413). Leukocytes were concentrated by centrifugation 
of heparinized blood at 2000g for 30 min at 4 °C. This resulted in the formation of a white disc 
(buffy coat) at the plasma-red cell interface. Plasma was collected and stored for future use; the 
buffy coat was discarded. The red cells were washed three times with 5 mL of ice-cold PBS. 
After the third wash, reticulocytes, which have a lower density compared to mature erythrocytes, 
were concentrated by centrifugation at 2000g for 30 min at 4°C. The supernatant was removed; 
400 µL of packed cells (reticulocyte-rich fraction) at the top of the tube was removed and added 
to 5 ml of ice-cold PBS. This red cell suspension was then layered on top of a column (prepared 
in a 10 mL syringe) consisting of 5 mL of a mixture containing 2 parts cellulose (C-8002; Sigma, 
India) and 1 part Sigmacell cellulose type 50 (50 μm) (S-5504; Sigma, India). The red cells were 
eluted by gentle centrifugation of the column at 150g at 4 °C for 1 min. The leukodepleted elute 
was washed three times using 5 mL of ice-cold PBS. After the third wash, the reticulocyte-
enriched, leukocyte-depleted pellet was vigorously mixed in 1 mL TRIzol LS (cat. no. 
10296028, Thermo Fisher Scientific, USA), using a vortex mixer. Samples were stored at -70
°
C 
till used further for RNA extraction. 
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3.7 Quantitative real-time PCR 
Reticulocyte-enriched samples homogenized in TRIzol LS were used for isolation of RNA. This 
was done according to the manufacturer’s instructions (as described in Study 1). One microgram 
of isolated RNA was used to synthesize cDNA, using the Reverse Transcriptase Core Kit 
(Eurogentec, Belgium) (as described in Study 1). Quantitative PCR reactions were carried out in 
duplicate, using the Takyon qPCR SYBR master mix (Eurogentec, Belgium) on a BioRad 
Chromo4 real-time PCR machine. The genes studied and the sequences of the primers used are 
listed in Table 6.4.2. The reaction conditions were identical to those described in study 1. The 
expression levels of these genes of interest were normalized to GAPDH, which was used as the 
reference gene (414). The MIQE check-list and qPCR validation data are provided in Appendix I 
and II (page 323 and 327). 
3.8 Statistical analysis 
Statistical analyses was done using SPSS version 16.0. The Shapiro-Wilk test was used to test 
for normality of distribution of data. For normally distributed data, one-way ANOVA followed 
by pair-wise comparisons using Bonferroni test was done. For skewed data, the Krushkal –
Wallis test followed by pair-wise comparisons using Mann Whitney test was done. For 
correlational analysis, Pearson’s correlation was used for normally distributed data and 
Spearman’s correlation for skewed data. Multivariate analysis was done using linear regression. 
A p-value less than 0.05 was taken to indicate statistical significance in all cases. 
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Table 6.4.2: Primers used for qPCR 
Sl. 
No. 
Gene 
Accession 
number 
Primer sequence 
Amplicon 
size (bp) 
1 ERFE NM_001291832.1 
CAGCAGTGAGCTCTTCACCA 
CAAGAACACGGAGGTCCACT 
76 
2 GDF-15 NM_004864.2 
CTGCAGTCCGGATACTCACG 
GAACAGAGCCCGGTGAAGG 
125 
3 TWSG-1 NM_020648.5  
GAATGTGTCTGTCCCCAGCA 
GGATGCTCCCATGGACTCAC 
136 
4 TFR1 NM_003234.2 
AGCAGGGAAAATCACCTTTGC 
GTCCCCAGATGAGCATGTCC 
141 
5 TFR2 NM_003227.3 
GTGGACCGACACGCACTAC 
TGTAGGGGCAGTAGACGTCAG 
134 
6 GAPDH NM_002046.5 
GAAGGTGAAGGTCGGAGTC 
GAAGATGGTGATGGGATTTC 
226 
 
 
 
 
 
 
 
253 
 
4. Results: 
4.1 Characteristics of participants in the study: 
One hundred and twenty subjects were recruited, based on the inclusion and exclusion criteria 
listed in section 3.2. They were classified as control subjects, pre-diabetics or diabetics, based on 
fasting plasma glucose levels (as per criteria of the American Diabetic Association) (ADA) 
(2015) (411), given in Table 6.4.1. There were 40 subjects in each group. Subjects in all three 
groups were similar in age and had similar anthropometric measurements (BMI, waist and hip 
circumferences and the waist-hip ratio) (Table 6.4.3). 
4.2 Metabolic parameters 
As expected, fasting plasma glucose (FPG) showed significant differences among the groups.  
Pre-diabetics had significantly higher plasma glucose levels than control subjects. The diabetics 
had significantly higher levels of plasma glucose than the control subjects and pre-diabetics (Fig 
6.4.1-A). Surprisingly, fasting insulin levels were similar in all three groups (Fig 6.4.1-B). 
HOMA-IR, an index of insulin resistance, was significantly higher among the diabetics than in 
control subjects and pre-diabetics; there was no significant difference between values in the 
control and pre-diabetic groups (Fig 6.4.2-A). HOMA-β, an index of pancreatic insulin secretory 
function, was significantly lower in the diabetic and pre-diabetic groups compared to the control 
group. Diabetics had significantly lower values compared to pre-diabetics (Fig 6.4.2-B). 
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Table 6.4.3: Age and anthropometric measurements of the study subjects 
Parameter 
Control 
subjects 
(mean ± SD) 
Pre-diabetics  
(mean ± SD) 
Diabetics   
(mean ± SD) 
 p value* 
Age (years) 45.8 ± 9 48.7 ± 9.8 45.9 ± 7.1 0.26 
Height (m) 1.7 ± 0.1 1.6 ± 0.1 1.6 ± 0.1 0.004 
Weight (kg) 72.7 ± 11.2 68.6 ± 9.8 70.6 ± 10.8 0.25 
BMI (kg/m
2
) 25.7 ± 3.7 25.8 ± 3.2 26 ± 3.6 0.9 
Waist circumference (cm) 92.4 ± 9.3 91.2 ± 9.3 91.8 ± 9.7 0.84 
Hip circumference (cm) 95 ± 7.5 92.1 ± 8.6 92.5 ± 9.6 0.27 
Waist-to-hip ratio 1 ± 0.05 1 ± 0.1 1 ± 0.04 0.11 
* Statistical analyses were done using ANOVA. 
 
 
 
 
 
255 
 
 
256 
 
 
257 
 
4.3 Hematological parameters 
Among the hematological parameters, values for mean corpuscular hemoglobin (MCH) and 
reticulocyte hemoglobin (CHr) were significantly lower in the pre-diabetic group than in control 
subjects. All the other hematological parameters (hemoglobin, RBC count, mean corpuscular 
volume [MCV] and reticulocyte count) were similar in the 3 groups (Table 6.4.4) 
4.4 Iron-related parameters 
Serum iron, TIBC and transferrin saturation were similar in the 3 groups (Table 6.4.5). Serum 
ferritin levels were significantly higher in the diabetic group than in the control and pre-diabetic 
groups; levels in the control and pre-diabetic groups were similar (Fig 6.4.3–A). Serum hepcidin 
levels were also higher in the diabetic group than in the control group. Levels in the diabetic 
group also tended to be higher than that in the pre-diabetic group (p=0.063). Hepcidin levels 
were similar in the control and pre-diabetic groups (Fig 6.4.3–B). 
4.5 Serum levels of CRP 
Serum levels of CRP, a marker of inflammation, tended to be higher in the diabetic group 
compared to the control subjects (p = 0.065); levels in the pre-diabetic group were higher than in 
control subjects, but not significantly so. Levels in the diabetic group were higher than in the pre-
diabetics, but once again, not significantly so (Fig 6.4.4).   
In order to ascertain whether the higher levels of serum ferritin and hepcidin seen in the diabetics 
were associated with inflammation, patients were categorized into sub-groups with low and high 
CRP levels. A cut-off value of 3.0 mg/L of CRP was used for this purpose (415). The results 
showed that, in the control group, both ferritin (p = 0.063) and hepcidin (p = 0.049) tended to be 
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higher in the high-CRP sub-group compared to the low-CRP sub-group. Among the diabetics, 
ferritin and hepcidin levels were slightly higher in the high-CRP sub-group, compared to the 
low-CRP sub-group (Fig 6.4.5), but not significantly so.  Levels in the pre-diabetics were similar 
in the 2 sub-groups.  
Sub-categorization was also done using a cut-off value for CRP of 6 mg/L, which is the upper 
limit of the reference range for CRP (416).  Both ferritin (p = 0.073) and hepcidin (p = 0.068) 
tended to be higher in the high-CRP sub-group compared to the low-CRP sub-group among the 
controls. No significant difference was seen between high and low CRP sub-groups in the pre-
diabetic and diabetic groups (Fig. 6.4.6).  
4.5 Expression of erythroid regulators of hepcidin in reticulocytes isolated from peripheral 
blood 
Reticulocytes were isolated from peripheral blood in a sub-set of control (n=20) and diabetic (n = 
21) subjects, and used to determine gene expression of erythroid regulators of hepcidin, viz., 
ERFE, GDF-15 and TWSG-1. ERFE mRNA was found to be expressed at low-to-moderate 
levels in reticulocytes and could be reliably quantitated by qPCR.  However, there was no 
significant difference in its expression levels in control and diabetic patients (Fig 6.4.7-A). 
Expression levels of GDF-15 and TWSG1, the other putative erythroid regulators, were found to 
be extremely low in all the samples; hence, these could not be reliably quantitated. On the other 
hand, TfR1 and TfR2 were found to be highly expressed in reticulocytes; there were, however, 
no significant differences in their gene expression in control and diabetic patients (Fig 6.4.7–B, 
C) 
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Table 6.4.4: Hematological parameters 
 
Control subjects Pre-diabetics Diabetics  
P value 
(Kruskal 
Wallis test) 
Hb (g/dL) 15.5 [14.6 - 16.4] 15.2 [14.5 -16.1] 15.9 [15.3 - 16.3] 0.113 
RBC count 
(x10
6 
cells/µL) 
5.21 [4.9 - 5.5] 5.41 [5.1 - 5.8] 5.48 [5.1 - 5.8] 0.074 
MCV (fL) 85.9 [82.9 - 89.7] 83.3 [81.2 - 87] 83 [80.6 - 88.8] 0.105 
MCH (pg) 29.9 [28.2 - 30.9] 28.8 [27.6 - 29.6]* 28.6 [28 - 30.7] 0.015 
Reticulocyte 
hemoglobin (pg) 
33.1 [31.5 - 34.3] 32.2 [30.5 - 33.1]* 32.3 [31.3 - 33.5] 0.022 
Reticulocyte 
count (x 10
4 
cells/µL) 
6.37  
[5.24 - 7.09] 
6.1  
[5.16 - 7.02] 
6.91  
[5.43 - 8.46] 
0.145 
Data are expressed as median [interquartile range]. Statistically significant values are shown in 
bold. * indicates p < 0.05 when compared to control group. 
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Table 6.4.5: Iron-related parameters 
 
Control subjects Pre-diabetics Diabetics 
P value 
(Kruskal 
Wallis test) 
Serum iron 
(µg/dL) 
98 [79 - 129.3] 95 [71.8 - 114.5] 97 [ 80.3 - 116.3] 0.628 
UIBC 
(µg/dL) 
239.5  
[200.3 - 278.5] 
256.5  
[232.3 -308] 
242.5  
[213 - 278.8] 
0.105 
TIBC 
(µg/dL) 
352 [307.3 - 372.5] 365.5 [318 - 402] 350 [324 - 366.8] 0.225 
Transferrin 
saturation 
(%) 
30.2 [22.8 - 38.4] 27.1 [19.3 -33.3] 29.8 [ 23 - 33.9] 0.242 
Hepcidin- 
ferritin 
ratio 
0.33 [0.22 - 0.52] 0.47 [0.21 - 0.78] 0.31 [ 0.17 -0.51] 0.437 
Data are expressed as median [interquartile range].  
UIBC, unbound iron binding capacity; TIBC, total iron binding capacity 
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4.6 Correlation analyses 
4.6.1 Serum ferritin 
Serum ferritin was positively correlated with serum hepcidin in all the three groups studied. A 
positive correlation with markers of iron status (serum iron and transferrin saturation) was seen 
in the control and pre-diabetic groups, but not in the diabetic group (in which ferritin levels were 
found to be significantly increased [Fig 6.4.3-A]). A positive correlation with CRP was seen only 
in the control group (Table 6.4.6).  
Stepwise multiple linear regression analysis showed an independent association of serum ferritin 
with MCH (B = 16.6, SE = 4.1, p < 0.001), HOMA-IR (B = 11.4, SE = 3.3, p = 0.001) and serum 
hepcidin (B = 0.36, SE = 0.15, p = 0.021). The model explained 24.8% of variation in serum 
ferritin (p < 0.001). 
 4.6.2. Serum hepcidin 
Similar to serum ferritin, serum hepcidin was positively correlated with markers of iron status 
(serum iron and transferrin saturation) in the control and pre-diabetic groups but not in the 
diabetic group. It did not correlate with CRP in any of the groups (Table 6.4.7).  
Stepwise multiple linear regression analysis showed that serum hepcidin was independently 
associated only with serum ferritin (B = 0.13, SE = 0.05, p = 0.013). However, serum ferritin 
explained only 4.7% of variation in serum hepcidin (p = 0.013). This indicates that other factors 
appear to influence hepcidin, apart from serum ferritin. 
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 4.5.3. Fasting plasma glucose 
Fasting plasma glucose (FPG) levels showed significant positive correlations with serum iron 
and transferrin saturation in the control group, but not in the pre-diabetic or diabetic group. It 
correlated positively with serum levels of hepcidin and ferritin, when data on all patients were 
considered. However, when data on the diabetic group alone was considered, glucose levels 
correlated negatively with hepcidin and insulin (Table 6.4.8).   
Stepwise multiple linear regression analysis showed that FPG was independently associated only 
with CRP (B = 4.47, SE = 1.63, p = 0.007). However, the association with CRP explained only 
5.6% of variation in FPG (p = 0.007). 
 4.5.4 Fasting serum insulin 
Fasting serum insulin showed a significant positive correlation with CRP in the control group 
and in the pre-diabetic group; no association was not seen in the diabetic group. Serum insulin 
did not correlate with any of the other metabolic, hematological or iron-related parameters (Table 
6.4.9). 
Stepwise multiple linear regression analysis showed that fasting insulin was independently 
associated with BMI (B = 0.71, SE = 0.2, p = 0.001) and CRP (B = 0.51, SE = 0.22, p = 0.021). 
The model explained 14.8% of variation in HOMA-IR (p <0.001). 
 
 
 
268 
 
Table 6.4.6: Correlation of serum ferritin with various parameters of interest (univariate analyses) 
 
 
Control 
subjects 
Pre-
diabetics 
Diabetics All subjects 
  Spearman’s correlation coefficients 
Metabolic 
parameters 
Fasting plasma 
glucose 
0.26 0.08 0.06 0.27** 
Serum insulin 0.07 0.14 0.09 0.14 
HOMA-IR 0.08 0.14 0.11 0.22* 
HOMA-β 0.003 0.09 0.082 -0.09 
Hematological 
parameters 
Hemoglobin -0.06 0.26 0.32* 0.24** 
RBC count -0.28 -0.11 0.16 -0.04 
MCV 0.26 0.31* 0.12 0.21* 
MCH 0.28 0.43** 0.18 0.30** 
Reticulocyte 
hemoglobin  
0.19 0.50** 0.17 0.31** 
Reticulocyte 
count 
0.01 0.21 0.05 0.14 
Iron-related 
parameters 
Serum hepcidin 0.55** 0.69** 0.42** 0.59** 
Serum iron 0.51** 0.49** 0.07 0.40** 
Transferrin 
saturation (%) 
0.59** 0.50** 0.06 0.44** 
Inflammation hsCRP 0.326* -0.071 0.123 0.164 
Spearman’s correlation coefficients are shown. Significant correlations are in bold font and 
highlighted. *p < 0.05, ** p < 0.01 
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Table 6.4.7: Correlation of serum hepcidin with various parameters of interest (univariate 
analyses) 
 
 
Control 
subjects 
Pre-diabetics Diabetics 
All 
subjects 
  Spearman’s correlation coefficients 
Metabolic 
parameters 
Fasting plasma 
glucose 
0.19 0.07 -0.32* 0.18* 
Serum insulin -0.08 0.11 0.04 0.05 
HOMA-IR -0.07 0.13 0.02 0.12 
HOMA-β -0.19 0.08 0.14 0.06 
Hematological 
parameters 
Hemoglobin 0.22 0.15 0.21 0.23* 
RBC count 0.08 -0.07 0.13 0.06 
MCV 0.26 0.38* 0.27 0.27** 
MCH 0.14 0.27 0.11 0.17 
Reticulocyte 
hemoglobin  
0.09 0.10 -0.19 0.03 
Reticulocyte 
count 
-0.02 0.01 -0.23 -0.05 
Iron-related 
parameters 
Serum ferritin 0.55** 0.69** 0.42** 0.59** 
Serum iron 0.46** 0.35* 0.16 0.33** 
Transferrin 
saturation (%) 
0.48** 0.38* 0.17 0.34 
Inflammation hsCRP 0.302 0.046 -0.074 0.123 
Spearman’s correlation coefficients are shown. Significant correlations are in bold font and 
highlighted. *p < 0.05, ** p < 0.01 
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Table 6.4.8: Correlation of fasting plasma glucose with various parameters of interest (univariate 
analyses) 
 
 
Control 
subjects 
Pre-diabetics Diabetics 
All 
subjects 
  Spearman’s correlation coefficients 
Metabolic 
parameters 
Serum insulin 0.08 0.16 -0.32* 0.03 
Hematological 
parameters 
Hemoglobin -0.07 -0.17 0.15 0.10 
RBC count -0.19 -0.02 0.08 0.17 
MCV 0.07 -0.18 -0.05 -0.16 
MCH 0.16 -0.13 0.08 -0.13 
Reticulocyte 
hemoglobin  
0.08 -0.03 0.25 -0.08 
Reticulocyte 
count 
0.15 -0.02 0.04 0.14 
Iron-related 
parameters 
Serum ferritin 0.26 0.08 0.06 0.27** 
Serum hepcidin 0.19 0.06 -0.32* 0.18* 
Serum iron 0.46** 0.01 -0.26 0.01 
Transferrin 
saturation (%) 
0.51** -0.08 -0.15 0.02 
Inflammation CRP 0.006 0.036 0.179 0.179 
Spearman’s correlation coefficients are shown. Significant correlations are in bold font and 
highlighted. *p < 0.05, ** p < 0.01 
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Table 6.4.9: Correlation of fasting serum insulin with various parameters of interest (univariate 
analyses) 
 
 
Control 
subjects 
Pre-diabetics Diabetics 
All 
subjects 
  Spearman’s correlation coefficients 
Metabolic 
parameters 
Fasting plasma 
glucose 
0.080 0.161 -0.318 0.027 
Hematological 
parameters 
Hemoglobin -0.121 0.037 -0.006 -0.013 
RBC count -0.161 -0.191 0.092 -0.066 
MCV -0.107 0.170 -0.154 -0.025 
MCH 0.039 0.302 -0.145 0.056 
Reticulocyte 
hemoglobin  
0.142 0.239 0.031 0.120 
Reticulocyte 
count 
-0.101 0.114 0.239 0.101 
Iron-related 
parameters 
Serum ferritin 0.075 0.138 0.087 0.136 
Serum hepcidin -0.087 0.108 0.042 0.057 
Serum iron -0.165 0.119 0.142 0.044 
TIBC -0.194 0.034 0.207 -0.004 
Transferrin 
saturation (%) 
-0.062 0.139 -0.045 0.026 
Inflammation hsCRP 0.375* 0.547** 0.178 0.349** 
Spearman’s correlation coefficients are shown. Significant correlations are in bold font and 
highlighted. *p < 0.05, ** p < 0.01 
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Table 6.4.10: Correlation among ERFE, TfR1 and TfR2 mRNA expression in reticulocytes, 
hemoglobin and serum hepcidin.   
 Spearman’s correlation coefficients are shown 
 
ERFE TfR1 TfR2 Hemoglobin 
Serum 
hepcidin 
ERFE - 0.365 0.296 -0.02 -0.214 
TfR1 0.692** - 0.831** -0.055 0.086 
TfR2 0.723** 0.932** - -0.106 0.200 
Hemoglobin -0.427* -0.039 -0.097 - 0.207 
Serum hepcidin 0.084 -0.026 -0.084 0.220 - 
 
 Control group,  Diabetes group 
Spearman’s correlation coefficients are shown. Significant correlations are in bold font. 
* p < 0.05, ** p < 0.01 
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 4.5.5 mRNA expression of ERFE, TfR1 and TfR2 in reticulocytes 
ERFE mRNA expression in reticulocytes correlated positively with TfR1 and TfR2 mRNA (in 
reticulocytes) and negatively with hemoglobin in the control group, but not in the diabetic group. 
TfR1 and TfR2 mRNA levels were highly positively correlated with each other in both groups 
studied. However, ERFE, TfR1 and TfR2 mRNA did not correlate with serum hepcidin levels 
(Table 6.4.10). 
5. Discussion 
There are many reports of dysregulated iron homeostasis in patients with diabetes mellitus (4,6–
9). However, in these studies, many factors that could influence the parameters of interest have 
not been adequately controlled for.  For example, factors such as duration of the disease, extent 
of glycemic control in the past or currently, therapeutic interventions used and presence or 
absence of chronic complications of diabetes can all have a significant bearing upon the 
outcomes studied (187). In an attempt to minimize the effects of these potential confounding 
factors, in the present study, only patients who were newly diagnosed to have diabetes mellitus 
were recruited. Those diagnosed to be pre-diabetic, a state in which patients are at increased risk 
of developing diabetes, were also recruited. As far as is ascertainable, there are no published 
studies on hepcidin and other iron-related parameters in such categories of patients. 
Only males were investigated in this study. This was because many factors are known to affect 
iron homeostasis in women. These include parity, phase of the menstrual cycle (in pre-
menopausal women) and menopausal changes (408,409).  
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Inflammation (417), anemia (418) and severe obesity (419–421) are other factors that are known 
to affect iron homeostasis. Hence, patients with CRP > 12 mg/dL, hemoglobin < 13 g/dL (422) 
and BMI > 35 kg/m
2
 (423) were excluded from the study. Subjects in all three groups (control, 
pre-diabetic and diabetic) were matched for age and BMI, as much as was possible (Table 6.4.3).  
Insulin resistance (IR) is a characteristic feature of T2DM, which is the most common type of 
diabetes mellitus. The natural history of T2DM is characterized by an early stage where IR is 
compensated by increased insulin secretion. However, this compensatory hyperinsulinemia tends 
to decline with progressively increasing IR and beta-cell fatigue (or failure) (424). In the present 
study, there was no evidence of hyperinsulinemia, either in the pre-diabetics or the diabetics (Fig 
6.4.1-B). HOMA-IR, a marker of insulin resistance, was not different in control subjects and in 
the pre-diabetics, but was ~ 2-fold higher in the diabetics (Fig 6.4.2-A). On the other hand, 
HOMA-β, a marker of the pancreatic insulin secretory capacity, was lower by 40% in the pre-
diabetics and by 76% in the diabetics (Fig 6.4.2-B), suggesting onset of beta cell failure. These 
results are consistent with previous reports that have shown early onset of beta cell failure among 
South Asians with varying degrees of dysglycemia (425–429). It has been shown that, compared 
to Caucasians and other ethnic groups, South Asians have decreased beta cell reserve (426), early 
onset of beta cell failure (426,429) and rapid deterioration  of beta cell function in the presence 
of IR (427). Iron has been implicated in the pathogenesis of beta cell damage, especially in type 
1 diabetes (232,430). However, very little is known about the role of iron in beta cell function 
and insulin secretion.  
It is generally held that serum levels of ferritin are indicative of iron stores in the body (53,431). 
However, the source of ferritin in the blood is not well-characterized. Circulating ferritin has 
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been shown to be made up of ferritin light chains that are iron-poor (432). In mice, it has been 
shown to be actively secreted by the macrophages, and is not a product of cell turnover, as was 
previously thought (52). However, the factors regulating the secretion of ferritin are not well-
characterized and how body iron stores influence serum ferritin levels is not known.  
The results of the present study show that, except for a significant increase in serum levels of 
ferritin and hepcidin in patients with diabetes (but not in pre-diabetes), parameters of iron status 
(such as serum iron, TIBC and transferrin saturation) (Table 6.4.4), were not different in the 
three groups studied. These results are in keeping with results of the EPIC-INTERACT study 
(194), which showed that diabetes mellitus was associated only with elevated ferritin levels and 
not with serum iron or transferrin saturation. In fact, among women, transferrin saturation >45% 
was associated with significantly decreased risk of diabetes (194). In the present study, 
multivariate analyses showed that serum ferritin was independently associated HOMA-IR and 
hepcidin, but not with serum iron or transferrin saturation. These results suggest that the 
etiopathogenesis of elevated serum ferritin levels associated with T2DM is more complex than 
previously thought and does not simply reflect an iron-overloaded state. 
Ferritin is an acute phase protein and its levels in blood increase in inflammatory conditions 
(285,286). Hepcidin is also induced by inflammation (417). Hence, serum levels of CRP, a 
marker of inflammation, were measured to ascertain whether inflammation was responsible for 
the elevations seen in serum levels of hepcidin and ferritin. Serum CRP levels tended to be 
higher in the diabetic group compared to those in control subjects (p=0.065) (Fig. 6.4.4). On 
classification of subjects based on the ‘high-risk’ cut-off for CRP (proposed by the American 
Heart Association) viz., >3.0 mg/dL (415), it was found that control subjects with higher CRP 
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levels had significantly higher hepcidin levels and a tendency to higher serum ferritin levels (p = 
0.063). However, these parameters were similar in the same sub-categories in the pre-diabetics 
and diabetics (Fig 6.4.5-A and B). These results suggest that the presence of inflammation may 
influence serum hepcidin and ferritin values, but this influence does not seem to be very distinct 
in the pre-diabetic and diabetic groups.  
Correlation analyses showed that ferritin and hepcidin were positively correlated with each other 
in all the three groups studied. However, they were not correlated with CRP or markers of iron 
status (serum iron and transferrin saturation). This is surprising, given that both ferritin and 
hepcidin are well-known to be linked to inflammation and iron status. The reasons for these 
observations are unclear.  
While multiple studies (described above) have consistently shown increased serum ferritin in 
patients with diabetes, studies that have looked at serum hepcidin levels have reported variable 
results. For example, Andrews et al (25) and Jiang et al (26) have reported increased serum 
hepcidin levels in patients with T2DM compared to control subjects. On the other hand, Suarez-
Ortegon et al (29), Pechlaner et al (407), Sam et al (28) and Aso et al (27) showed lower levels in 
diabetics. Guo et al (30) showed no significant differences in hepcidin levels in diabetics and 
non-diabetics. In all of the studies mentioned above, the subjects recruited were patients who 
were already known to be diabetic. Hence, many factors such as duration of condition, extent of 
glycemic control, etc. may contribute to variations seen. These have not been controlled for in 
these published studies.  
In the present study, serum hepcidin was found to be increased in the diabetic group, but not in 
the pre-diabetic group. As discussed above, the contribution of inflammation to this increase is 
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not clear (Fig 6.4.5-B). Adipose tissue has been shown to secrete hepcidin and contribute 
significantly to serum hepcidin levels in obese patients (433). Hence, it is possible that the 
adipose tissue may be the source of increased serum hepcidin in the diabetic group. However, 
patients in all the 3 groups studied had similar mean values for BMI; none of them were obese. 
Little is known about the effects of factors, such as iron content in the adipose tissue and 
inflammation, on expression of hepcidin in adipose tissue. It has been suggested that increased 
iron content in adipose tissue iron may play a role in the pathogenesis of IR (17,225,349). A few 
studies, using magnetic resonance (MRI) imaging for quantification of tissue iron, have shown 
increased iron content in the liver, skeletal muscle and adipose tissue in patients with diabetes 
mellitus (348,419,434). Overall, the role of tissue iron overload, especially in the adipose tissue, 
in the pathogenesis of diabetes mellitus is poorly understood and is an under-investigated area. 
Hepcidin is known to be regulated by factors secreted by the erythroid precursors. In the present 
study, patients with pre-diabetes and diabetes tended to have higher RBC counts and lower MCH 
and reticulocyte hemoglobin (Table 6.4.4). ERFE mRNA was found to be expressed at low-to-
moderate levels in reticulocytes and could be reliably quantitated by qPCR.  Therefore, 
reticulocyte ERFE expression may be considered a surrogate marker of ERFE expression in late 
erythroid precursors in subjects in whom it is not ethically possible to obtain bone marrow 
samples. The present results showed that ERFE expression was similar in control and diabetic 
patients; expression levels of GDF-15 and TWSG-1 (the other putative erythroid regulators of 
hepcidin) in reticulocytes were too low to be reliably determined. 
Expression of TfR1 in the bone marrow has been shown to mediate hepatic hepcidin expression, 
probably by regulating the expression of the erythroid regulators of hepcidin (390). Expression 
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of TfR2, a component of the EpoR complex, which mediates EPO-induced expression of ERFE 
(391), has also been shown to affect hepcidin expression (405). A significant positive correlation 
was seen between ERFE, TfR1 and TfR2 mRNA expression in reticulocytes among the control 
patients; this was not observed in the diabetics. In addition, ERFE was negatively correlated with 
hemoglobin in the control subjects, but not in the diabetics (Table 6.4.10). These results possibly 
indicate alterations in iron-related proteins in the erythroid cells obtained from patients with 
diabetes. Expression levels of TfR1 and TfR2 were highly correlated, both in the controls and the 
diabetics. This finding suggests that the expression of TfR1 and TfR2 are coordinately regulated. 
Further investigations would be required to elucidate the physiological importance of these 
findings. 
A limitation of the present study is the fact that, although only newly diagnosed diabetic/ pre-
diabetic patients were recruited, it was not possible to know how long these patients had been 
diabetic/ pre-diabetic prior to diagnosis at the time of recruitment.  
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6. Summary and conclusions: 
As far as is ascertainable, this is the first study that has determined hepcidin and other iron-
related parameters in patients newly diagnosed with diabetes or pre-diabetes. The results of this 
study show that serum levels of ferritin and hepcidin were elevated in patients with diabetes 
mellitus (but not in those with pre-diabetes), compared to control subjects.   
Serum levels of CRP tended to be higher in the diabetics and may have some bearing upon the 
elevations seen in serum levels of hepcidin and ferritin. Markers of iron status, apart from ferritin 
(serum iron, TIBC and transferrin saturation) were not significantly different in the 3 groups 
studied. Expression of erythroferrone, the erythroid regulator of hepcidin, in reticulocytes was 
similar in control and diabetic patients. Surprisingly, although the patients recruited in this study 
were diagnosed to have pre-diabetes/diabetes for the first time, they showed evidence of beta cell 
dysfunction. These results add to the growing body of evidence that South Asians are prone to 
early onset of beta cell failure. How iron is linked to this is currently unclear.   
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7. SUMMARY OF RESULTS 
A summary of the major findings of this study is given below: 
Study 1: Iron induces basal activation of Akt but decreases its activation in response to 
insulin in mouse primary hepatocytes 
- Mouse primary hepatocytes loaded with iron in vitro showed phosphorylation-mediated 
activation of the Akt pathway and AMP-activated protein kinase (AMPK). These effects 
tended to be attenuated by treatment with an iron chelator, desferrioxamine.  
- Hepatocyte glucose production was significantly decreased in iron-loaded hepatocytes. Iron 
also attenuated forskolin (a glucagon agonist)-induced activation of the key gluconeogenic 
enzyme, glucose-6-phosphatase.  
- On the other hand, iron decreased protein levels of insulin receptor substrates 1 and 2 (which 
are upstream of Akt in the insulin signaling pathway), resulting in decreased insulin-
stimulated Akt activation.  
In conclusion, the results show that high intracellular iron had a dual effect on the insulin 
signalling pathway in hepatocytes. It increased Akt activation in a ligand-independent manner 
(in the absence of insulin), but decreased insulin-induced Akt activation resulting in insulin 
resistance.  
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Study 2: Interactions between insulin resistance and dysregulated iron homeostasis, 
produced by high-fat feeding in mice: a time-course study 
- In a mouse model of type 2 diabetes mellitus, induced by feeding male C57Bl/6 mice a high-
fat diet, progressive worsening of insulin resistance (with increasing duration of HFD-
feeding) was associated with dysregulation of systemic iron homeostasis and 
hyperinsulinemia.  
- Onset of insulin resistance appeared to precede the onset of iron dysregulation. This suggests 
that it is unlikely that dysregulated iron homeostasis in the liver plays a causative role in the 
pathogenesis of IR in this model.  
- Hepatic steatosis was independently associated with IR and decreased hepatic iron stores, 
suggesting that ectopic lipid accumulation in the liver may play a role in the pathogenesis of 
IR, as well as in hepatic iron dysregulation.  
- The decrease in hepatic iron stores was associated with concomitant increases in the iron 
content and metabolic dysfunction in the adipose tissue. Since increased iron in the adipose 
tissue has been reported to induce IR, it is possible that this may contribute to the increase in 
IR in response to high-fat feeding. 
- Levels of hepcidin, the chief iron regulatory hormone, were decreased in high-fat diet-fed 
mice. Factors that regulate hepcidin, such as inflammation, serum iron levels and hepatic 
BMP6 were not significantly affected by HFD-feeding. Protein levels of TfR2 (known to 
induce hepcidin expression) were independently associated with hepatic hepcidin expression 
in HFD-fed mice. Further studies would be required to further elucidate its role in hepcidin 
regulation in this setting. 
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In conclusion, the results showed that IR induced by HFD-feeding was associated with 
dysregulation of iron homeostasis in the liver and adipose tissue. Ectopic lipid accumulation in 
the liver may play a role in the pathogenesis of IR, as well as in hepatic iron dysregulation. 
Increased iron in the adipose tissue induced by HFD-feeding may play a role in the pathogenesis 
of IR in response to high-fat feeding. 
Study 3: Effect of high-fat diet-induced insulin resistance on erythroid maturation and 
erythroid regulators of hepcidin in the bone marrow in mice 
- Flow cytometric analyses of maturation and differentiation of erythroid progenitors in the 
bone marrow showed no significant effects of HFD-feeding on terminal erythroid 
differentiation.  
- An increase in reticulocytes in the marrow of HFD-fed mice suggested impaired reticulocyte 
maturation and release into the circulation. 
- Gene expression of the putative erythroid regulators of hepcidin, such as erythroferrone, 
growth differentiation factor 15, twisted gastrulation factor 1 was not affected by HFD-
feeding.  
In conclusion, HFD-feeding induced IR did not affect erythroid maturation in the bone marrow 
or gene expression of the putative erythroid regulators of hepcidin. Hence, it appears unlikely 
that these factors play a role in the down-regulation of hepcidin seen in response to high-fat 
feeding.  
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Study 4: Dysregulated iron homeostasis in patients newly diagnosed with diabetes 
mellitus or pre-diabetes 
- Male patients newly diagnosed to have diabetes mellitus and pre-diabetes showed evidence 
of beta cell failure. 
- Diabetics (but not pre-diabetics) had significantly elevated levels of serum ferritin and 
hepcidin compared to controls. However, other markers of iron status (serum levels of iron, 
total iron-binding capacity and transferrin saturation) were similar in the 3 groups studied 
(controls, pre-diabetics and diabetics).  
- Serum levels of CRP tended to be higher in the diabetics. Inflammation may therefore have 
some bearing upon the elevations seen in serum levels of hepcidin and ferritin. 
- Expression of erythroferrone, the putative erythroid regulator of hepcidin, in reticulocytes, 
was not significantly different between control and diabetic patients.  
In conclusion, patients newly diagnosed with diabetes mellitus and pre-diabetes showed evidence 
of beta cell failure. Dysregulation of iron homeostasis was seen in the diabetics but not in the 
pre-diabetics. Erythroferrone, an erythroid regulator of hepcidin, did not appear to play a role in 
regulation of hepcidin in the diabetics. 
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8. CONCLUSIONS 
Currently, management of diabetes is primarily based on attempts to achieve adequate glycemic 
control in an effort to delay/prevent chronic complications of diabetes (such as nephropathy, 
neuropathy, and retinopathy). There are very few effective strategies aimed at primary 
prevention in genetically pre-disposed persons, other than measures to reduce body weight and 
increase physical activity. Iron stores in the body can be easily manipulated by dietary means, 
phlebotomy or by using iron chelators. A better understanding of the role of iron in the 
pathogenesis of diabetes will possibly provide newer therapeutic options, based on manipulation 
of body iron stores, in the management of diabetes.  
Overall, this study attempted to address the question “Why does iron overload associated with 
insulin resistance occur?” using multiple approaches - in vitro (using hepatocytes in culture), in 
vivo (using a mouse model of diabetes) and in patients newly diagnosed with diabetes 
mellitus/pre-diabetes.  
The results show that increased intracellular iron impaired insulin signalling, resulting in insulin 
resistance (study 1). In the mouse model of insulin resistance, onset of insulin resistance 
preceded that of iron dysregulation (study 2). In addition, in the human study, dysregulation of 
iron homeostasis was seen in the diabetics but not in the pre-diabetics (study 4). These results 
suggest that dysregulation of iron homeostasis is unlikely to play a causative role in the 
pathogenesis of diabetes mellitus. In the mouse model of insulin resistance, hepatic steatosis 
decreased iron levels in the liver, while increasing iron levels in the adipose tissue. Iron overload 
in the adipose tissue may play an important role in the progression of insulin resistance (study 2).  
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Although the erythroid regulators of hepcidin are known to regulate hepcidin expression, there 
was no evidence for a role for these regulators (erythroferrone, growth differentiation factor – 15 
and twisted gastrulation factor 1) in regulation of hepcidin in the mouse model of insulin 
resistance (study 3) or in humans newly diagnosed with diabetes mellitus/pre-diabetes (study 4). 
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9. RECOMMENDATIONS AND FUTURE DIRECTIONS 
The present study has attempted to address several questions related to the interactions between 
iron homeostasis and insulin resistance in the pathogenesis of diabetes mellitus. The results have 
also raised several new ones.  
The results of study 1 show that increased levels of intracellular iron impaired insulin signaling 
in hepatocytes. Based on these results, we speculate that similar mechanisms may be operational 
in other tissues as well, such as skeletal muscle and adipose tissue. This would be a new and 
interesting avenue for further research in this area. As far as we have been able to ascertain, such 
avenues have not been explored. Studies of this nature would contribute significantly to the field.   
At the time that the current study was designed, it was generally accepted that increased body 
iron stores were associated with diabetes. However, these conclusions were based on estimations 
of serum ferritin, which was used a surrogate marker of body iron stores. More recent studies 
have shown that iron overload is not invariably associated with diabetes and that iron 
dysregulation in diabetes mellitus is a complex phenomenon. The results of study 2 have shown 
the interactions between insulin resistance and systemic iron homeostasis in a mouse model of 
insulin resistance. One of the key findings was that insulin resistance was associated with 
increased iron stores in the adipose tissue. A few studies have shown that iron in the adipose 
tissue in humans can contribute to insulin resistance (1,2); however, the molecular mechanisms 
involved have not been studied in detail. This is an important area for future research. 
Results from study 2 showed that hepatic steatosis induced by high-fat feeding in mice resulted 
in a decrease in iron stores in the liver. Ferritinophagy is a specialized form of autophagy that 
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specifically targets ferritin, the iron storage protein, for lysosomal degradation. It is not known 
whether activation of ferritinophagy plays a role in steatosis-induced decrease in liver iron. This 
is an interesting possibility that would require further experimental work for confirmation. 
Hepatic iron stores are important regulators of hepcidin expression. However, the molecular 
mechanisms by which iron stores in the liver signal to regulate hepcidin are not clear. 
Interestingly, results of study 2 showed that protein levels of transferrin receptor 2 (TfR2) in the 
liver were independently associated with hepatic hepcidin expression. In addition, the role of 
matriptase-2 (a negative regulator of hepcidin) and iron-induced epigenetic changes in hepcidin 
regulation are not clear. Further work would be required to clarify the role of these molecules in 
regulation of hepcidin, in response to changes in liver iron stores. 
Results of study 4 show increased serum levels of ferritin and hepcidin in patients with diabetes, 
but not in those with pre-diabetes. However, the reason(s) for these findings are not clear. Future 
work aimed at elucidating the dysregulation of iron metabolism in adipose tissue of patients with 
diabetes/pre-diabetes may throw light on this aspect. 
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11. APPENDIX 
APPENDIX I 
Minimum Information for Publication of Quantitative Real-Time PCR Experiments 
(MIQE) checklist 
Item to check Importance* Response 
EXPERIMENTAL 
DESIGN 
  
Definition of experimental 
and control groups 
E 
 
Details provided in methods section of each 
study. 
Number within each group E Details provided in methods section of each 
study. 
Assay carried out by core lab 
or investigator's lab? 
D 
 
All assays were carried out in the investigators’ 
lab 
SAMPLE   
Description E Details provided in methods section of each 
study. 
Volume/mass of sample 
processed 
D 
 
Details provided in methods section of each 
study. 
Microdissection or 
macrodissection 
E 
 
Not applicable 
Processing procedure E Details provided in methods section of each 
study. 
If frozen - how and how 
quickly? 
E 
 
All samples were snap-frozen in liquid nitrogen 
and immediately transferred to a -70°C freezer 
If fixed - with what, how 
quickly? 
E 
 
Not applicable 
Sample storage conditions 
and duration (especially for 
FFPE samples) 
E 
 
All samples were stored at - 70°C until processed 
for RNA isolation 
NUCLEIC ACID 
EXTRACTION 
  
Procedure and/or 
instrumentation 
E 
 
Guanidinium thiocyanate-phenol-chloroform 
extraction method using Tri-reagent (Sigma) 
Name of kit and details of any 
modifications 
E 
 
Not applicable 
Source of additional reagents 
used 
D 
 
Chloroform and isopropanol used for RNA 
isolation were of molecular biology grade 
obtained from Sigma. 
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Details of DNase or RNAse 
treatment 
E 
 
DNAase treatment using the Ambion TURBO 
DNA-free kit was done. 
Contamination assessment 
(DNA or RNA) 
E 
 
All samples were run on 1% agarose gel to look 
for DNA contamination and RNA integrity. 
Nucleic acid quantification E Done using a NanoDrop spectrophotometer 
Instrument and method E NanoDrop2000c from Thermo Fischer 
Purity (A260/A280) D A260/A280 for all samples were > 1.80 
RNA integrity 
method/instrument 
E 
 
All samples were run on a 1% agarose gel. Only 
those samples that showed clear and distinct 
bands corresponding to 18s and 28s rRNA were 
used for cDNA construction 
RIN/RQI or Cq of 3' and 5' 
transcripts 
E 
 
Not done 
REVERSE 
TRANSCRIPTION 
  
Complete reaction conditions E Reaction buffer containing 5mM MgCl2, 500µM 
dNTPs, 2.5µM random nonamers, 0.4U/µL 
RNAase inhibitor, 1.25U/µL reverse 
transcriptase (final concentration) 
Amount of RNA and reaction 
volume 
E 
 
One microgram of total RNA was added to a 
total volume of 20µL 
Priming oligonucleotide (if 
using GSP) and concentration 
E 
 
Oligo dT 2.5µM (final conc.) 
Reverse transcriptase and 
concentration 
E 
 
Moloney Murine leukemia virus reverse 
transcriptase 1.25U/µL (final conc.) 
Temperature and time E 25°C for 10 min, 48°C for 30 min, 95°C for 5 
min 
Manufacturer of reagents and 
catalogue numbers 
D 
 
Reverse Transcriptase Core kit from Eurogentec, 
Belgium (Catalogue no. RT-RTCK-05) 
Storage conditions of cDNA D -20°C 
qPCR TARGET 
INFORMATION 
  
If multiplex, efficiency and 
LOD of each assay 
E Not applicable 
Sequence accession number D Information provided in methodology section of 
each study. 
Amplicon length E Information provided in methodology section of 
each study 
In silico specificity screen 
(BLAST, etc) 
E 
 
Primer BLAST 
(http://www.ncbi.nlm.nih.gov/tools/primer-
blast/) was used to check the specificity of each 
primer-pair used. 
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Pseudogenes, 
retropseudogenes or other 
homologs? 
D 
 
No 
Location of each primer by 
exon or intron (if applicable) 
E Not applicable 
What splice variants are 
targeted? 
E 
 
Primers were designed to amplify all splice 
variants of the target genes 
qPCR 
OLIGONUCLEOTIDES 
  
Primer sequences E Information provided in methodology section of 
each study. 
RTPrimerDB Identification 
Number 
D 
 
Not applicable 
Probe sequences D Not applicable 
Location and identity of any 
modifications 
E 
 
Not applicable 
Manufacturer of 
oligonucleotides 
D 
 
Sigma, India 
qPCR PROTOCOL   
Reaction volume and amount 
of cDNA/DNA 
E 
 
10 µL reaction volume containing 2 µL cDNA 
diluted 1:10 
Primer, (probe), Mg++ and 
dNTP concentrations 
E 
 
Final concentrations were: 
Primer: 250nM 
Mg
2+
 : 2.5mM 
dNTPs: not specified by the kit manufacturer 
Polymerase identity and 
concentration 
E 
 
Takyon
TM
 DNA polymerase (concentration not 
specified by the kit manufacturer) 
Buffer/kit identity and 
manufacturer 
E 
 
Takyon
TM 
No Rox SYBR MasterMix dTTP Blue 
(Catalogue number: UF-NSMT-B0701) 
Exact chemical constitution 
of the buffer 
D 
 
Information not provided by the kit manufacturer 
Additives (SYBR Green I, 
DMSO, etc.)  
 
E Not applicable 
Manufacturer of plates/tubes 
and catalog number 
D 
 
96-well plates from Axygen Scientific (catalogue 
number: PCR-96-FS-C) 
Complete thermocycling 
parameters 
E 
 
95°C for 5 min, followed by 40 cycles of 95°C 
for 10 sec and 60°C for 60 sec) 
Reaction setup 
(manual/robotic) 
D 
 
Manual 
Manufacturer of qPCR 
instrument 
E 
 
BioRad Chromo4 real-time PCR machine 
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qPCR VALIDATION   
Specificity (gel, sequence, 
melt, or digest) 
E 
 
Melt curve analysis was done for all PCR runs 
for all the genes. Single peaks were detected. No 
primer dimers were seen in any of reaction wells. 
For SYBR Green I, Cq of the 
NTC 
E Information provided in Appendix II 
Standard curves with slope 
and y-intercept 
E 
 
Information provided in Appendix II 
PCR efficiency calculated 
from slope 
E 
 
Information provided in Appendix II 
r2 of standard curve E Information provided in Appendix II 
Linear dynamic range E Information provided in Appendix II 
Cq variation at lower limit E Information provided in Appendix II 
If multiplex, efficiency and 
LOD of each assay. 
E 
 
Not applicable 
DATA ANALYSIS   
qPCR analysis program 
(source, version) 
E 
 
MJ Opticon Monitor Analysis Software Version 
3.1 (BioRad) 
Cq method determination E Manual 
Outlier identification and 
disposition 
E 
 
Not applicable 
Results of NTCs E Information provided in Appendix II 
Justification of number and 
choice of reference genes 
E The reference gene used was RPL19. The choice 
was based on previous publications which have 
used RPL19 as the reference gene. 
Description of normalisation 
method 
E 
 
The delta Ct method was used for normalization 
Number and stage (RT or 
qPCR) of technical replicates 
E All reactions were conducted in duplicate when 
qPCR was carried out. 
 
Repeatability (intra-assay 
variation) 
E 
 
Average of Cq values for duplicates was taken 
for calculation. Runs were repeated in samples 
where the Cq SD exceeded 0.2 
Statistical methods for result 
significance 
E 
 
The Kruskal Wallis test was used to detect 
statistically significant changes occurring in the 
different groups of mice. Mann Whitney test was 
used for all pair-wise comparisons. 
Software (source, version) E SPSS version 16.0 
* E – essential, D - desirable 
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APPENDIX II 
QUANTITATIVE POLYMERASE CHAIN REACTION (qPCR) VALIDATION DATA 
Sl. 
No 
Gene 
Standard 
curve 
slope 
R
2
 of 
standard 
curve 
Linear 
dynamic 
range 
(cDNA 
dilution) 
Standard 
deviation of Ct 
at lower limit 
of dynamic 
range 
Primer 
dimer 
(melting 
curve 
analysis) 
Ct of 
amplification (if 
any) in the NTC 
Mouse  
1 Fasn -3.061 0.998 1:5 to 1:625 0.14 In NTC 32 
2 Pck1 -3.677 0.998 1:5 to 1:625 0.14 None - 
3 Irs1 -3.435 0.993 1:5 to 1:625 0.09 In NTC 36 
4 Irs2 -3.149 0.999 1:5 to 1:625 0.11 In NTC 38 
5 Tfrc -3.689 0.999 1:5 to 1:625 0.06 None - 
6 Hamp1 -3.332 0.996 1:5 to 1:625 0.16 None - 
7 Gck1 -3.668 0.999 1:5 to 1:625 0.13 None - 
8 Slc40a1 -3.485 0.998 1:5 to 1:625 0.01 None - 
9 G6pc -3.397 0.999 
1:10 to 
1:10000 
0.49 In NTC 33 
10 FtL -3.631 0.997 1:5 to 1:625 0.05 In NTC 36 
11 Rpl19 -3.638 0.997 1:5 to 1:625 0.26 In NTC 32 
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Sl. 
No 
Gene 
Standard 
curve 
slope 
R
2
 of 
standard 
curve 
Linear 
dynamic 
range 
(cDNA 
dilution) 
Standard 
deviation of Ct 
at lower limit 
of dynamic 
range 
Primer 
dimer 
(melting 
curve 
analysis) 
Ct of 
amplification (if 
any) in the NTC 
12 Acaca -3.158 0.998 
1:10 to 
1:10000 
0.02 In NTC 31 
13 Bmp6 -3.155 0.997 
1:10 to 
1:10000 
0.02 In NTC 35 
14 Tmprss6 -3.609 0.996 1:5 to 1:3125 0.1 None  - 
15 Tfr2 -3.541 0.997 
1:10 - 
1:10000 
0.02 None - 
16 Efre -3.229 0.997 1:5 to 1:625 0.1 None - 
17 Gdf15 -3.516 0.999 1:5 to 1:625 0.15 In NTC 34 
18 Twsg1 -3.479 0.997 1:5 to 1:625 0.12 None - 
19 Ppargc1a -3.551 0.999 1:5 to 1:3125 0.07 None - 
20 Pparg2 -3.253 0.998 1:5 to 1:625 0.09 In NTC 34 
21 Adipoq -3.205 0.999 1:5 to 1:625 0.12 None - 
22 Pnpla2 -2.970 1 1:5 to 1:625 0.11 In NTC 36 
23 Lipe -3.189 1 1:5 to 1:625 0.04 In NTC 32 
24 Ftl -3.631 0.996 
1:10 to 
1:10000 
0.34 None - 
25 Fth -3.722 0.997 
1:10 to 
1:10000 
0.24 None - 
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Sl. 
No 
Gene 
Standard 
curve 
slope 
R
2
 of 
standard 
curve 
Linear 
dynamic 
range 
(cDNA 
dilution) 
Standard 
deviation of Ct 
at lower limit 
of dynamic 
range 
Primer 
dimer 
(melting 
curve 
analysis) 
Ct of 
amplification (if 
any) in the NTC 
Human 
26 ERFE -3.201 0.996 1:1 to 1:125 0.1 None - 
29 TFRC -3.238 0.999 1:5 to 1:625 0.06 None - 
30 TFR2 -3.209 0.995 1:5 to 1:625 0.07 None - 
31 GAPDH -3.32 0.996 1:5 to 1:625 0.1 In NTC 35 
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APPENDIX III - COMPOSITION OF CONTROL DIET (CD) – D12450J 
 
Source: http://www.researchdiets.com/opensource-diets/custom-diets/control-diets 
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APPENDIX IV – COMPOSITION OF HIGH-FAT DIET (HFD) – D12492 
 
Source: http://www.researchdiets.com/opensource-diets/stock-diets/dio-series-diets 
332 
 
APPENDIX V  
PATIENT INFORMATION SHEET 
Title of the study: Why does iron overload associated with insulin resistance occur? 
The Department of Biochemistry, in association with the Department of Community Health, is 
carrying out research to understand changes in the way iron is handled in the body in patients 
who have diabetes mellitus. Iron levels in the body are often higher than normal in this situation 
and may worsen the disease. We do not fully understand why iron accumulates in the body in 
this condition. We would like to study this problem to understand it better. For this, we would 
like to ask if you would be willing to donate 15 ml of your blood to help us study this. You may 
not benefit directly from this study. However, if you are willing to allow us to take this sample, it 
will help us try to understand why iron accumulates in the body in patients with diabetes mellitus 
and may help improve treatment for the disease. 
The blood sample that we request will be used purely for scientific research and any remaining 
sample will be discarded. The collection of the 15 ml of blood sample will not cause harm to 
your health in any foreseeable manner. All your personal information obtained by us from you 
will be kept completely confidential. 
If you do not wish to give the blood sample requested, you are free to say so. It will not affect the 
treatment that you will receive in the hospital.  
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APPENDIX VI 
INFORMED CONSENT  
 
-----------------------   has explained the details of the study proposed and what it involves to me. I 
have understood what has been said including the following: 
1. A sample of blood amounting to 15 ml in quantity will be collected from me. 
2. It will not affect my health in any foreseeable manner. 
3. The sample will be used to study what happens to the process by which iron is handled in 
the body in patients with diabetes mellitus. It will be used only for research purposes.   
 
I am willing to donate 15 ml of blood voluntarily and without any coercion from the 
investigators of this project. 
 
Signature of donor                                                                    Signature of investigator 
Name of Donor        
 
 
Signature of witness 
Date: 
 
In case you have additional queries, please feel free to contact me:  
Dr. Joe Varghese  
Assistant Professor, 
Department of Biochemistry, 
Christian Medical College, 
Bagayam, Vellore, Tamil Nadu - 632002 
INDIA 
Phone: +91-416-2284267 (office), +91 – 9843243682 (mobile) 
E-mail: joevarghese@cmcvellore.ac.in 
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APPENDIX VII 
PATIENT INFORMATION SHEET (TAMIL) 
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APPENDIX VIII 
INFORMED CONSENT (TAMIL) 
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APPENDIX IX 
PROFORMA FOR COLLECTION OF DEMOGRAPHIC AND OTHER DETAILS 
REGARDING THE PATIENT 
        Date: 
Name  
 
Age (years)  
Sex  
 
Hospital No  DOB  
Address  
 
 
 
 
Phone 
Number 
 
Education/
Occupation 
 
 
1. Medical history: 
Reason for current visit/presenting complaint: 
History of previous diagnosis of diabetes/prediabetes: 
2. Final diagnosis: 
 
3. Family history:  
Diabetes: Hypertension:   Any other: 
4. Personal history: 
Diet: Veg/non-veg Alcohol use:    Smoking: 
Any other: 
5. Clinical examination:   
Acanthosis nigricans:  Pallor:   BP: 
Any other significant finding: 
 
6. Anthropometric measurements: 
Height: Weight:   BMI: 
Waist circumference: Hip circumference:  
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7. Laboratory investigations: 
Haemoglobin              
  : 
CRP   Any other analytes measured 
as part of clinical 
management 
Fasting glucose  Post prandial 
glucose 
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Formatting techniques used in preparation of Compact Disc (CD) 
 
 
- Microsoft Office 2010 software was used to prepare the contents of this CD 
- The sources of the figures, when obtained from published literature, have been acknowledged 
in the figure legends.  
- The figures were downloaded from PDF documents and incorporated in to the Microsoft 
Word (MS Word) document at their appropriate places.  
- Images of western blots in the results section were captured using a gel documentation 
system (Alpha Innotech, USA).  
- All figures in the results section were prepared using Microsoft PowerPoint 2010 software 
and the images were incorporated into the MS Word document.  
- References were incorporated into the text using Zotero reference management software. 
- After the final formatting of the document was done, the MS Word file was converted to a 
Portable Document Format (PDF) file using the conversion option available in the MS Word 
2010. 
- The softcopy of the completed thesis work was copied on compact disc (CD). 
